Bublar’s Otherworld Heroes™ wins Auggie Awards 2020

The world’s first location-based massively multiplayer online role-playing Swedish mobile game Otherworld Heroes™ is the Auggie Award winner 2020 in the category Best Game or Toy. The Auggie Awards, hosted by Augmented World Expo in Silicon Valley, has been the most recognized industry AR & VR awards show in the world since 2010. The Best Game or Toy category connects to solutions that enable digital interaction with the physical world or physical interaction in the virtual world. “We’re immensely proud, truly honored and incredibly happy! We started this journey with a dream to build an innovative location-based game that is unique and will end up in a sweet spot in the best of worlds from World of Warcraft and Pokémon GO, says Wictor Hattenbach, Game Studio Director, Bublar Group. Otherworld Heroes is built on Bublar's proprietary mobile gaming platform and is the world's first location-based MMORPG where players can both see and collaborate with each other on the map. This is unique! The technical platform makes it possible to create games that need to process large volumes of data traffic in real time and are linked to physical locations in the real world. “I am not surprised that our talented Otherworld Heroes team made this happen. They have created a story told in a mobile game that is unique in the industry, developed on our own superpower technology platform,” says Maria Grimaldi, CEO of Bublar Group. Mobile gaming made up 45 percent of the global games market in 2019 and reached around 68 billion USD. The market share for mobile games has increased sharply. The gaming market totaled 148.8 billion USD in 2019 with an annual growth rate of 7.2 per cent. The game was soft launched and is available in Sweden, Poland and Indonesia on iOS and Android free of charge to download via Google Play or App store. More markets will be added as soon as the countries ease their restrictions due to Covid-19. Bublar had yet another nomination that made it to the finals called “VR Fire Trainer.” All winners were announced on stage at AWE USA 2020 at the Auggie Award Ceremony on May 29. Auggie Award winners 2019 and 2018 in the Game & Toy Category were Magic Leap and Star Wars: Jedi Challenge by Lenovo, respectively. Listen to our Otherworld Heroes’ team stories: Sara Mena  Per Storloekken  Axel Ljung   Otherworld Heroes nomination video in Auggie Awards. Watch the video: Otherworld Heroes Auggie Awards Winner 2020   For more information contact: Wictor Hattenbach, Game Studio Director, Bublar Group email: wictor.hattenbach@bublar.comPhone: +46 763 188 097 Maria A Grimaldi, CEO Bublar Group, email: maria.grimaldi@bublar.com,Phone: +46 70 828 38 34  Follow Otherworld Heroes on Social Media: Facebook    Otherworld Heroes Facebook Instagram    Otherworld Heroes Instagram Twitter         Otherworld Heroes Twitter Reddit         Otherworld Heroes Reddit   Otherworld Heroes Trailer    Bublar GroupBublar Group AB (publ) is the Nordic region's leading listed XR technology company specializing in Augmented Reality (AR) and Virtual Reality (VR). The company offers XR solutions in E-commerce, Entertainment, Training and Manufacturing. The company includes the subsidiaries Vobling, Sayduck and Virtual Brains. Bublar is headquartered in Stockholm and is listed on Nasdaq First North Growth Market. In essence, Bublar Group will change the game. We change how we Work, Shop and Play. The company has G & W fondkommission as Certified Adviser, Kungsgatan 3, Stockholm, email: ca@gwkapital.se, phone +46 8-503 000 50   Bublar Group AB (publ)   Kungstensgatan 18, SE-113 57 Stockholm, Sweden  Phone +46 8 559 251 20 www.bublar.com

Elekta Nomination Committee’s proposed Board of Directors for the 2020 Annual General Meeting

STOCKHOLM, June 1, 2020 – The Nomination Committee of Elekta (EKTA-B.ST) proposes that the 2020 Annual General Meeting re-elect Board members Laurent Leksell, who is also proposed to be re-elected as Chairman of the Board, Caroline Leksell Cooke, Johan Malmquist, Wolfgang Reim, Jan Secher, Birgitta Stymne Göransson and Cecilia Wikström. Tomas Puusepp has declined re-election. The Nomination Committee’s complete proposal will be published in the notice of Elekta's Annual General Meeting 2020, to be held on August 26, 2020. The Nomination Committee, prior to the 2020 Annual General Meeting, comprises the following members: Laurent Leksell (Chairman), with direct and indirect holdings; Per Colleen, appointed by Fjärde AP-Fonden; Filippa Gerstädt, appointed by Nordea Fonder; Thomas Flodén, appointed by AMF and AMF Fonder; and Caroline Sjösten, appointed by Swedbank Robur Funds. The chairman of the Nomination Committee is Laurent Leksell. # # # For further information, please contact:Cecilia Ketels, Head of Investor RelationsTel: +46 76 611 76 25, e-mail: Cecilia.Ketels@elekta.comTime zone: CET: Central European TimeAbout ElektaFor almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com  or follow @Elekta  on Twitter.

Polygiene Stays Fresh Technology now available with Royal Enfield’s new range of apparel

  A number of items including headgears will be launched with a combination of Polygiene® Biostatic and Odor crunch stays fresh technologies, that stops the growth of odor causing bacteria and makes products feel fresh and clean in all conditions and environments. More products will be added in the coming seasons, both from the protective and lifestyle lines. The treated headgear will fuel Royal Enfield’s drive to encourage people to cover their faces using the headgear as a voluntary public health measure. Understanding the problem at hand, Royal Enfield is urging their community to teach people how to use their headgear, how to wash, sanitize and reuse it - all to keep themselves protected and safe. The Royal Enfield brand is owned by Indian automaker Eicher Motors Limited, that is listed on the India stock market (BSE and NSE). The apparel business is growing and Eicher Motors is adopting a strategy that mirrors what other iconic brands have successfully monetized, adding apparel products to enhance the motorcycling experience. “Our constant endeavour is to level up the collection every season and to stay relevant to the ever-evolving needs of riders. In order to be sustainable and provide the best for the riders, this partnership is a step forward. With reduced washes through Polygiene technology, I definitely feel that we are offering the best to our riders and will continue to make products that enhance the riding experience”, says Puneet Sood, Head, Apparel Business at Royal Enfield. ”We are very proud to start a joint partnership with Royal Enfield. Our aim is to create an added value for every customer and in terms of this iconic brand we hope to add a real advantage for the end-users, the riders. When on the road they now will stay fresh, can travel light, and wash less. We are looking forward to adding unique advantages with our technology to the entire product range of Royal Enfield apparel going forward”, says Ulrika Björk, CEO at Polygiene. ”And on a final note, we are very happy to help spread the important message of #REGearUp, together with Royal Enfield.” About Royal Enfield Apparel:Started in 2014, Royal Enfield Apparels division was conceived with a single aim - to create an ecosystem around pure motorcycling and enhance the motorcycling experience. Safety is the prime consideration for Apparel, with three important parameters - protection, comfort and style. It strengthens the Pure Motorcycling way of life and allows emerging aspirants and existing loyalists to express themselves with the brand in numerous new ways. Relevance and being accessible for the end user are the other key attributes that Royal Enfield considers. Our apparel range consists of lifestyle apparel and protective gear.For more information visit: https://store.royalenfield.com/. Subscribe here to get reports, press releases and News:http://ir.polygiene.com/en/press/subscribe/

MATINS Update

Faron Pharmaceuticals Oy (“Faron” or the “Company”) ·Safety and efficacy results from Part I of MATINS study presented in poster at ASCO20 Virtual · Patient recruitment for Part II in multiple cohorts progressing well    Company announcement, 01 June 2020 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the safety and efficacy results from Part I of the MATINS trial have been presented in a poster at the virtual ASCO20 (American Society of Clinical Oncology) Annual Meeting.  Separately, the Company is also pleased to announce below an update on Part II of the MATINS trial. ASCO Poster Presentation The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of Clevegen (FP-1305), Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour associated macrophages (TAM), in selected metastatic or inoperable solid tumours. Data were presented on all 30 patients in Part I of the trial, who had advanced solid tumours and had exhausted all standard therapeutic options. The poster included previously announced data, reporting that ·Clevegen was well tolerated without dose-limiting toxicities; · CLEVER-1 inhibition led to immune cell activation and downregulation of several checkpoint molecules; · Interferon gamma and chemokine CXCL10 responses were associated with clinical responses observed in target or non-target lesions. The poster, Immune activation in fi­rst-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part 1 dose-escalation, safety and efficacy results, is available at the ASCO meeting library with identification code 3097. MATINS Trial Part II update Part II of the MATINS study has begun and the Company is pleased that patient recruitment continues to be strong, despite the COVID-19 pandemic. This Part II now contains cohorts of nine different cancers at 1.0 mg/kg dosing and three colorectal cancer (CRC) cohorts at 0.3, 1.0 and 3.0 mg/kg. Of these, the 0.3 mg/kg cohort has already recruited, with the additional two CRC cohorts expected to be recruited by mid-summer 2020. The Company intends to present data from these test cohorts (10 patients at each dosing levels) to the FDA at the end-of-phase II meeting to obtain advice ahead of expansion into the pivotal Part III stage of the trial. Dr. Petri Bono, the Principle Investigator of the MATINS study, said:  “The MATINS trial’s Part I results have shown a  tolerable safety profile for Clevegen, as well as exciting clinical activity in the target lesions of several terminal cancer patients. Clevegen represents a novel mechanism of action and this macrophage checkpoint inhibition has already, in Part I of the trial, shown clinical response in immunologically ‘cold’ tumours traditionally not responsive to currently available checkpoint inhibitors. I very much look forward to continuing patient enrolment for Part II of the trial, which is progressing well for the selected tumour types.” Dr. Markku Jalkanen, Faron's CEO, said: “Despite the study patients’ very advanced stage of disease and several lines of previous therapies, including PD-1 and CTLA-4 inhibitors, the early results from this dose finding stage of the MATINS study are very encouraging for single agent efficacy.” This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"). For more information please contact: Faron Pharmaceuticals Oy Dr Markku Jalkanen, Chief Executive Officer investor.relations@faron.com Panmure Gordon (UK) Limited, Nomad and Broker Emma Earl, Freddy Crossley (Corporate Finance) James Stearns (Corporate Broking) Phone: +44 207 886 2500 Sisu Partners Oy, Certified Adviser on Nasdaq First North Juha Karttunen, Jussi Majamaa Phone: +358 (0)40 555 4727 Consilium Strategic Communications Mary-Jane Elliott, David Daley, Lindsey Neville Phone: +44 (0)20 3709 5700 E-mail: faron@consilium-comms.com About the MATINS study The MATINS study is the first-in-human open label Phase I/II clinical trial with an adaptive design to investigate the safety and efficacy of Clevegen in selected metastatic or inoperable solid tumours. The selected tumours under investigation are cutaneous melanoma, hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancer, all known to host a significant number of Clever-1 positive tumour associated macrophages (TAM). All together these five target groups consist of approximately 2 million annual cases worldwide. Cancer patients with high Clever-1 expression are identified with a simple blood myeloid cell staining with Clevegen ("liquid biopsy").   Part I of the trial deals with tolerability, safety and dose escalation to optimize dosing. As the trial is an open label study, the Company expects to report findings as the dosing progresses. The cohort expansion during Part II will focus on identification of patients who show an increased number of Clever-1 positive circulating monocytes and the safety and efficacy of the treatment. Colorectal cancer and ovarian cancer have been selected as the first and second expansion cohorts in Part II. During Part III, the main focus will be on assessing the efficacy of Clevegen on study subjects who show an increased number of Clever-1 positive circulating monocytes, making the treatment precisely targeted and maximizing the chances of success for efficacy. The treatment, if successful, may ultimately be used as a standalone therapy or in combination with other immunotherapies like PD-1 inhibitors. About Faron Pharmaceuticals Ltd Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company’s pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine. Faron is based in Turku, Finland. Further information is available at www.faron.com Caution regarding forward looking statements Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should", "expect", "hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In particular, the early data from initial patients in the MATINS trial may not be replicated in larger patient numbers and the outcome of clinical trials may not be favourable or clinical trials over and above those currently planned may be required before the Company is able to apply for marketing approval for a product.  In addition,  other factors which could cause actual results to differ materially include the ability of the Company to successfully licence its programmes within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors.  Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

New CEO starts at Resurs - Nils Carlsson is focused on continued growth, data-driven innovation and customer experience

Resurs is the Nordic countries’ leading niche bank with extensive experience of developing flexible payment and financing solutions for retailers and their customers. The banking industry finds itself in rapid transition, with modernised customer behaviour and increased competition from new types of companies. Nils Carlsson believes that his background and experience of driving innovation and profitability will be important for Resurs to continue its journey of growth. “This is a special time to be taking on a new role, and it feels great to have started work. The industry is in the middle of rapid structural and technical changes, which makes my assignment particularly interesting. Competition in the industry is complex and places new requirements on us to be efficient, innovative and sustainable. I look forward to bringing my previous experience to the table and ensuring that Resurs is part of leading the development of the industry moving forward,” says Nils Carlsson, CEO, Resurs Bank. At the same time as developing Resurs’s commercial offering, Nils Carlsson points out the importance of continuing to build on Resurs’s employees and strengthen corporate culture with a focus on partners, customers and long-term sustainable business. “We have a fantastic network of strong partners and an extensive customer base in the Nordic market that is the basis of our business. We will continue to develop both of these aspects by remaining close to our partners and creating excellent customer experiences. In particular, our work with responsible credit lending is the foundation of a good customer experience and is also something that helps us take responsibility as a company and make an important contribution to a more sustainable society,” concludes Nils Carlsson. More information:Nils Carlsson, CEO, nils.carlsson@resurs.se +46 766 44 77 00 Press contact:press@resurs.se

Azelio business update - Continued progress and increased capital requirements due to Covid-19

Azelio has previously announced that Covid-19 will postpone the company's overall time plan by one quarter because of existing travel restrictions. At the same time, investments related to the start of production have been moved forward, which is why the company is now financed until December 2020 (earlier September 2020). Three months' delay is also expected to be valid until Azelio reaches positive cashflow, leading to an increased funding need of approximately SEK 75 million. Concretization of the increased need has emerged after evaluating the project's impact from the postponed time plan. As a result, Azelio's remaining financing needs are now estimated to be SEK 375 million compared to the previously stated SEK 300 million. Azelio is at an eventful and positive stage. The inauguration of the company's energy storage at the world-leading solar park Noor in Morocco has attracted considerable attention worldwide. This led to a large influx of interesting new opportunities from potential customers with relevant projects as well as potential partners. Commercial development continues with new Memorandums of Understanding. The latest is with VOGT, a leading supplier of pump systems in Latin America, including supply to the mining industry. The verification of the company's energy storage technology began as planned during Q1 2020. Due to COVID-19 and travel restrictions, the verification is initially focused on the installation at the company's development centre in Åmål, Sweden instead of the identical installation in Morocco, which was the original plan. The adjustments for COVID-19 have been implemented without the need to cancel any projects or lay off personnel. Azelio's storage technology can produce distributed electricity around the clock, completely without emissions and without the use of rare earth metals. The storage medium itself can be reused time and time again without lost capacity. The cost of Azelio's solution is very competitive in many applications. This applies not least as an alternative to diesel-powered generators that are used worldwide today for the approximately 3 billion people who do not have a reliable connection to an electricity grid. In accordance with previous communications, Azelio expects the first commercial installation in Q4 2020 and the start of serial production in Q3 2021. At the RISE research institute, controlled by the Swedish state, a life-cycle analysis of Azelio's technology is now underway to determine its environmental effects. The ongoing evaluation of utilizing the heat from the system shows commercially interesting results for this part as well. For more information, contactJonas Eklind – CEO at Azelio                       Email: jonas.eklind@azelio.com                  Tel: +46 709 40 35 80                                                                                                         This press release contains such information that Azelio AB (publ) is required to publish in accordance with the EU Market Abuse Regulation. The information was published for public disclosure on June 1st, 2020 at 08:00 CET through the agency of the contact person set out above.  About AzelioAzelio is a public Swedish company specialising in thermal energy storage with dispatchable and low-cost Stirling-based electricity and heat production. The technology is revolutionary for its unique capability to produce electricity and heat from the storage at 13 hours on nominal power. The system stores energy in recycled aluminium and has a total efficiency of up to 90 % from energy to heat and electricity. It is scalable and cost-efficient from 0,1 MW up to 100 MW and the storage suffers no reduced capacity over time. Azelio has over 150 employees, is headquartered in Gothenburg with production facilities in Uddevalla, development centres in Gothenburg and Åmål, as well as a presence in Stockholm, Beijing, Madrid, and Morocco. Since its establishment in 2008, the company has invested over SEK 1,5 billion in technical development. Azelio is listed on Nasdaq Stockholm First North. FNCA Sweden AB is the company’s certified adviser: +46(0)8-528 00 399, info@fnca.se. More about Azelio: www.azelio.com  

New analysis confirms that multiple myeloma patients in the OCEAN study stay on treatment longer than previously estimated - results expected H1-2021

OCEAN is a randomized, comparative study between melflufen and pomalidomide in patients with relapsed refractory multiple myeloma (RRMM). The patients enrolled in the study have previously been treated with at least an immunomodulator (IMiD) and a proteasome inhibitor (PI) and have all developed resistance to their last line of therapy and to lenalidomide (IMiD), the most commonly used drug for the treatment of multiple myeloma. The primary endpoint of the phase 3 study is Progression Free Survival (PFS). The results will be evaluated once 339 patients have progressed in their disease. “A recent analysis indicates that patients enrolled in the OCEAN-study continue treatment for a longer period of time than originally estimated, which speaks to the potential benefit patients can have by participating in this trial”, says Jakob Lindberg, CEO of Oncopeptides. “However, this most likely increases the time required to reach the number of disease progression events needed to complete the study. We will continue patient enrollment to enable an analysis of results within a reasonable timeframe.” Oncopeptides is preparing an application for accelerated approval in Q2 2020 based on the results from the ongoing pivotal phase 2 study HORIZON, evaluating melflufen in RRMM patients. Data from the pivotal phase 3 study OCEAN, will form the basis for a submission of a supplemental New Drug Application (sNDA) to the US FDA in H2 2021, followed by a submission of a Marketing Authorization Application (MAA) in Europe.  For more information, please contact:Jakob Lindberg, CEO of OncopeptidesE-mail: jakob.lindberg@oncopeptides.com  Telephone: +46 8 615 20 40 Rein Piir, Head of Investor Relations at OncopeptidesE-mail: rein.piir@oncopeptides.com  Cell phone: +46 70 853 72 92  The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person above, on June 1, 2020 at 08.00 (CET).  About melflufenMelflufen (melphalan flufenamide) is a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the increased intracellular alkylator concentration. Melflufen displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies. About OncopeptidesOncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen (melphalan flufenamide), a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides’ headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

NENT Group to restore Viaplay sports package pricing

· Viaplay sports packages revert to regular pricing from 1 July in Sweden, Denmark and Finland, with Norway to follow at a later date · Premier League to restart on 17 June, with Superliga, NASCAR, Bundesliga, UFC and several other sports already underway · NENT Group has rights to show more than 50,000 hours of the world's best live sporting action every year on its streaming services and TV channels Nordic Entertainment Group (NENT Group), the Nordic region’s leading streaming company, will revert to the regular pricing for its Viaplay sports packages in Sweden, Denmark and Finland from 1 July as a number of major global sports events restart. NENT Group temporarily reduced the prices of its Viaplay sports packages in March following the postponement of sports events due to the worldwide spread of the coronavirus. From 1 July, Viaplay’s sports packages will return to their previous monthly prices of SEK 399 in Sweden, DKK 309 in Denmark and EUR 29.99 in Finland. The monthly prices of Viaplay’s Total packages, which include series, films and sports, will also return to their previous levels of SEK 449 in Sweden, DKK 339 in Denmark and EUR 34.99 in Finland. Viaplay’s Total package in Norway will return to its regular price point at a later date. NENT Group launched a Viaplay Total package in Iceland on 15 May and the price of this offering remains unchanged at ISK 1,599 per month. Many of the major sports events or competitions to which NENT Group holds the rights have recently restarted or have announced their intention to do so. The Premier League will provisionally return on 17 June, while the Danish Superliga, Danish 1. Division and Germany's Frauen-Bundesliga have restarted in recent days. NASCAR began again on 17 May, Germany’s Bundesliga on 16 May and UFC on 10 May. IndyCar motorsport will resume on 6 June and PGA European Tour golf will tee off again in July, when Formula 1 is also expected to restart. NENT Group is restarting the expensing of sports rights as leagues and competitions recommence. Viaplay viewing levels have increased substantially in recent months, with limited churn amongst sports subscribers. The total number of streams started by non-sports subscribers on Viaplay across the Nordic region was up 42% between 1 April and 27 May compared with the same period in 2019, while sports subscribers started 40% more streams of non-sports content. The number of films bought or rented in the Viaplay Store was up 57% during this period compared with last year. Anders Jensen, NENT Group President and CEO: “Just like sports fans everywhere, we are delighted to see live sports returning to the screen, and we expect even more to follow in the coming weeks. The situation in recent months has been unprecedented, and our fast and proactive move in March to lower our sports prices was the right thing to do for customers. We were the first to do this and most others have followed suit. It has been fantastic to see how much our sports subscribers have enjoyed the full range of originals, films, series, documentaries and kids’ content on Viaplay. Fans can now look forward to watching even more live Premier League, Superliga and Bundesliga games, and much more, at the discounted price during June before we return to our normal pricing in July.” NENT Group has rights to show more than 50,000 hours of the world's best live sporting action every year on its streaming services and TV channels. The company's rights portfolio includes NHL and KHL ice hockey, UEFA Champions League and UEFA EURO 2020, Premier League, Bundesliga, Ligue 1, UEFA Europa League and UEFA Europa Conference League, Formula 1, IndyCar, NFL American football, boxing, UFC, tennis, basketball, handball and golf. NENT Group will also be the Nordic home of FIS winter sports from 2021. **** NOTES TO EDITORS Nordic Entertainment Group AB (publ) (NENT Group) is the Nordic region’s leading entertainment provider. We entertain millions of people every day with our streaming services, TV channels and radio stations, and our production companies create content that is experienced around the world. We make life more entertaining by telling stories, touching lives and expanding worlds – from live sports, movies and series to music and original shows. Headquartered in Stockholm, NENT Group is listed on Nasdaq Stockholm (‘NENT A’ and ‘NENT B’). Contact us:press@nentgroup.com (or Nicholas Smith, Acting Head of External Communications; +46 73 699 26 95)investors@nentgroup.com (or Stefan Lycke, Head of Investor Relations; +46 73 699 27 14) Download high-resolution photos: Flickr  Follow us:nentgroup.com  / Facebook  / Twitter  / LinkedIn  / Instagram  Privacy policy:To read NENT Group’s privacy policy, click here 

Caverion Industry is born – Finland's largest provider of industrial operation and maintenance services

Caverion Industry is born – Finland's largest provider of industrial operation and maintenance services Maintpartner's operations in Finland have been fully integrated into Caverion's Industrial Solutions division, which will simultaneously start to operate under a new name – Caverion Industry, as of today, 1 June 2020. The legal company name Caverion Industria Oy will remain. The transaction, in which Caverion acquired Maintpartner's operations in Finland, Estonia and Poland, was announced in March 2019 and approved by the competition authorities in November 2019. In Finland, the renewed Industry division employs 2,500 industrial professionals and experts responsible for the maintenance and operation of industrial plants throughout the country. "The integration process has been very smooth, and produced a lot of insight and views also to the field on how well both parties’ – Maintpartner and Caverion’s – services and expertise complement each other. We have also found synergies by merging our operations and offices. The personnel have been involved in the change with a positive mind-set and have been happy to get to know new colleagues”, says Elina Engman, Head of Caverion's Industry division.  “Our customers have also expressed their satisfaction and support for the fact that two strong, competent players will now become one unified, stronger and more versatile service provider. This simplifies their service procurement and makes it more manageable – even from the customer's point of view,” Engman continues. Caverion Industry’s services cover all phases of the industrial life cycle, from construction and projects at an industrial plant to many types of technical maintenance assignments. The development of maintenance and operation is supported by the latest IoT and AI-based as well as other digital solutions and strong development project expertise with even more traditional methods. In addition, there are 400 industry professionals and experts with a Maintpartner background in Poland. In Poland, the integration is underway and will be completed by the end of the year. In Estonia, Maintpartner's operations ended on 31 December 2019.

Scandinavian ChemoTech AB (publ) Interim report Q1 January – March 2020 Executive Summary of the first quarter

First quarter · Net sales amounted to  kSEK 90 (20) · Order intake amounted to kSEK 631 · The order book amounted to kSEK 1,125 at the end of the quarter · Profit before tax amounted to kSEK -3,464 (-2,579) · Earnings per share amounted to SEK -1.02  (-1.02) · Cash flow from operating activities totaled to kSEK -4,120 (- 3,711) Important events during the first quarter · Signed a loan agreement that secures financing of  MSEK 4 from shareholders and investors · Signed a collaboration agreement for clini-cal validation and distribution with Femaug Logistics and Services Ltd (FLS) in Nigeria · New Finance manager took office · Signed a service agreement with HealthCa-re Global Enterprises Ltd. (HCG) in India · Updated forecasts due to COVID-19 Important events after the end of the period · Carried out a new share issue with prefe-rential rights for the company’s existing shareholders. The rights issue was oversub-scribed and the oversubscription option was  exercised. More than MSEK 13 was ad-ded to the company before issuance costs · Signed a distribution agreement with and received order from Lee Imaging Ukraine LLC · Election of new Board of Directors SUMMARY ChemoTech had a successful beginning of 2020 with orders from Nigeria and increasing sales of treatment kits in India. The order intake totaled kSEK 631 and net sales amounted to kSEK 90 (20) for the period. The loss before taxes amounted to kSEK -3,464 (-2,579) and earnings per share totaled SEK -1.02 (-1.02). Several important collaboration, service and distribution agreements were concluded during the first quarter, most notably an agreement including both commercial validation and clinical development with the HCG Group, which operates more than 20 cancer hospitals in India. Furthermore, a collabo-ration agreement was concluded with Femaug Logistics and Services Ltd (FLS) in Nigeria regarding clinical validation and distribution. In the Animal Care business area, the new veterinary medicine product VetIQure™ for Dynamic Electroporation on animals showed promising results in its first clinical evaluation, which paves the way for future commercialization.  The COVID-19 situation impacted the operations, and thus the result, by forcing ChemoTech to cancel marketing activities and postpone deliveries and training of local doctors on how to perform electro-poration with the IQwave™ system. In response, a savings package was adopted, strengthening cash flow. Cash flow from operating activities amounted to kSEK -4,120 (-3,711). An MSEK 4 loan agreement was signed in January to ensure the continuity of financing. The CE mar-king process for IQwave™ proceeded, but was delayed by restricted opportunities for dialogue with the company’s Notified Body; due to the one-year postponement of MDR, Chemotech will continue to CE mark IQwave™ in accordance with MDD. After the end of the period, a new share issue with preferential rights for existing shareholders was carried out; the issue was over-subscribed and provided the company more than MSEK 13 before issuance costs. Chemotech also entered its first European distribution agreement, which included an initial order, with Lee Imaging Ukraine LLC. 

IFS launches MindFuel, a series of engaging online sessions curated by industry, to help businesses navigate the road ahead

 Society cannot adjust to a “new normal” without businesses evolving too. Each industry has its challenges and opportunities to innovate—making now the time for forward-thinking businesses to transform. MindFuel is a series of industry-specific sessions curated for the Construction; Defense; Energy, Utilities & Telecoms; Field Service; and Manufacturing industries. The series is for anyone looking to engage in panels, learn from peers, structure their thinking in workshops, and take inspiration from thought leaders. In a first wave, MindFuel attendees will be able to access C-level thought-leadership delivered by fellow companies from their industry, technology experts, leading industry analysts, and innovators. Visitors will also hear industry-specific predictions and advice on how to prosper ahead of an economic recovery. “The future is shaped by the way we chose to respond to challenges and our ability to use constraints as a springboard to build smarter solutions and business models,” IFS Chief Marketing Officer, Oliver Pilgerstorfer, said. “To create something positive in the current crisis, we saw the need to bring people and ideas together. MindFuel is the coming together of great minds, positive energy, and exciting ideas to build the future.” All MindFuel sessions are free to consume, and last between 10–60 minutes.Want to uncover new processes, technologies and work models to enable your organization to adapt and be more efficient? Visit mindfuel.ifs.com  and join the discussion.

OssDsign Announces Planned Change of Chief Executive Officer

Outgoing CEO Anders Lundqvist indicated to the Board earlier in the year that having reached the age of 65, he wished to retire from his role once an appropriate successor had been found. The search included multiple high-quality candidates from multiple geographies and following an exhaustive process Morten Henneveld, currently Senior Vice President, Business Transformation and Strategy and member of the Executive Leadership Team for GN Hearing,  a global leader in hearing aids, has been appointed to the role. He will take up his position on 1[st] September 2020.  Chairman Simon Cartmell OBE commented: ‘Anders Lundqvist has overseen an extraordinary period of development for OssDsign. He led the private placement and IPO last year, has driven consecutive quarterly growth in line with our targets, has expanded our market presence with approvals and reimbursement in France and Japan in the past 12 months and has managed the planned transition from a master distributor to OssDsign USA Inc. He has delivered all we planned to do in 2019 and 2020 and is leaving with our thanks and best wishes for his retirement’. In response, Lundqvist replied: ‘it has been my privilege to lead OssDsign these past 6 years and I am delighted to hand over the leadership to someone as well suited to the role as Morten Henneveld. The company under his direction is posed for exciting growth ahead and I wish him and the team at OssDsign all the best for the future’. Newly appointed CEO Morten Henneveld has extensive international and medical device experience having worked as Director, Commercial Excellence for Coloplast during 2008-2012, including a period working in the USA, and then, based in Malmo, working as Managing Director, Sweden and Regional Vice President, Nordics for Biomet and subsequently Vice President, EMEA Spine for Zimmer Biomet from 2012-2016.  He said: ‘OssDsign has great technology and a substantial global sales presence. The company is well positioned for sustained growth and I look forward to using my orthopaedic and commercial experience, and together with the OssDsign organization, lead the delivery of our targets over the coming years’.  For further information, please contact:Anders Lundqvist, CEO, OssDsign ABTel: +46 73 206 98 08Email: al@ossdsign.com Certified Adviser:Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se. About OssDsignOssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

Scania plans major staff reductions

The support packages for short time work that the company, governments, unions and employees together have contributed to have helped reduce the impact and the scope of these staff  reductions in the longer term.  Scania’s union representative on the Board of Directors and the Executive Board share a common view of the situation caused by the crisis and are working together in identifying solutions for cost savings, without ruling out staff redundancies. There is also agreement on the need for acquiring new skills and competencies to meet the transition to new technologies and new business models. “The Coronovirus crisis forces us to reduce our activity level and that means we estimate we have 5,000 more staff globally than needed. This includes a review of up to 1,000 white-collar positions at our Head Office in Södertälje,” says Scania’s President and CEO Henrik Henriksson. “Our assessment is that it will take long before market demand reaches pre-crisis levels and we therefore need to adapt the organisation to the new situation already this year. These will be company-wide measures and formal notices of redundancies are not excluded. The measures also include parts of Scania that normally are not impacted by short term  changes in production volume.” “For employees in production we already have the instruments to deal with short-term variations in demand, such as our time bank and temporary employment as well as a way of working that continuously generates gains in efficiency. Thanks to these tools, we estimate that we will be able to handle possible staff reductions through our normal processes,” says Michael Lyngsie, employee representative on the Board of Directors. Since global market demand in the foreseeable future is expected to be lower, there is an excess of staff in the global sales and service organisation. The lower level of activity in the company also affects several parts of the Head Office organisation, including research and development. To reach the overall needed and substantial cost savings during 2020 and 2021, the executive management is working together with the union representatives on different cost reduction measures, where reducing the number of consultants is one.  “As always at Scania, we will strive to minimise the effects for our employees, also in these difficult times. Among the white-collar unions, we fully advocate the continued disengagement of consultants,” explains Lisa Lorentzon, employee representative on the Board of Directors. “This requires transferring needed competence and skills to Scania’s permanent staff - which is part of our local collective agreement - in order to secure the company’s long-term survival.” The management and unions will now initiate discussions to oversee the staffing situation at the organisational level.  

Former President of Eli Lilly Research Labs and Head of R&D Dr. Jan Lundberg invests in Sigrid Therapeutics and joins the Company’s Scientific Advisory Board

Dr. Jan Lundberg has more than 20 years of leadership experience from executive positions in the global pharmaceutical companies AstraZeneca (1996-2009) and Eli Lilly (2010-2018). He has overseen the development of more than 200 candidate drugs, with 25 approved products across multiple therapeutic areas. Before joining AstraZeneca, Dr. Lundberg held the position of Professor of Pharmacology at the Karolinska Institute in Solna, Sweden. His research achievements led to the publication of 500 articles in peer reviewed scientific journals. “Sigrid has developed a very promising technology with the potential to improve the lives of millions of people suffering from obesity and at risk of developing type 2 diabetes. I am excited to join the Company at this stage of development and look forward to contributing to the team’s continued success”, says Dr. Jan Lundberg. “We are absolutely delighted to welcome Dr. Jan Lundberg as an investor and member of Sigrid’s Scientific Advisory Board”, says Sana Alajmovic, Co-founder & CEO, Sigrid Therapeutics. “Dr. Lundberg’s vast R&D and business experience will be invaluable in advancing our first product to market within the next 2 years. In addition to his considerable Big Pharma experience, Dr. Lundberg serves on the boards of Ardelyx, Metabolon, TB Alliance, Imaging Analysis Group, Anocca and Betagenon. He has also been a member of several governmental committees in both the European Union and the United States. For more information, please contact: Sana Alajmovic, Co-Founder & CEO, Sigrid Therapeutics Phone +46 72 389 3396, Email: sana@sigridthx.com. About Sigrid Therapeutics Sigrid Therapeutics (Sigrid) is a clinical-stage technology startup pioneering a new class of engineered materials to prevent and treat metabolic disease and disorders, including type 2 diabetes. The Company’s lead product candidate, SiPore15[TM], is an orally-administered medical device based on the Company’s proprietary platform technology, SiPore15[TM]. Designed to act locally in the gut, SiPore15[TM], consists of precisely engineered micron-sized silica particles with tailored porosity. Clinical data confirms SiPore15[TM:]’s beneficial effects on a range of metabolic parameters and its excellent safety profile. Upon its approval, SiPore15[TM] will be the first medical device available for reduction of blood sugar levels in people at risk of developing type 2 diabetes. https://www.sigridthx.com/.

Nordic Waterproofing has signed an agreement to acquire 25% of the shares in Playgreen Finland Oy, a company offering sales and installations of solar energy solutions

Playgreen Finland Oy was founded in 2010 in Porvoo, Finland, and has for 10 years supported their customers to design, select and install solar PV powerplants. The company offers environmentally friendly tailor-made renewable energy solutions to their customers to be installed on public buildings, industries, farms or private houses. Customers throughout Finland are provided with a range of high-quality solar panel solutions tailored for their specific needs. Playgreen Finland Oy also has the capacity to design and install charging stations for electric cars. The company does not have its own production, the office is located in Helsinki.  “Within Nordic Waterproofing we are very pleased to get the opportunity to do this acquisition. Playgreen Finland Oy has a very interesting position in the rapidly growing solar panel market and we can see good synergies with our existing businesses in Finland, in both Products & Solutions and in Installation Services”, says Martin Ellis, President and CEO of Nordic Waterproofing. “Through this initial investment in Playgreen Finland Oy, Nordic Waterproofing demonstrates and enhances its commitment towards sustainable and environmentally efficient solutions for the building industry”. "Playgreen Finland Oy has for several years grown rapidly and this is a natural step to increase the speed of the development of the company", says Jouni Penttinen, CEO of Playgreen Finland Oy. "We are pleased to get a strong owner with a long-term focus and good understanding of our business, and we see great potential for synergies, primarily in marketing and market expansion but also in installation services and solution development", Jouni continues. Nordic Waterproofing Holding A/S’s Finnish subsidiary, Nordic Waterproofing Oy, has signed an agreement to acquire 25 percent of the shares in Playgreen Finland Oy for a total of EUR 120,000, corresponding to a consideration of SEK 1.3 m. The signing and closing occurred simultaneously. The acquisition will be financed within Nordic Waterproofing’s current credit facilities. Furthermore, Nordic Waterproofing has an option to within two years acquire an additional 55% of the shares in the company. Acquisition-related costs amount to less than SEK 1 m in the form of consulting fees in connection with the acquisition process and will affect the income statement during the second quarter of 2020. The acquisition is expected to have a minor positive effect on Nordic Waterproofing's earnings per share in 2020. This information was submitted for publication, through the contact person set out below, on 1 June 2020, at 12.00 p.m. CEST.

SSAB, LKAB and Vattenfall one step closer to production of fossil-free steel on an industrial scale

SSAB, LKAB and Vattenfall are taking the next important step to be the first in the world with a value chain for fossil-free steel. Within the framework of the HYBRIT initiative, preparations are now under way for the construction of a demonstration plant on an industrial scale, and consultations have  begun for deciding on placement of the plant in Norrbotten, Sweden. The plan is for construction to start in 2023, with the goal of taking the plant into operation in 2025.  The intention is to be able to demonstrate full-scale production with a capacity of just over one million metric tonnes of iron per year, i.e., 20% of LKAB’s total processing capacity at Malmberget and almost half of the production capacity of SSAB’s blast furnace in Luleå. The goal is to be first in the world to produce fossil-free steel as early as 2026. HYBRIT is now starting an investigation into the selection of a location for the demonstration plant. Parallel consultations are being launched at two sites in Sweden: the Vitåfors industrial estate in Gällivare Municipality, where LKAB has mining operations, and the Svartön industrial estate in Luleå, where facilities including SSAB’s steel mill and LKAB’s ore port are located. The purpose is to consult and conduct an open dialog about the location and design of the plant ahead of the upcoming selection of the site and permit application. Consultation with government agencies, organizations and the public will begin in June and conclude in September 2020. The choice of location will have a major impact on future competitiveness and climate benefits. Investment decisions will be made once the authorization procedure and other investigations have been completed. “We want to build the plant in Norrbotten. There’s good access to fossil-free electricity and competence here, as well as close collaboration with academia and the community. A demonstration plant for fossil-free iron production would also be positive for growth and jobs in the region, as well as contributing to a major climate benefit,” says Martin Pei, Chief Technical Officer at SSAB and Chairman of HYBRIT. “For LKAB, HYBRIT is an important piece of the jigsaw puzzle in a green transition, in which we want to climate-optimize the whole chain from mine to finished steel by the year 2045. We want Norrbotten to be a world-leading arena for innovation and a center of knowledge for the global mining and minerals sector,” says Markus Petäjäniemi, Senior Vice President Market and Technology at LKAB. “It’s very positive that Vattenfall, together with our partners, is continuing to take clear steps forward with HYBRIT. Electrification with fossil-free electricity and hydrogen means that fossil-free steel will be making a very important contribution to our fossil-free future,” says Andreas Regnell, Senior Vice President Strategic Development at Vattenfall. HYBRIT’s pilot phase will run in parallel with the demonstration phase. In Luleå, the pilot plant for fossil-free steel will be fully constructed during the summer, and preparations are also under way to initiate construction of a temporary hydrogen store in order to test the technology for storing hydrogen in caverns.  About HYBRITHybrit Development is a joint venture between the steel manufacturer SSAB, the mining company LKAB and the energy company Vattenfall. The objective of the joint-venture is to develop the world’s first fossil-free, ore-based steelmaking process. The byproduct of using fossil-free electricity and hydrogen in steelmaking, instead of coke and coal, will be water instead of carbon dioxide. The initiative has the potential to reduce Sweden’s total carbon dioxide emissions by 10 percent. The HYBRIT initiative has been granted financial support from the Swedish Energy Agency. www.hybritdevelopment.com   FOR PRESS INFORMATION Mia WidellPress manager, SSABmia.widell@ssab.com+46 76 5272501 Magnus KryssarePress secretary, Vattenfallmagnus.kryssare@vattenfall.com+46 76 769 56 07 Fredrik BjörkenwallActing Press manager, LKABFredrik.bjorkenwall@lkab.com+46 980 715 44

Organizational update - New board member and new CFO

Kirsti Gjellan is new board member of OxThera as of 19 May 2020. “It is my pleasure to welcome Kirsti to the board of OxThera”, said Dr. Georges Gemayel, Chairman of Oxthera. “Her deep biologic manufacturing experience and successful track record of business leadership over her career will be of important value to Oxthera in its development of Oxabact for treating Primary hyperoxaluria.” “I am honored to join OxThera”, says Kirsti Gjellan. “I believe the company is poised to make a real difference in patients suffering from this devastating rare disease. I am excited to share my insights with the OxThera Board and its management team to help the company deliver on the promise of this new therapy.” Kirsti has a PhD in Pharmaceutical Technology with over 30 years of experience culminating with senior executive roles in, Development, Quality and Manufacturing at Astra Zeneca, Pfizer and most recently at Sobi where she led global biologics manufacturing and development operations.  Kirsti is also a member of the board of directors at Bio-Works Technologies AB. Mats-Olof Wallin has been appointed new CFO of OxThera as of 1 June 2020. Former CFO Hugo Petit will leave the company for a new assignment outside OxThera. “I am very pleased that Mats-Olof has joined the company. He has a long and successful track record as CFO from several listed companies in the life science sector.” said Matthew Gantz. “I would also like to thank Hugo Petit for his contributions and hard work in developing OxThera and wish him the best of luck in his future endeavors” said Matthew Gantz. Mats-Olof has previously been CFO in several listed companies such as Karo Pharma, Sobi and Biotage.

Calliditas Therapeutics launches US IPO roadshow and targets a capital raise of MUSD 75

Stockholm, June 1, 2020 - Calliditas Therapeutics AB (publ) (“Calliditas”) announces that it has today filed an updated preliminary prospectus with the U.S. Securities and Exchange Commission (the “SEC”) and will commence an investor roadshow for a global offering with a target size of MUSD 75 in gross proceeds, plus a potential over-allotment of 15 percent. Copies of the updated preliminary prospectus related to the contemplated initial public offering in the United States (the “U.S. Offering”, and together with the concurrent private placement, the “Global Offering”) are available at www.sec.gov. An application to list the American Depositary Shares (“ADSs”) on The Nasdaq Global Market, under the symbol “CALT”, has been submitted. Calliditas will announce the outcome of the Global Offering after pricing in a subsequent press release, however, any further details regarding the offering remain subject to market conditions and investor demand and the offering may not be consummated. Calliditas’ common shares are currently listed on Nasdaq Stockholm under the symbol “CALTX” and Calliditas intends to maintain the listing on Nasdaq Stockholm. The filing of the preliminary prospectus in the United States with the SEC has no implications for Calliditas’ listing on Nasdaq Stockholm in Sweden. This company announcement does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A registration statement relating to the ADSs referred to herein has been filed with the SEC, but has not yet been declared effective. These ADSs may not be sold, nor may offers to buy these ADSs be accepted prior to the time such registration statement becomes effective. Citigroup Global Markets Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated are acting as the global coordinators and joint book-running managers of the Global Offering. Carnegie Investment Bank AB is acting as co-manager of the Global Offering. Citigroup Global Markets Inc. and Jefferies LLC are acting as representatives of the underwriters in the U.S. Offering. Citigroup Global Markets Limited and Jefferies International Limited are acting as representatives of the underwriters in the concurrent private placement. Copies of the preliminary prospectus relating to the U.S. Offering may be obtained from Citigroup Global Markets Inc., Attention: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at +1 (800) 831-9146; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, via telephone: +1 877-821-7388 or via email: Prospectus_Department@Jefferies.com or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at +1 (415) 364-2720 or by email at syndprospectus@stifel.com. For further information, please contact: Renée Aguiar-Lucander, CEO at Calliditas Tel.: +46 722 52 10 06, e-mail: renee.lucander@calliditas.com Mikael Widell, Head of Communications and IR Tel.: +46 703 11 99 60, e-mail: mikael.widell@calliditas.com The information in the press release is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on June 1, 2020 at 13:00 (CEST). About Calliditas Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX). Important information No announcements or information regarding the proposed initial public offering may be disseminated to the public in jurisdictions where a prior registration or approval is required for such purpose. No steps have been taken, or will be taken, for the offering of common shares or ADSs in any jurisdiction where such steps would be required. The issue or sale of common shares or ADSs, and the subscription for or purchase of common shares or ADSs, are subject to special legal or statutory restrictions in certain jurisdictions. Calliditas is not liable if these restrictions are not complied with by any other person. This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. Calliditas has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection therewith. In any EEA member state, this communication is only addressed to and is only directed at qualified investors in that member state within the meaning of the Prospectus Regulation. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it. Safe Harbor/Forward-Looking Statements This announcement contains forward-looking statements, including with respect to the timing and terms of the Global Offering described herein and the company’s use of the net proceeds therefrom. These statements are based on expectations in light of the information that is currently available, as well as assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from such statements. These risks and uncertainties include, but are not limited to, domestic and international economic conditions, industry and market conditions, and changes of interest rate and currency exchange rate, in general, and completion and discontinuation of clinical trials, obtaining regulatory approvals, claims and concerns about product safety and efficacy, technological advances, domestic and foreign healthcare reforms, and changes of laws and regulations, in particular, with respect to Nefecon. Calliditas disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. This announcement contains information on pharmaceuticals (including pharmaceuticals under development) but is not intended to, and does not, make any representations, warranties or claims regarding the efficacy or effectiveness of these pharmaceuticals or provide medical advice of any kind.

Alligator Bioscience’s collaboration with Biotheus Inc. proceeds and second payment is received

Lund, Sweden, June 1, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the company received an additional USD 0.5 million in a second installment of the upfront payment from the Chinese company Biotheus Inc. A first installment of USD 0.5 million was received in August 2019 in connection with Alligator entering into a licensing agreement with Biotheus with a total value up to USD 142 million. The agreement concerns the Chinese rights to an immune-activating antibody from the antibody library ALLIGATOR-GOLD[®], with the intention of creating up to three new bispecific molecules. ”It is very gratifying that Biotheus has chosen to continue the collaboration after conducting a thorough scientific and technical evaluation of our antibody. It serves as an additional validation of our antibody library and of our capacity to develop immune-activating antibodies, while giving Alligator further presence in the important Chinese pharmaceutical market,” said Per Norlén, CEO Alligator Bioscience. The license agreement includes exclusive rights to an immune-activating antibody directed to a receptor within the Tumor Necrosis Factor Receptor-superfamily (TNFR-SF), a collective name for a number of target molecules with similar functions, and applies to the China, Hong Kong, Taiwan and Macau markets. In addition to the received upfront payment totaling USD 1 million, the license agreement gives Alligator the right to receive additional milestones and option fees at a potential total value of up to USD 141 million, as well as royalties on future sales and share of any sub-license revenue. For further information, please contact:Cecilia Hofvander, Director Investor Relations & CommunicationsPhone +46 46 540 82 06E-mail: cecilia.hofvander@alligatorbioscience.com This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 1:30 p.m. CEST on June 1, 2020. About Alligator BioscienceAlligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes five lead clinical and preclinical drug candidates: mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com. About Biotheus Inc.Biotheus is a fast-growing biotechnology company based in Zhuhai, Guangdong, China focusing on the development of the next generation of antibody-based cancer treatments. Biotheus' management team has broad experience in everything from discovery research to regulatory applications in China. Biotheus has a broad project portfolio focusing on immuno-oncology with the aim to develop their leading candidate drugs towards market approval. Biotheus is actively looking for clinical development and commercialization partners to fulfill these aims.

SBB updates its Green Financing Framework, eligible for green financing instruments totalling approximately SEK 10bn

Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) updates its green financing framework in order to be able to issue green financing instruments, currently totalling SEK 10bn. The green financing framework has been subject to an independent external assessment by the Center for International Climate and Environmental Research in Oslo, Norway (CICERO). “Sustainability is a central part of our business model and the updated green financing  framework will support our Sustainability Vision 2030 with the target to become 100 per cent climate neutral in 2030,” comments Ilija Batljan, CEO and Founder of Samhällsbyggnadsbolaget i Norden AB. SBB’s green financing framework is in line with the so-called Green Bond Principles, which have been developed by the International Capital Market Association (ICMA). SBB has commissioned and received an independent valuation by CICERO of the green financing framework and associated steering documents and routines for assessing the environmental impact of the projects. In light of their assessment of project types, steering documents goals and reporting standards, SBB’s green financing framework has received a “Medium Green” assessment by CICERO. SBB has worked with Citi to develop the green financing framework. For further information, please contact: Marika Dimming, IR and Head of Sustainability, +46 70 251 6689, marika@sbbnorden.se

Paradox Interactive Founds New Studio in Barcelona

STOCKHOLM - June 1, 2020 - Paradox Interactive, a publisher and developer of games that age well, today announced the opening of Paradox Tinto, a new development studio to be located in Barcelona. This is the seventh studio operated by Paradox Interactive, now present in four countries.  Paradox Tinto will start operations in Barcelona in the immediate future under the direction of studio lead Johan Andersson, 25+ year veteran of Paradox Development Studio and original creator of the Europa Universalis video game franchise. Andersson will assemble a small core team to initially oversee ongoing development on Paradox’s iconic grand strategy game, Europa Universalis IV, and later move on to new games in the grand strategy genre. Jobs are now available at Paradox Tinto, with details available on the Paradox website at https://career.paradoxplaza.com/jobs. “People love our games and we love the fact that we are growing to create more for them, we’re particularly pleased to expand for the first time with a new studio focusing on the core game genre we’re famous for: grand strategy,” said Charlotta Nilsson, Chief Operations Officer at Paradox Interactive. “The success of our studios over the last few years has allowed us to continually add more capabilities and new ideas, with more games going into active development and more ambitious plans every day. We currently have around 70 open positions across our seven studios, with plans to recruit roughly 200 people in 2020 alone.” “I am excited and grateful for this opportunity to build up a new studio in a new location, putting the knowledge accumulated through the decades of building games and development studios into good use,” said Johan Andersson, Studio Manager at Paradox Tinto. “My goal is to assemble a team and create a fully functional studio to keep on developing the Europa Universalis brand, and later design and develop new grand strategy games.” The new studio joins the growing Paradox roster, which also includes Paradox Development Studio in Stockholm; Paradox Arctic in Umeå, Sweden; the Paradox development team in Malmö, Sweden; Paradox Tectonic in Berkeley, California; Triumph Studios in Delft, The Netherlands; and Harebrained Schemes in Seattle.

EIA program of the Päiväneva mine and concentrator site submitted to the coordinating authority

Keliber has prepared the environmental impact assessment (EIA) for the expansion of its lithium mine site and has submitted the EIA to the Center for Economic Development, Transport and the Environment of Southern Ostrobothnia for official review on May 29, 2020 as part of the assessment. The EIA program involves assessment on the options for the implementation of mines and concentrator and the impact of the different options. The current state of the area's environment and the impacts of future activities on the environment, soil and bedrock, surface and groundwater, flora and fauna are reviewed during the EIA process. The effects on the landscape, land use and community structure of the area are also investigated. Keliber is also preparing an update on the Natura 2000 assessment which was carried out in 2017. “The environmental impact of operations plays an important role in our decision to locate the concentrator in the main mining area, and in addition this move will improve the cost efficiency and return on investment. I would like to thank all who are working on the EIA on their contribution to the process. Together, we will ensure that the impacts are carefully considered and that the EIA process is taken forward on schedule,” says Hannu Hautala, President and CEO. For more information, please contact: Kari Wiikinkoski, Environmental Manager tel. +358 50 3753204 Hannu Hautala, President and CEO, tel. +358 40 712 2432

Össur hf: Össur closes acquisition of College Park Industries

1 June 2020 Össur closes acquisition of College Park Industries As previously announced, Össur signed an agreement to acquire College Park Industries in July 2019 and the acquisition was approved by the Federal Trade Commission (FTC) in April 2020. The transaction has now been officially closed and College Park is now wholly owned by Össur. As part of the transaction, the Espire Elbow line has been acquired by UK-based Steeper Group. College Park’s pro-forma FY2019 sales excluding the Espire sales amount to approximately USD 20 million. College Park is a global provider of prosthetic devices and supporting services headquartered in Michigan, USA. As previously communicated, College Park will largely remain independent and continue to diligently serve its customer base, while allowing the combined entity to achieve strategic efficiencies. Össur remains committed to growing the College Park brand globally over the coming years. The acquisition is yet another display of Össur’s commitment to elevate customer experience and improving people’s mobility. Further information David Hreidarsson, Investor Relations Manager, dhreidarsson@ossur.com, +354 661 8225 Helga Danielsdottir, Investor Relations Analyst, hdanielsdottir@ossur.com, +354 766 4959 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail please register at http://www.ossur.com/investors About Össur  Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. A recognized “Technology Pioneer,” Össur focuses on improving people’s mobility through the delivery of innovative technologies in Prosthetics and Bracing & Supports, by investing significantly in research and product development to create award-winning designs with consistently strong market positions. Successful patient and clinical outcomes are further empowered via Össur’s educational programs and business solutions.  As part of Össur’s long-standing commitment to social responsibility, the company has been a signatory to the United Nations Global Compact since 2011 and participates in the Nasdaq Nordic and Baltic exchanges’ voluntary guidelines for Environment, Social and Corporate Governance (ESG). Össur is headquartered in Iceland, with major operations in the Americas, Europe and Asia, and additional distributors worldwide. www.ossur.com About College Park Industries College Park Industries is an established global provider of broad and competitive prosthetic solutions. It has been well recognized for providing a varied portfolio of prosthetic feet, with the Truestep and Odyssey lines becoming frequent solutions clinicians reach out for. With its 2015 acquisition of Liberating Technologies, College Park ventured into the upper limb arena with its first bionic product – the Espire Elbow launched in April 2019. College Park is the 2018 recipient of the Hanger Service Excellence Award, a demonstration of its continued commitment to deliver unsurpassed customer service alongside competitive products. To learn more, visit www.collegeparkindustries.com  

The Nomination Committee's proposal for the Board of Directors and adjusted proposal for the Annual General Meeting 2020

In the notice of the Annual General Meeting of Brighter AB (publ) published on May 13, 2020, the Nomination Committee announced that it would get back with a proposal for the election of Board members. The Nomination Committee's proposal is presented below. The shareholder Recall Capital Nordic AB has also requested an adjustment of the proposed incentive program for the Board of Directors, which is described in full on Brighter's website https://brighter.se/. The Nomination Committee's proposalsThe Nomination Committee proposes that Truls Sjöstedt, Jan Stålemark, Emanuel Lipschütz and Tove Andersson is re-elected. Peter Sibirzeff and Anna Bernsten are proposed to be elected as new Directors of the Board. Truls Sjöstedt is proposed as Chairman of the Board. Anna BernstenAnna Bernsten is a professional board director with more than 25 years of operational experience in international business development, strategy, management and branding in lifescience. Anna has previously worked with companies such as GE Healthcare and ASSA Abloy and has served on the Board of, among others, Oatly, Fagerhult, Nolato, Arcam, Björn Axén, Pågen, Medivir, Probi, Moberg Pharma and CellaVision. Peter SibirzeffPeter Sibirzeff is a proven business leader with extensive international experience from the banking and finance industry, FinTech companies and HealthTech companies. Peter is currently Director of the American data visualization company 3Forge and has previously held leading roles in, among others, Orc Software, Alphacet and Jiway (Morgan Stanley/OMX joint venture). Adjustment of the proposed incentive program for the Board of DirectorsThe shareholder Recall Capital Nordic AB (the "Shareholder") has proposed that the Annual General Meeting 2020 in Brighter AB (publ) ("Brighter") shall decide on an incentive program for the Board of Directors of Brighter ("the Board program"). According to the original proposal, a maximum of 995 181 so-called performance share rights could be allocated to participants in the program, and in total, the proposal meant that a maximum of 1,307,866 warrants could be issued to secure allotment and costs as a result of the program, corresponding to 0.66 percent of the number of shares and votes in Brighter. The shareholder has requested that the proposal for the Board program should be amended so that the number of Performance Share Rights that can be allocated to the participants is increased to a maximum of 1,540,000 and that a maximum of 2,023,868 warrants can be issued to secure allotment and costs as a result of the program, which corresponds to 1.01 percent of the number of shares and votes in Brighter. According to the Shareholder's amended proposal, a maximum of 440,000 of the warrants can be allocated to the Chairman of the Board (formerly 497,591) and a maximum of 220,000 of the warrants may be allocated to each ordinary Board member (formerly 99,518). For further information, please contact: Truls Sjöstedt, Executive Chairperson+46 729 99 38 60 truls.sjostedt@brighter.se Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se. About Brighter AB (publ)Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.

Oncoinvent Announces Dosing of First Patient with Radspherin[® ]in Phase 1 Clinical Trial

Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that the first patient has been dosed in the phase 1, first-in-human clinical trial of it’s lead candidate compound Radspherin[®]. “Radspherin[®] represents a promising new approach for treating patients with metastates to the peritoneal cavity from colorectal cancer that may potentially provide a better outcome with longer progression free survival for patients that undergo cytoreductive surgery together with hypertherm intraperitoneal chemotherapy,” said Stein Gunnar Larsen, M.D., Section Leader Department of Surgical Oncology, Oslo University Hospital, Norway and lead clinical investigator in the trial. “We are always looking for opportunities to improve patient outcomes and give patients a better quality of life. Radspherin[®] has demonstrated preclinical activity in a range of cancer models, and we are excited to further investigate it in this Phase 1 study.” “Radspherin[®] is a potentially transformative approach for a range of difficult-to-treat metastatic cancers,” said Øyvind S. Bruland, M.D., Chief Medical Officer of Oncoinvent. “The mode of action of Radspherin[®] is to deliver a lethal dose of short range alpha radiation to remaining tumour cells in the peritoneum after surgery. Radium-224 emits alpha particles with high linear energy transfer (LET). There are no known cellular resistance mechanisms to this type of ionizing radiation, which may therefore be effective against dormant and chemo-resistant cancer cells remaining after surgical resection of macroscopic visible tumours and thereby increase the prospect of a complete response. We believe it could provide a profound benefit for patients that are in dire need of new therapies.” About the Study The phase 1 open-label, dose-escalation clinical trial is designed to assess the dose, safety and tolerability of Radspherin[®], an α-emitting radionuclide therapy, administered into the intraperitoneal cavity in subjects with peritoneal carcinomatosis from colorectal carcinoma following complete cytoreductive surgery and HIPEC.  Key objectives in the study include determining maximum tolerated dose, abdominal biodistribution, and preliminary anti-tumor activity. Please refer to www.clinicaltrials.gov for additional clinical trial details.

BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL

Bergen, Norway – 02 June 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that dosing has commenced in the UK Government-backed Phase II clinical trial assessing bemcentinib in hospitalised COVID-19 patients. Bemcentinib was selected as the first candidate to be tested as part of the ACcelerating COVID-19 Research & Development platform (ACCORD) study, launched by the Department of Health and Social Care (DHSC) and UK Research and Innovation (UKRI) on 28[th] April 2020.  ACCORD brings together a single, UK-wide clinical trial platform to rapidly test potential drugs through early stage clinical trials and feed them into the UK's large-scale COVID-19 studies. The first patient has been dosed with bemcentinib at the University Hospital Southampton NHS Foundation Trust. The study is open in a further seven sites across the UK. The Phase II study will recruit 120 subjects in total, assessing the safety and efficacy of bemcentinib as an add‑on therapy to standard of care (SoC) in 60 hospitalised COVID-19 patients with a further 60 control group patients receiving SoC.   BerGenBio anticipates that top line data will readout later in the summer. Data will be open source and freely available to enable global knowledge sharing and collaboration. If positive results are seen, bemcentinib will advance rapidly into the large-scale Phase III trials in the UK. The study is fully funded by the DHSC and UKRI and is being managed by clinical research company IQVIA. Drug material and other trial resources will be provided by BerGenBio.   Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are delighted that dosing has commenced with bemcentinib in the ground-breaking ACCORD study and we hope that patients will swiftly start to see benefits. Initiating this clinical trial in such short order is the result of tremendous teamwork between my colleagues at BerGenBio and the teams at IQVIA and UHS, among many others. This illustrates exactly what can be achieved when we all work together and focus on delivering the best experimental drug candidates to patients that so urgently need them.  We look forward to providing results as soon as is practically possible and very much hope our drug can fulfil the aims of the study and be used to treat thousands of COVID-19 patients worldwide.” Professor Tom Wilkinson, ACCORD clinical academic lead based at the National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, said: “The ACCORD platform is allowing us to rapidly test potential new treatments in response to the COVID-19 emergency. This unique national platform for developing COVID-19 drug candidates will access the world-class expertise and resources of the NIHR Respiratory Translational Research Collaboration and allied centres nationwide. We believe this programme will be key to developing effective new treatments and are delighted to see the first candidate, bemcentinib, enter the clinic today.” About BerGenBio BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers and COVID-19 infections. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to identify those patient populations most likely to benefit from bemcentinib or tilvestamab: this is expected to facilitate more efficient registration trials and support a precision medicine-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com For more information, please contact Richard Godfrey CEO, BerGenBio ASA+47 917 86 304 Rune Skeie, CFO, BerGenBio ASArune.skeie@bergenbio.com+47 917 86 513 International Media Relations Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs Consilium Strategic Communications bergenbio@consilium-comms.com +44 7780 600290 Media Relations in Norway Jan Petter Stiff, Crux Advisersstiff@crux.no+47 995 13 891 Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Seadrill Limited (SDRL) - First Quarter 2020 Results

Highlights ·Revenue down 19% at $321 million with lower proportion of reimbursable revenues ·Technical utilization of 95% and economic utilization of 93% ·Operating Loss of $1,284 million after making material asset impairments ·Adjusted EBITDA of $55 million, representing 17.1% margin ·Net loss attributable to shareholder of $1,564 million equivalent to net loss per share of $15.59 ·During the quarter we added $77 million in backlog, maintaining a total backlog figure of $2.5 billion ·Closing cash of $1.2 billion   Subsequent Events ·Significant market challenges arising from the sharp decline in the oil price ·Additional operational and logistic challenges arising through COVID-19 pandemic restrictions  ·Financial and legal advisors appointed to evaluate comprehensive restructuring alternatives to reduce debt service costs and overall indebtedness ·Announced on June 1, 2020, decision to delist from NYSE and maintain a single listing on the Oslo Stock Exchange   Anton Dibowitz, President and CEO, commented: "First and foremost, we need to recognize the way in which the whole Seadrill community has risen to the operational and logistical challenges arising because of COVID-19. We have continued our record of strong operational delivery in the quarter, working across 28 locations with over 4,000 employees from 57 different countries. Whilst our onshore personnel get used to a new mode of working, we have many offshore personnel whose continuous time working to maintain safe operations for our customers is now measured in terms of months rather than weeks. I continue to be humbled by the dedication of our people who deliver safe and efficient operations during this trying time, including some of whom will be leaving us as we maintain our focus on our cost competitiveness and adjust staffing levels to account for lower activity levels. "This industry has two fundamental challenges which are emphasized by recent events - there are too many rigs carrying too much debt. In the quarter we took an impairment of $1.2 billion as we recognize, along with others in the sector, that a number of our assets are increasingly unlikely to return to the market and need to be scrapped. Assets across the industry also carry debt levels which are unlikely to be sustainable and consequently we should expect to see substantial indebtedness being converted to equity. Only when the industry addresses both of these issues will we be in a position where the balance of market supply and demand can deliver reasonable investment returns to stakeholders."   This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.  

SynAct Pharma´s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency

In the Phase IIa study, AP1189 will be tested in a double-blind, placebo-controlled multicentre study as add-on therapy to ACE-inhibitor or Angiotensin-2 receptor antagonists in a once-daily dose regimen for four weeks with the primary purpose to show treatment effect on urinary protein excretion relative to pre-treatment levels and placebo. The patients will be dosed with either 100 mg AP1189 or Placebo in a 2:1 randomization in up to 24 patients. Nephrotic syndrome (NS) is a relatively rare condition characterized by loss of protein in the urine that is associated with development of edema, hypoalbuminia and elevated plasma lipids, ie development of NS. NS can further develop into chronic kidney disease and is associated with risk for development of hypertension and ischemic cardiovascular disease.  Idiopathic membranous nephropathy (iMN), is one of the most common causes of Nephrotic Syndrome in adults. In most case, iMN is due to circulating antibodies against the M-type receptor of phospholipase 2 (Anti-PLA2r). These antibodies bind to the PLA2r on a specific cell type in the kidneys called podocytes thereby inducing morphological and functional changes in the kidneys resulting in high levels of protein in the urine. Podocytes express melanocortin Type 1 receptors (MC1r) and it has been shown that MC1r stimulation preserved the structure of the podocytes and reduce proteinuria in experimental models of NS. In patients compounds as ACHTAR Gel with the MCr agonist ACTH as active ingredients have been shown to reduce proteinuria even in difficult to treat patients as patients with glucocorticoid resistant NS. AP1189 is a biased MC1r and MC3r that in an animal models of NS mimicking iMN and have shown to induce treatment effect comparable to what has been reported for other MCr agonists and in a head to head study with ACTH showed superior treatment effect with significantly lower levels of proteinuria following 4 weeks treatment (Patent application no: WO/2019/243625) First-line treatment of iMN is Angiotensin-converting-enzyme inhibitors or Angio­tensin II receptor blockers to control blood pressure and decrease the protein loss in the urine. If continued symptoms follow in six months, the patients will be treated with glucocorticoids, immunosuppressives, or ACTH. These treatment options are associated with often treatment-limiting side effects and a fraction of patients will despite treatment continue to have symptoms.  The market potential is considered very attractive with Mallinckrodt sales of 300 Mio. USD./year.[1]  There is therefore a need for new treatment options where AP1189 as a compound with anti-inflammatory and pro-resolving effects and the specific ability to stimulate the MC1r on the podocytes could be a new treatment option. CSO Dr. Thomas Jonassen highlights “SynAct Pharma has therefore decided to set up a proof of concept study in NS, where the first study will be in iMN patients. It would be possible at a later stage to broaden out the treatment to other diseases that cause NS, including minimal change disease (MCD) and focal segmental glomerulonephritis (FSGS). The global FSGS-market is estimated to rise 8.0% CAGR over the course of the forecast period from 2017 to 2025. Expanding at this pace, the market which was worth US$7.82 bn in 2016, is projected to attain a value of US$15.83 bn by 2025-end.[2]  With the approval from the Danish Medicinal agency and an expected approval for the local Ethical Committee (where the handling of the application is delayed due to the Covid-19 pandemic), the company aim to initiate the Phase IIa-study in NS by the end of June 2020.” Detailed information of the study will be available at www.clinicaltrial.gov following study initiation. This information is such information that SynAct Pharma AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the below contact person, for publication on June 2, 2020.

Nordic Nanovector to Present at Upcoming Jefferies Virtual Healthcare Conference and ABG Sundal Collier Virtual Oncology Seminar

Oslo, Norway, 2 June 2020 Nordic Nanovector ASA (OSE: NANO) announces that members of its management team will present at Jefferies Virtual Healthcare Conference, taking place 2-4 June 2020. Nordic Nanovector will also present at ABG Sundal Collier Virtual Oncology Seminar 10 June 2020. Presentations details are as follows: Jefferies Virtual Healthcare ConferenceDate: Tuesday, 2 June 2020Time: 16:30 CET ABG Sundal Collier Virtual Oncology SeminarDate: Wednesday, 10 June 2020Time: 10:25 CET The company presentation will be available on Nordic Nanovector’s Investors and Media page at the same time. For further information, please contact: IR enquiries Malene Brondberg, CFOCell: +44 7561 431 762Email: ir@nordicnanovector.com Media Enquiries Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)Tel: +44 203 926 8535Email: nordicnanovector@citigatedewerogerson.com About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin[®], a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin[®] and intends to actively participate in the commercialisation of Betalutin[®] in the US and other major markets. Further information can be found at www.nordicnanovector.com. This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

Zwipe appoints new Executive Vice President Strategy & Channels

OSLO, NORWAY– 02 June 2020 – Zwipe AS announces that Bishwajit Choudhary has accepted the position of Executive Vice President Strategy & Channels at Zwipe, commencing 2 June 2020.  He will lead Zwipe’s engagement efforts towards banks, global and domestic card schemes, selected retailers and other important payments ecosystem stakeholders. Based in Oslo, Mr. Choudhary brings two decades of experience from Nets where he led many new business initiatives within Digital-ID, electronic signatures and mobile authentication for international clients. As the Group SVP (Strategy) he led Nets' market intelligence and strategy execution and played a key role in many commercial initiatives, notably open-banking data analytics, customer advisory, strategic alliances and fintech partnerships. Prior to joining Zwipe, he was Chief Commercial Officer at UserTribe, a global leader in delivering deep customer insights in 100+ countries based on live experience data. “With increasing activity in payment cards and wearables in general, and biometrics in particular, and with Zwipe poised to take a technology and cost leadership position in this high potential market, timing is right for Zwipe to complement our growing engagements with our direct customers, the smart card manufacturers, by embarking on a “pull strategy”. This means that we will step up our engagements with banks and neo-banks, as well as new players in card issuance, such as retailers and tech companies. With deep insights in the payments industry, Bishwajit will add a valuable breadth in our payments expertise and lead our strategy and channel development,” said André Løvestam, CEO of Zwipe. ###

SKF factories to be carbon neutral by 2030

Gothenburg, 2 June 2020: Since 2015, SKF has decreased its manufacturing carbon footprint by 36% and is already operating two carbon neutral factories. Today, SKF announces its aim to achieve a fully carbon neutral manufacturing footprint by 2030. The 2030 target will cover SKF’s own manufacturing operations, i.e. SKF’s scope 1 and 2 emissions. It will be achieved by a combination of process improvements, energy efficient machinery, and procurement and generation of renewable energy. As a last resort, SKF may also purchase high quality carbon offsets. Alrik Danielson, President and CEO, says: “Reducing emissions is necessary to combat the climate crisis and as a global company it is important that we show leadership. We strive to reduce the climate impact in the full value chain, from the raw material we buy, to the customer’s use, and beyond. The responsibility to act starts in our own operations – we will act with speed and purpose to achieve this goal. Carbon neutrality will further improve our competitiveness and aligns the interests of SKF, our customers and the environment.” Patrick Tong, President, Industrial Sales, Asia, says: “Climate change presents the world with huge challenges but also opportunities which we will leverage by delivering both environmental and economic value to our customers and other stakeholders. This is key to SKF’s strategy, which is based on sustainable development.” SKF offers a number of solutions and products that contribute to the circular economy. SKF’s AI-driven Rotating Equipment Performance offer is aimed at reducing waste by making assets run as long and as efficiently as possible. SKF offers remanufacturing of bearings, which reduces emissions in the production phase by up to 90% compared with a new bearing. SKF RecondOil’s innovative oil regeneration system enables circular use of oil, reducing waste and improving environmental performance. Aktiebolaget SKF       (publ)

Changes in Alfa Laval Group Management

“Peter has played a key strategic role in the company over more than 20 years,” says Tom Erixon, President and CEO of the Alfa Laval Group. “In that time period Alfa Laval has developed into a world leader in many applications, supporting our customers to transit into more sustainable business models. Peter’s branding and strategic communication expertise have served us well.” Peter Torstensson joined Alfa Laval in 1999 as a member of the Group Management, with responsibility for brand and communications. "Working for Alfa Laval during the past 20 years has been a pleasure and a privilege. It has been a period with radical changes, including a rebirth of the company and the brand, the return to the stock exchange and the strategic journey with three CEOs,” says Peter Torstensson. A new operating model for Marketing & Communications will stepwise be implemented during the third quarter. About Alfa Laval                                                                                                                 Alfa Laval is active in the areas of Energy, Marine, and Food & Water, offering its expertise, products, and service to a wide range of industries in some 100 countries. The company is committed to optimizing processes, creating responsible growth, and driving progress – always going the extra mile to support customers in achieving their business goals and sustainability targets. Alfa Laval’s innovative technologies are dedicated to purifying, refining, and reusing materials, promoting more responsible use of natural resources. They contribute to improved energy efficiency and heat recovery, better water treatment, and reduced emissions. Thereby, Alfa Laval is not only accelerating success for its customers, but also for people and the planet. Making the world better, every day. It’s all about Advancing better™. Alfa Laval has 17,500 employees. Annual sales in 2019 were SEK 46.5 billion (approx. EUR 4.4 billion). The company is listed on Nasdaq OMX. www.alfalaval.com   For more information please contact:Peter TorstenssonSenior Vice President, CommunicationsAlfa LavalTel: + 46 46 36 72 31Mobile: +46 709 33 72 31

Vator Securities: Xbrane Biopharma: Pop up on your boards – “the third wave” of biosimilars is rather a tsunami.

Xbrane provides an exceptionally attractive exposure to the rapidly growing biosimilars market without the significant clinical and approval risk that is often present in biotech companies. 2019 proved to be a real tipping point with rapid uptake of the more recent biosimilar launches. It is nowadays  trivial to question the attractiveness of the biosimilar market opportunity; the interesting question is rather which players have the best fit to capture this opportunity. We believe that Xbrane stands well-positioned for this with Xlucane progressing through the low-risk pivotal phase III study and with well-reputed, established commercial partners covering Europe and North America targeting global launch in mid 2022. With the recent progress, Xbrane has reinforced its ownership base with institutional investors and secured funding to take Xlucane to the market and accelerate development of the preclinical candidates that are biosimilars to Opdivo (Xdivane) and Cimzia (Xcimzane). Moreover, the exclusive licensing agreement with Bausch + Lomb – a global leader in eye health with a well-established sales infrastructure to leverage - for commercialization of Xlucane in the US and Canada is a significant de-risking factor that maximizes the likelihood of a successful launch and rapid market penetration. The competitors that will launch the two other Lucentis biosimilars in North America are far from having a comparable sales presence in ophthalmology. We view the increasing focus on other pipeline candidates as an important step. We see Xdivane and Xcimzane as particularly interesting assets and expect the advancements of these to be key long-term value drivers for Xbrane, offering significant upside to our base case with Xlucane. We maintain the Outperform rating and raise the target price to SEK 155 per share, corresponding to an equity value of SEK 3 billion non-diluted, derived from a project-based, risk-adjusted DCF valuation of the lead asset Xlucane with fairly conservative estimates; real-world data on biosimilars supports an even more bullish outlook. As the majority of development risk-reduction is achieved early on in biosimilar development, we will include Xdivane and Xcimzane in our model as Xbrane provides updates on preclinical progress and data packages Läs mer och ladda ned analysen: http://vatorsecurities.se/wp-content/uploads/2020/06/Xbrane-Biopharma-Pop-up-on-your-boards-the-third-wave-of-biosimilars-is-rather-a-tsunami-200602.pdf Detta är ett pressmeddelande från Vator Securities. https://vatorsecurities.se

Tele2 first in Sweden to offer 5G roaming

Tele2 switched on Sweden’s first public 5G network on May 24 2020, which enables Tele2 customers with a Tele2 Unlimited subscription and a 5G ready phone to get free access to 5G. Today Tele2 launches the first 5G roaming agreement, between Tele2 Sweden and Tele2 Latvia, and by that becomes the first operator in Sweden to provide international 5G compatibility to customers. – We want to serve our customers’ continuously increasing need for connectivity and give them a superior mobile experience while traveling abroad. The launch of Sweden’s first 5G roaming agreement is an important milestone for the geographical expansion of 5G, and we will now continue to actively develop our 5G coverage and roaming capabilities, says Thomas Helbo, Executive Vice President Technology at Tele2. Tele2’s Swedish 5G network will from the start be available in Stockholm, Malmö and Gothenburg and Tele2 is the only operator in Sweden that provides speed over 1 Gbit/s, in accordance with global standards. – Tele2 customers can enjoy real 5G speeds, which is more than four times faster than 4G and 50 percent faster than what our competitors in Sweden can offer today. As soon as the current travel restrictions are lifted, we look forward to provide our customers with high-speed connectivity also outside of Sweden, says Thomas Helbo. Additional offers and international agreements will be presented going forward, while Tele2’s 5G roll out will continue successively throughout Sweden and the Baltics.For more information, please contact:Louise Ekman, Head of B2C Communications, Phone: +46 705 22 21 17Marcus Lindberg, Head of Investor Relations, Phone: +46 73 439 25 40

Attendo divests its operations in Norway

“Attendo has been at the forefront for a long time to develop working methods, quality systems and activities that improve the quality of life for the residents in our elderly homes in Norway. Despite highly appreciated operations, there is little opportunity for Attendo and other private companies to develop new establishments and our current agreements will expire in the coming years. I am convinced that Lovisenberg will take good care of our residents and employees and continue the work to develop compassionate care”, says Ammy Wehlin, Business Area Manager for Attendo Scandinavia. Attendo currently operates five nursing homes in Norway, one under own operations and four outsourcing contracts whose contracts expire beginning in July 2020 (in Stavanger) and until 2022. The turnover of the business transferred amounted to approximately SEK 300 million in 2019 and contributed marginally to Attendos results. The completion of the transaction is pending approval from relevant authorities in Norway. Attendo AB (publ) For further information, please contact: Andreas Koch, Communications and IR-Director AttendoPhone: +46 705 09 77 61E-mail: andreas.koch@attendo.com The transaction is not of the kind subject to disclosure obligation by Attendo pursuant to the EU Market Abuse Regulation._________________________________________________________________________________Attendo - the leading care company in the NordicsAttendo is the leading private provider of publicly financed care services in the Nordic region. The company was founded in 1985 and was first to provide outsourced care for older people in Sweden. In addition to care for older people, Attendo provides care for people with disabilities and social care for individuals and families. Attendo has approximately 25,000 employees and is locally anchored with more than 700 operations in around 300 municipalities in Sweden, Finland, Norway and Denmark. www.attendo.com

Citycon Group contemplates to issue Euro denominated notes in a tap issue

NOT TO BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN OR INTO OR TO ANY PERSON LOCATED IN OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (TOGETHER THE "UNITED STATES"), AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Citycon Group intends to issue Euro denominated guaranteed notes around EUR 150 million as a tap issue. The notes would be issued under the same terms and conditions as the existing 10-year notes issued by Citycon Treasury B.V. on 1 October 2014 and maturing on 1 October 2024 (the “2024 Notes”). If issued, the notes will be consolidated and form a single series with the 2024 Notes. The notes would be offered mainly to European, including Nordic, institutional investors through a book building procedure. The notes would be guaranteed by Citycon Oyj. Citycon Treasury B.V. would apply for the notes to be admitted to the Official List of the Euronext Dublin and to trading on its regulated market.The net proceeds from the tap issue would mainly be used to refinance existing debt and for general corporate purposes of the Citycon Group, including for the development of existing properties.Citycon Group has mandated Danske Bank, Deutsche Bank, Nordea, OP, SEB and Swedbank AB as joint lead managers. Citycon Group will announce further information after the placement of the bond.CITYCON OYJFor further information, please contact:Eero SihvonenExecutive VP and CFOTel. +358 50 557 9137eero.sihvonen@citycon.com Laura JauhiainenHead of Investor RelationsTel. +358 40 823 9497laura.jauhiainen@citycon.comCitycon is a leading owner, manager and developer of urban, grocery-anchored shopping centres in the Nordic region, managing assets that total almost EUR 4.5 billion. Citycon is No. 1 shopping centre owner in Finland and among the market leaders in Norway, Sweden and Estonia. Citycon has also established a foothold in Denmark. Citycon has investment-grade credit ratings from Moody's (Baa3), Standard & Poor's (BBB-) and Fitch (BBB-). Citycon Oyj’s share is listed in Nasdaq Helsinki.Important regulatory notice This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to buy or subscribe for, any securities in the United States or any other jurisdiction nor shall it (or any part of this announcement) or the fact of its distribution form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or commitment.  Recipients of this announcement who intend to purchase any securities are reminded that any such purchase or subscription must be made solely on the basis of the information contained in any final form prospectus published in connection with any such securities, which if and when published will be available on the website of the Central Bank of Ireland.  The transaction described above and the distribution of this announcement and other information in connection with the transaction in certain jurisdictions may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction.  Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.This communication is not an offer of securities for sale in the United States, Australia, Canada, Japan or any other jurisdiction where to do so would be unlawful.  Neither Citycon Oyj nor Citycon Treasury B.V. has registered, or intends to register, securities in any of these jurisdictions or to conduct an offer of securities for sale in any of these jurisdictions.  In particular, no securities of Citycon Oyj or Citycon Treasury B.V. have been or will be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and such securities may not be offered, sold or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.This announcement is directed only at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within the definition of "investment professionals" in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as "relevant persons").

Qlife to develop SARS-CoV-2 total antibody test

The first phase of developing the antibody test will be outsourced to an existing partner and is expected to take approximately three months. Thereafter, the project will be transferred to in-house specialists for integration to the Egoo device, analytical data collection and product optimization. Qlife expects to be able to CE mark for professional use late 2020 and submit a file for CE mark home use during the first quarter 2021. “With a relatively limited investment we can complement our COVID-19 tests for active viruses and run the antibody tests on our existing device. IgG/IgM antibody tests are currently developing into a very competitive field with a large interest, especially in mass testing solutions, and we see several segments within elderly homes, larger workplaces, sports events etc.  which for a long time will have the need for decentralized and fast antibody testing.” comments Thomas Warthoe, CEO Qlife. Qlife’s total antibody IgG/IgM test will be based on the particle-enhanced Immunoturbidimetry principle that allows quantitative determination of the total concentration of the IgM/IgG antibodies against COVID-19 virus. The principle of particle-enhanced immunoturbidimetry is based on particles coated with SARS-CoV-2 antigens forming complexes with the specific antibodies. If the IgM/IgG antibodies are present in the capillary blood, Egoo will measure signal changes at 570nm that are directly correlated to the total concentration of the total IgM/IgG antibodies. The assay is expected to take between 6-7 minutes using a drop of blood. With this new Egoo IgM/IgG test it will be possible to follow the total antibodies concentration over time. The new Egoo antibody test will be a full quantitative test just like the laboratory-based ELISA test with comparable specificity.  

Epiroc gives notice of termination in Sweden

The notices are for 350 positions in Örebro and 75 positions in Fagersta, Sweden, of which half are positions in production. The action is the result of Epiroc facing a significant drop in demand from customers due to the Covid-19 pandemic’s effects on the global economy. The work reductions are also part of Epiroc’s continuous effort to become as agile and efficient as possible, and follows various efficiency measures taken worldwide since 2019. “We are taking these actions to adapt to the new market situation following the Covid-19 pandemic and to make us stronger and more resilient for the future. Unfortunately we must take such a drastic action as giving notice of termination. We regret the negative consequences this will have for our colleagues and those close to them, and we will support our employees in this difficult situation,” says Helena Hedblom, Epiroc’s President and CEO. “These actions will allow us to continue to prioritize innovation and to develop our technology leadership in order to support our customers’ operations and improve their productivity.” Epiroc is on the forefront of several technological shifts that are making the mining and infrastructure industries more productive, safe and climate friendly, including automation, digitalization and electrification. Örebro is a main manufacturing and research and development hub for Epiroc’s underground and surface equipment as well as for service and spare parts supply, and Fagersta is home to Epiroc’s rock drilling tools business. Epiroc has about 3 100 employees in Sweden, out of a global workforce of approximately 14 000. For more information please contact:Ola Kinnander, Media Relations Manager+46 70 347 2455media@epiroc.com Epiroc is a leading global productivity partner for the mining and infrastructure industries. With ground-breaking technology, Epiroc develops and produces innovative, safe and sustainable drill rigs, rock excavation and construction equipment and tools. The company also provides world-class service and solutions for automation and interoperability.  Epiroc is based in Stockholm, Sweden, had revenues of SEK 41 billion in 2019, and has more than 14 000 passionate employees supporting and collaborating with customers in more than 150 countries. Learn more at www.epirocgroup.com.

DIGITAL VIRGO to acquire DOCOMO Digital’s Solutions’ business division

London, 2[nd] June 2020 DOCOMO Digital, NTT DOCOMO’s international mobile commerce-related business, announced a definitive agreement to sell its Solutions business division to DIGITAL VIRGO. DOCOMO Digital, a wholly owned subsidiary of NTT DOCOMO, has been at the forefront of mobile commerce, and digital content and payments’ ecosystem. DOCOMO Digital’s Solutions business division encompasses the technical, licensing, and distribution needs of telecom operators, to help them drive monetisation and user engagement. DIGITAL VIRGO is an international player in Monetisation, Payment and Digital Marketing solutions dedicated to Telecom Operators and Merchants. Since 2008, the Group has built a global network by setting up local offices to expand geographically and through acquisitions to bring new expertise or technologies to strengthen its position in existing markets.  Making acquisitions and integrating new teams has been part of its DNA with over fifteen acquisitions over the last decade. “The transaction is in line with our strategy and vision to build on the strength of our core payments’ business, capitalising on the surge in digital payments’ volumes we are witnessing today. Our Solutions business division performed well over the years, and we believe becoming a part of DIGITAL VIRGO will create a clear market leader in the space.,” said Jonathan Kriegel, CEO at DOCOMO Digital. “This deal is consistent with our strategy and meets our recently announced ambitions. Firstly, this acquisition will consolidate our position in strong markets such as payment and monetisation, and secondly, it will also accelerate our international growth and local presence. Being as close as possible to the local considerations of our clients, telecom operators and merchants has always been a prerequisite for all our actions. There are a lot of synergies between our business units but also between the teams. Professionals from DOCOMO Digital’s Solutions’ business division, recognised experts in their fields, will join us and will be important assets for the future.,” commented Guillaume Briche, CEO at DIGITAL VIRGO group. The deal has been approved by the shareholders and labour unions on both sides, and the definitive agreement was signed on 28[th] May 2020. EY and Baker McKenzie served as the M&A transactions advisors. About DIGITAL VIRGO Created in 2008, Digital Virgo Group is one of the most leading French Tech companies in the world. Located in more than 25 countries, its teams operate in the Payment and Monetisation markets using Direct Carrier Billing. Positioned at the heart of an ecosystem made up with Operators, Merchants (Content producers, Media, Ticketing companies) and Digital Advertising Platforms (Google, Facebook …),  its role is to connect these players to meet their main challenges: optimise payment, monetise contents, services and audiences and ensure performance through mobile marketing campaigns. +40 countries in operation | €270 Million of revenue in 2019 | 700 people worldwide More information on digitalvirgo.com  and social platforms.    

Tobii Pro Glasses 3 – groundbreaking wearable eye tracker to analyze human behavior

Tobii Pro , the global leader in eye tracking research solutions, today launched Tobii Pro Glasses 3 – its next-generation of wearable eye tracker built for measuring attention in any real-world scenario. Users can now get unbiased insights into human behavior more easily. For businesses, this means more informed decisions on design and marketing investments and a deeper understanding of the workplace for improved productivity and safety. For scientific researchers, Tobii Pro Glasses 3 will lead to new discoveries and increased data confidence. Featuring Tobii’s ground-breaking and proprietary eye tracking technology, Tobii Pro Glasses 3 integrates cameras and illuminators inside the glass itself enabling the unique combination of outstanding eye tracking performance in dynamic environments with a sleek and unobtrusive design. This is combined with an improved wide-angle scene camera capturing much more of the surrounding environment. Together with Tobii Pro’s software and services, Pro Glasses 3 represents the most capable and most advanced wearable eye tracking solution available for critical real-world research.     Tobii Pro Glasses 3 collects eye tracking data on the wearer’s visual attention pattern and records a video of the surrounding environment with sound. When the data is analyzed, users can draw conclusions on what drives behaviors and decision making. For the wearer, the sophisticated eye tracking technology in Pro Glasses 3 is virtually invisible. The experience is exactly like putting on and wearing a standard pair of eyeglasses. “For the last ten years our scientific and commercial customers have utilized our wearable eye trackers in their quest to understand the why behind human behavior. Tobii Pro Glasses 3 is our flagship product and with the new revolutionary design and tech innovations we are making it easier than ever to study behavior in real contexts”, said Tom Englund, Division CEO, Tobii Pro. “The scene camera’s increased field of view in Tobii Pro Glasses 3 makes a major difference when conducting wayfinding research, especially in an outdoor environment where, with a narrower field of view, we would lose track of the gaze data. I am also pleased to see how well the calibration worked, both at dusk and in sunlight, something of major importance to maintain the calibration between different levels of illumination. The design of Pro Glasses 3 is very comfortable, making them unobtrusive to wear which is an important factor to collect unbiased insights”, says Professor Barbara Chaparro, who leads the Research in User eXperience Lab at Embry-Riddle Aeronautical University. Building on the experience from the wide usage of its predecessors, technical features and benefits of Tobii Pro Glasses 3 include: 1. Integration of four, extremely small, eye cameras and 16 illuminators into the lenses which provides a unique combination of improved eye tracking performance and no obstruction from the wearer’s field of view. 2. Wide-angle scene camera which captures much more of the surrounding environment. 3. App controller capable of running on Android and Windows devices allows for wireless control of recordings which provides ease of use and flexibility. 4. Eye tracking data is collected at 50 or 100 hertz and slippage compensation technology enables consistent eye tracking data throughout recordings, even if the glasses move on the user’s head, or are taken off and on. 5. Accessory kit including add-on IR blocking safety lenses support research in outdoor/bright environments as well as situations requiring eye protection. 6. New slim and more robust design allows Tobii Pro Glasses 3 to be worn under personal protective equipment (PPE) such as helmets and headgear, which facilitates a wide range of occupational and research settings. Sample application areas: Scientific researchers get a unique vantage point into human behavior and a deeper understanding of a person’s cognitive process. They make it possible to take research out of the lab and into the real world within endless research areas such as interface interactions on new technologies, social interactions, traffic safety and more.   Consumer insight professionals and UX researchers can visualize and measure the true customer experience in any scenario. They can gain insights on for example which package design will catch the most attention and convert to purchase? Which point of sales materials get noticed and what gets ignored? How do I design a car dashboard to be the most intuitive while keeping the driver’s eyes on the road?  Operational managers, team leads, and operators can see each other’s reality from a first-person perspective. For example, the eye tracking videos generated are an ideal input to a manufacturing plant’s ongoing work to continuously improve their operations, increase productivity and upskill their staff. Tobii Pro Glasses 3 can help businesses understand important operational details, offering vital insights into what the best visual strategy is for worker safety and productivity, or whether standard procedures are being followed consistently. More information and media assets: · Product video  · Product imagery  · B-roll footage  · Product page 

Can renewable energy save Japan’s historic spas?

  Decades of economic recession have forced many onsen owners into bankruptcy. Last year one inn closed after having operated continuously since 704, and this year the sudden decline of Chinese tourists due to the COVID-19 has caused still others to shutter. But what if the onsens could stay open by capitalizing on their hot water resources in another way? More than just an onsen On June 1, 2020, Baseload Power Japan commissioned its second power plant in Japan, at an onsen in Gifu. “We first got the idea when we were driving around Japan and started noticing signs for closed onsens,” says Baseload Capital COO Pernilla Wihlborg. “we started asking onsen owners if they might be interested in making money by creating power from their hot water and in parallel, we established our local subsidiary. Eventually we came into contact with onsen owner Ms. Midori Mizunami.” Midori’s spa has been in operation for 14 years, but the ups and downs of the tourism business can be challenging. “For business owners, it is a relief to have income from two different sources,” says Midori. “Now, when the tourist business is down, I will still have money coming in from the power being generated from the Climeon heat power plant.” At many onsens the water coming out of the spring is so hot that it must be cooled before guests can bathe in it. “That’s one extra benefit we can offer onsen owners,” says Masahiro Ito, Representative Director of Baseload Power Japan K.K. “The power plant can lower their costs by cooling the water at the same time that it creates electricity.” The renewable energy frontier Since the Fukushima Daiichi disaster, Japan has stopped producing energy at most of its nuclear plants, and is one of the few nations in the world building coal plants in order to provide its citizens with reliable power. “Even though Japan has amongst the highest geothermal potential in the world, there simply aren’t enough geothermal energy plants in operation to guarantee their effectiveness and justify a large-scale roll-out,” explains Pernilla Wihlborg. “Midori’s plant is an indication that this could work at many of the 30,000 natural hot springs all across Japan, which would enable the country to offset more power produced by fossil fuels with renewable energy.” “It can be a tough step to be a pioneer, because you are taking a risk by doing something no one else has done before,” says Ms. Midori Mizunami. Hopefully her bravery will reward not only her, but many generations to come and maybe it was a step towards moving Japan in the forefront when it comes to renewable energy through geothermal power.

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT MAY 2020

The revenue in May for Zinzino's sales markets increased by 34% to MSEK 80.5 (60.2) primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 5% and amounted to MSEK 3.5 (3.7) due to high level of internal production. Overall, the Group increased revenues by 31% to MSEK 84.0 (63.9) compared with the previous year. Accumulated revenue for January – May 2020 increased by 43% MSEK 414.2 (289.0). Revenues distributed as follows: Regions,MSEK 20 May 19 May Change YTD 2020 YTD 2019 ChangeNordic Markets 30.1 33.0 -9% 157.9 155.9 1%Europe Other Markets 40.8 20.1 103% 187.3 81.0 131%Baltic Markets 4.7 4.4 7% 27.4 22.1 24%North America 3.1 2.0 55% 13.9 9.4 48%Australia 1.8 0.7 157% 6.9 1.0 590%Zinzino 80.5 60.2 34% 393.4 269.4 46%Faun Pharma 3.5 3.7 -5% 20.8 19.6 6%Zinzino Group 84.0 63.9 31% 414.2 289.0 43%   For more information:Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com Pictures for publication free of charge:Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollblom@zinzino.com Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00,email: certifiedadviser@penser.se Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 13:00 the 2nd of June 2020. Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Adelaide. Zinzino is a public company and its shares are listed on Nasdaq First North Growth Market.

Ericsson commences the three-year term of the monitorship

As previously communicated, Ericsson (NASDAQ: ERIC) has entered into a three-year Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice. As part of this resolution, Ericsson agreed to engage an independent compliance monitor for three years. The process of selecting a monitor has now been completed and Dr. Andreas Pohlmann of the firm Pohlmann & Company – Compliance and Governance Advisory LLP has been appointed as Ericsson’s monitor. The appointment marks the start of the three-year term of the monitorship. The monitor’s main responsibilities include reviewing Ericsson’s compliance with the terms of the settlement and evaluating the Company’s progress in implementing and operating its enhanced compliance program and accompanying controls as well as providing recommendations for improvements. Ericsson has in recent years been taking significant steps to improve its Ethics and Compliance program. For more information on this work, please see:  https://www.ericsson.com/en/about-us/sustainability-and-corporate-responsibility/responsible-business NOTES TO EDITORS: FOLLOW US: Subscribe to Ericsson press releases here . Subscribe to the Ericsson Blog here . www.twitter.com/ericssonwww.facebook.com/ericssonwww.linkedin.com/company/ericsson MORE INFORMATION AT:Ericsson Newsroom  media.relations@ericsson.com(+46 10 719 69 92) investor.relations@ericsson.com(+46 10 719 00 00) About EricssonEricsson enables communications service providers to capture the full value of connectivity. The company’s portfolio spans Networks, Digital Services, Managed Services, and Emerging Business and is designed to help our customers go digital, increase efficiency and find new revenue streams. Ericsson’s investments in innovation have delivered the benefits of telephony and mobile broadband to billions of people around the world. The Ericsson stock is listed on Nasdaq Stockholm and on Nasdaq New York. www.ericsson.com

Sanderling Renal Services joins the rank of US dialysis providers selecting Redsense

Sanderling Renal Services, headquartered in Nashville, Tennessee, has purchased 10 Redsense devices for one of their Nashville facilities. Sanderling is a US dialysis provider with a nation-wide network of clinics. “Sanderling Renal Services has a focus on high quality patient care and pioneering use of innovative equipment and technology,” says Brendan Kane, US Director of Sales at Redsense: “Their decision to deploy the Redsense system at one of their facilities is an indication of that ambition, and fits well with their specific interest in patient safety, further; we are pleased to be able to contribute to that and to the safety of their patients.” The Redsense System improves patient safety during hemodialysis by continuously monitoring the blood access site for Venous Needle Dislodgement (VND) – a potentially life-threatening complication. “Adopting the Redsense alarm as a safety device is quickly becoming a standard practice among dialysis providers. Redsense is already supplying several of the largest providers on the market with the solution, and the growing provider SRS is a welcome addition. We are looking forward to a fruitful relationship with the Sanderling Renal Services team,” saysPatrik Byhmer, CEO of Redsense Medical AB. About Sanderling Renal Services Sanderling Renal Services opened its first clinic in Oklahoma in 2013, and has since extended operations across the country, driven by a strong dedication to develop renal care services close to patients through remote clinical services and the establishment of smaller facilities in the proximity of underserved communities in need.  The founder, Dr. Tannenbaum, has a 30-year track-record of successful development of dialysis clinics, previously serving as founder, Chairman, and CEO of REN Corporation, National Nephrology Associates and DSI Renal – three of the largest dialysis operators in the United States. Before Sanderling's inception, DSI's clinics were acquired by DaVita, the second-largest dialysis provider in the United States; DaVita currently serves more than a third of the US patients.

OssDsign selected as one of the Nordic region’s 50 leading companies of the future

The Techarenan Challenge, arranged for the seventh year, is open to all Swedish and Nordic companies in the startup and growth phase regardless of the industry. The competition is aimed at all companies with a unique innovation or business concept holding the potential for global commercialization. The companies have been evaluated by an expert jury where great focus has been on scalability, sustainability and well-defined growth opportunities. "This year's final field is one of the strongest so far in terms of both breadth and apex. It is obvious that Sweden and the Nordic countries are a breeding ground for exceptional entrepreneurs and companies. Many of the companies have already gained a foothold internationally and have created a strong position for further expansion, " says Omid Ekhlasi, Founder and Competition Manager Techarenan. "We are very pleased to have been selected as one of the foremost future companies in the Nordic countries and we look forward to the semi-final of the Techarenan Challenge on November 13 in Stockholm," says Anders Lundqvist, CEO of OssDsign. For more information on Techarenan Challenge 2020 visit: https://techarenan.se/challenge/ (in Swedish)   For further information, please contact: Anders Lundqvist, CEO, OssDsign ABTel: +46 73 206 98 08Email: al@ossdsign.com Certified Adviser:Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se. About OssDsignOssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

Wärtsilä and partners develop emissions-free barge concept

· Zero Emission Services founded to make inland waterway shipping more sustainable · Replaceable battery containers used for fully electric propulsion · Innovative ‘pay-per-use’ financing model keeps OPEX low The technology group Wärtsilä has joined a consortium of key partners to form Zero Emission Services B.V. (ZES) , an enterprise aimed at making inland waterway shipping more sustainable. The other founders of ZES are ING Bank, energy and technical service provider Engie, and the Port of Rotterdam Authority. The concept is supported by the Dutch Ministry of Infrastructure and Water Management. Within the Netherlands transport sector, inland navigation accounts for 5 percent of carbon dioxide (CO2) emissions. By switching from diesel fuelled propulsion to fully electrically powered transport, an important step can be taken towards realising the Paris Climate Agreement goals. The concept is based on the use of replaceable battery containers, to be known as ‘ZESPacks’. These will be charged using energy from renewable sources. A network of open access charging points will be set up for exchanging depleted battery containers for ready-charged replacements, thereby keeping waiting time to a minimum. The ZESPacks are designed for multiple applications, enabling them to be utilised for temporary onshore use, such as stabilising the local electricity grid or meeting short-term demand for electrical power. “This innovative concept aligns completely with Wärtsilä’s commitment to lessening the environmental impact of shipping. Our deep in-house know-how in maritime battery systems, shore power connections and remote connections, plus our extensive experience in serving inland waterway applications, were all key reasons for Wärtsilä to join this project and it is something we are proud to be a part of,” says Tamara de Gruyter, President, Marine Systems & Executive VP, Wärtsilä. The system is future-proof since it is independent of the energy provider. Initially batteries will be employed but should, for example, hydrogen become a viable alternative at some point, containers equipped with hydrogen technology could supply power in the same way. To make it easier for barge operators to sign-on to the concept, a ‘pay-per-use’ financing model has been developed. In this way, ZES charges only for the cost of consumed renewable energy plus a rental fee for the battery container, so the skipper’s operating costs remain competitive. However, vessels must be equipped with an electric propulsion line. The project will initially be employed along the Zoeterwoude – Alpherium – Moerdijk corridor. Following this, it will be expanded to include the Amsterdam – Rotterdam – Antwerp corridor, making a connection to Nijmegen. The emphasis during the initial stage will be on converted and newly-built container carriers.  The HEINEKEN beer company has entered into an agreement with ZES to utilise the service for transporting beer from its brewery in Zoeterwoude to Moerdijk, thus becoming the first end customer for the enterprise.   Image caption: Wärtsilä and its fellow ZES partners are committed to promoting emissions-free operations for inland waterway transport. Copyright: ZES. Media contacts: Ms Marit Holmlund-SundGeneral Manager, Positioning, Marine Business MarketingWärtsilä CorporationTel: +358 10 709 1439marit.holmlund-sund@wartsila.com All Wärtsilä releases are available at https://www.wartsila.com/media/news-releases and at http://news.cision.com/wartsila-corporation where also the images can be downloaded. Wärtsilä in brief:Wärtsilä is a global leader in smart technologies and complete lifecycle solutions for the marine and energy markets. By emphasising sustainable innovation, total efficiency and data analytics, Wärtsilä maximises the environmental and economic performance of the vessels and power plants of its customers. In 2019, Wärtsilä’s net sales totalled EUR 5.2 billion with approximately 19,000 employees. The company has operations in over 200 locations in more than 80 countries around the world. Wärtsilä is listed on Nasdaq Helsinki.www.wartsila.com

Hydrocyn® aqua inactivates the coronavirus causing COVID-19

In collaboration with the Swedish National Veterinary Institute (SVA), tests have been conducted with Hydrocyn on a viral culture of the new corona virus (SARS-CoV-2) that causes COVID-19. The result shows that 99.9% of the virus particles were inactivated – which means, they were no longer functional and thus not contagious. “The result is important in the fight against the spread of COVID-19. There is no vaccine yet and no effective COVID-19 drugs are available, so there is great need for effective prevention. Health care and the public need access to products that protect against the new coronavirus. We are therefore pleased that we have been able to prove that Hydrocyn is effective against this new virus and hope that we will soon be able to offer it to Swedish consumers,” says Stefan Grass, Bactiguard's Chief Medical Officer, MD PhD and formerly active as specialist physician in anesthesia and intensive care. “In addition to documented effects against coronavirus, Hydrocyn is also effective against bacteria and fungi. Unlike disinfectants based on, for example, alcohol, Hydrocyn is also kind to the body and does not cause irritation or tissue damage,” adds Stefan Grass. Bactiguard launched Hydrocyn in the Swedish market in mid-March and received customer orders, including from the Police Authority, in the first days after the launch, at a total value of just over SEK 20 million. This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-06-02, at. 16.40.  For further information, please contact:Stefan Grass, Chief Medical Officer and Deputy CEOe-mail stefan.grass@bactiguard.se, mobile +46 707 25 24 48 Cecilia Edström, CEO, e-mail cecilia.edstrom@bactiguard.se, phone: +46 8 440 58 80   About Hydrocyn® aquaBactiguard launched Hydrocyn® aqua in Sweden on March 12. Hydrocyn® aqua is an advanced disinfectant that is pH-neutral and water-based and can be used as a disinfectant solution for, for example, skin and surfaces. Unlike alcohol-based disinfectants, Hydrocyn® aqua is not irritating, toxic or harmful to the body. It is also not flammable. The active substance (HOCl) is a natural part of the human immune system. The product is CE marked (approved in the EU), registered by the US FDA and approved by the Swedish Chemicals Agency.

Idogen has been approved for listing on Nasdaq First North Growth Market

Idogen AB (”Idogen” or the ”Company”) has today received approval for admission to trading on Nasdaq First North Growth market. First day of trading on Nasdaq First North Growth Market is on Thursday, June 4, 2020. Nasdaq Stockholm has today announced that Idogen fulfills the listing requirements on Nasdaq First North Growth Market and the Company has received approval for admission to trading on Nasdaq First North Growth Market. The first day of trading on Nasdaq First North Growth Market is on Thursday, June 4, 2020. Idogen has previously been listed on the Spotlight Stock Market and the last day for trading on Spotlight Stock Market is on Wednesday, June 3, 2020. In connection with the listing on the Nasdaq First North Growth Market, Idogen has appointed Erik Penser Bank as the Company's Certified Adviser. The Idogen share will continue to trade with ISIN code SE0014428561 and under the ticker IDOGEN. The Company's shareholders do not need to take any measures in connection with the change of listing venue.                                                                                                                     For further information, please contact:Anders Karlsson, CEO, Idogen ABTel: +46 70 918 00 10E-mail: anders.karlsson@idogen.com The information was submitted for publication, through the agency of the contact persons set out above, on June 2, 2020. The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of haemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.

Handicare Group announces new President Patient Handling North America

Having spent the last 12 years with Sunrise Medical and over 25 years in the healthcare sector, Randi Binstock brings strong leadership and operating experience to Handicare. During her tenure at Sunrise Medical, Randi held several senior leadership roles including operating responsibility for Sunrise Medical Canada, Business Development and Global Strategic Marketing. Randi is a CPA and has an MBA in Entrepreneurship from DePaul University. “I look forward to welcoming Randi to the Handicare team. Her energy and enthusiasm, combined with her industry and operating experience, will support the growth and the continued improvements that we envision for the North American business”, says Johan Ek, CEO of Handicare Group. “I’m very excited for the opportunity to join Handicare North America and to continue to deliver products and services that improve the everyday lives of our end users and their families”, says Randi Binstock. Randi will take on her new responsibilities on 1 July 2020.  Stockholm, June 2, 2020Handicare Group AB   For further information, please contact: Pernilla Lindén, CFO & IRPhone: +46 708 775 832   About Handicare Handicare offers solutions to increase the independence of disabled or elderly people, and to facilitate for their care providers and family. The offering encompasses a comprehensive range of curved and straight stairlifts, transfer, lifting and repositioning aids and vehicle adaptations. Handicare is a global company with sales in more than 40 countries and is one of the market leaders in this field. The head office is in Stockholm, Sweden and manufacturing and assembly is located at four sites distributed across North America, Asia and Europe. In the twelve-month period to March 2020, revenue amounted to MEUR 265 and the adjusted EBITA margin was 7.6%. Employees amounted to 1,034 and the share is listed on Nasdaq Stockholm. For more information, www.handicaregroup.com.

Dr Richard Hausmann resigns as President and CEO of Elekta

STOCKHOLM, June 2, 2020 – Elekta (EKTA-B.ST) announced today that Richard Hausmann, President and Chief Executive Officer, has decided to resign for personal reasons with immediate effect. Elekta’s Board of Directors has initiated a recruitment process and has appointed Gustaf Salford as Acting President and CEO effective from today. Dr Laurent Leksell, Chairman of the Board, said: “We are grateful for Richard’s contributions to Elekta over the past four years. He has successfully driven, among other things, our strategic innovation agenda supporting our future growth, including the introduction of our breakthrough clinical solution, Unity. We acknowledge Richard’s desire to resign from Elekta, we sincerely thank him for his contributions and wish him all the best for the future.” “It has been a privilege to lead Elekta’s journey over the past four years, helping our customers to improve the life of millions of cancer patients around the world. I am proud to have been part of driving Elekta forward to revolutionize cancer care. I wish Elekta and all its employees every success in the coming years. I now look forward to pursuing my interests and other things in life,” said Richard Hausmann. Gustaf Salford has held senior management positions in Elekta for eleven years and, until today, the position as Executive Vice President and Chief Financial Officer. Johan Adebäck, Group Treasurer, with more than 15 years’ experience from senior Finance management positions in Elekta, has been appointed Acting Chief Financial Officer.   # # # For further information, please contact:Cecilia Ketels, Head of Investor RelationsTel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.comTime zone: CET: Central European Time Mattias Thorsson, Head of Corporate Communications and Public AffairsTel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.comTime zone: CET: Central European Time This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 20:00 CET on June 2, 2020. (REGMAR)  About ElektaFor almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com  or follow @Elekta on Twitter.

Neste opens Europe’s first RFID-based self-service store in Finland – purchases can be scanned through a shopping bag

Neste Corporation, Press Release, 3 June 2020 at 7:30 am (EET) Neste opens a new fully automated Easy Deli store on 3 June 2020 in the center of Helsinki, Finland. The store uses RFID technology, developed in Finland by Nordic ID, which scans all purchases made by the customer at once, for example, through a shopping bag or a backpack. It is the first self-service convenience store in Europe using RFID technology. “Consumer shopping behavior is changing rapidly. We want to be part of this development and offer new kinds of smoother and faster customer experiences. The Easy Deli product scanner is the first of its kind in Finland and a huge leap forward compared to conventional self-checkouts. This makes the shopping experience much quicker and easier. The closest references are found in China where the RFID-based shops have received positive feedback for their user-friendliness,” says Jukka Peltoniemi who is responsible for automated services at Neste.  The Easy Deli store will be opened in conjunction with the Neste Express station in Ratakatu, Helsinki. During the summer of 2020, Neste will also open another Easy Deli store using the RFID technology in the Helsinki area. The company aims to further open new Easy Deli stores in conjunction with unmanned Neste stations in Riga, Latvia, during 2020. The 24-hour self-service stores complement Neste’s range of services alongside conventional stations.   Quicker service and less waste with RFID technology Nordic ID develops RFID-based (Radio Frequency Identification) item tracking and tracing services for collecting product data. RFID technology allows individual products to be scanned without visual contact. As a result, a large number of products can be scanned in only a few seconds. Furthermore, there are less scanning errors, as not every product needs to be scanned separately.  “The idea for this solution was triggered by the changes in consumers’ shopping behavior. People want to go shopping when it suits them – close to their home and around the clock. They do not want to wait in line and may even abandon their purchases if the line is perceived too long. Using barcode- based self-checkouts may even take longer than traditional manned checkouts. Scanning the barcode of every product may be inconvenient for customers not familiar with the system, making purchasing even slower,” says Juuso Lehmuskoski, CEO of Nordic ID. In the retail industry, fashion and apparel were the first to adopt RFID technology. In addition to making shopping more precise and quicker, the technology enables anticipating and reducing food waste and preventing theft. “No more barcodes or scanning products one by one” To enter the Easy Deli store in Ratakatu, customers start by registering in the Neste mobile app. This ensures secure shopping and prevents any misuse and vandalism.  After registering, customers pick out their products and place them on the RFID-based self-checkout, which scans all the products simultaneously in only a few seconds. Finally, customers pay for their purchases using Apple Pay, Google Pay or a payment card.  “The Easy Deli concept was previously tested in Vantaa, Finland, with consumer experiences being encouraging. In addition to quick and smooth shopping, the Easy Deli store is versatile thanks to its mobility. The store can be set up quickly without any construction or excavation work. It has been built using sustainable and eco-friendly materials, and its energy consumption has already been minimized during the building stage. If there is enough demand in the market, we could expand the shop concept in new locations,” Peltoniemi says.  More information: www.neste.fi/easydeli Neste Corporation Susanna SieppiVice President, Communications (act.) Further information: Jukka Peltoniemi, responsible for automated services, Neste. Please contact Neste’s media service, tel. +358 50 458 5076 / media@neste.com (weekdays from 8:30 a.m. to 4:00 p.m.). Nordic ID: Juuso Lehmuskoski, CEO, Nordic ID. Tel. +358 40 510 3790 / juuso.lehmuskoski@nordicid.com.

Clas Ohlson year-end report 2019/20

Financial year – 1 May to 30 Apr • Sales in the Nordics increased by 2% to 8,666 MSEK (8,489), organic growth up 3%, and total sales and organic growth were unchanged at 8,758 MSEK (8,772). • Online sales increased by 25% to 542 MSEK (432). • Operating profit, including non-recurring costs and costs linked to the CO100+ action programme, totalled 549 MSEK (94). Excluding the effect of IFRS 16, operating profit amounted to 454 MSEK. • Underlying operating profit amounted to 581 MSEK (497) (excl. IFRS 16) • The operating margin was 6.3% (1.1). • Profit after tax totalled 376 MSEK (72) • Earnings per share amounted to 5.94 SEK (1.13) • Macroeconomic trends and their impact on retail sector as a result of Covid-19 remain uncertain. At this stage, the Board intends to safeguard Clas Ohlson's solid financial position and flexibility and therefore proposes that no dividend be paid for the 2019/20 financial year. Events after the end of the reporting period • Sales in the Nordics in May decreased by 1% to 626 MSEK (631), organic growth up 5% and total sales decreased by 2% to 630 MSEK (641), organic growth up 4% • Online sales in May increased by 68% to 61 MSEK (36)   CEO Lotta Lyrå comments on fourth quarter/financial year 2019/20:  A relevant offering generates growth The corona pandemic has resulted in major consequences for all people and for society at large. At Clas Ohlson, the safety of our employees and customers is, and remains, our highest priority. At the same time, we are working to adapt to new customer requirements caused by the pandemic. Many people are spending more time at home and we have seen elevated demand for products for both the home office and DIY. Accordingly, we have worked intensely during the quarter to adapt the commercial agenda and most of the operations. This has generated results. A relevant range combined with our store network, convenient online shopping on our own and other companies’ platforms, such as Mathem and Kolonial, and flexible delivery options have created an attractive mix. The outcomes for our sales and profitability have thus been relatively favourable for the first few months of the corona pandemic. In April, we grew organically and online sales increased by a full 61 per cent, corresponding to 10 per cent of sales for the month. Fourth-quarter organic sales in the Nordics were at the same level as in the year-earlier period. Although the weak NOK had a negative impact, the Norwegian operations have proven the strength of Clas Ohlson’s offering and brand. In Sweden, COVID-19 primarily affected sales in the form of a lower footfall in central store locations in the large cities and in stores that normally benefit from cross-border shopping. In Finland, we continued our work on strengthening Clas Ohlson’s position in the market but the restrictions imposed to stop the spread of coronavirus had a significantly negative impact on sales for the quarter. By more effectively controlling inventory we have been able to offset weaker sales and reduce inventory levels by about 200 MSEK compared with 30 April last year. Corona has, to date, had a limited effect on our supply chain and we are confident in the supply of goods as we approach the summer. The gross margin was at 39.9 per cent for the quarter compared with 38.2 per cent in the preceding year. We are delivering on our promises The CO100+ action programme ended this quarter. The operating margin (excluding IFRS 16) of 5.2 per cent means that we achieved the target of 4-6 per cent announced when our growth strategy was launched two years ago. Underlying operating profit for the fourth quarter amounted to -31 MSEK compared with -52 MSEK last year, and for the full-year was 581 MSEK compared with 497 MSEK last year. This shows that both our systematic and goal-oriented cost and growth initiatives under the CO100+ programme and the closure of the store networks in Germany and the UK have yielded the promised results. The initiatives thus have a positive effect on the margin in the short term, and also provide us with a better platform for profitable growth going forward. According to plan, we have reduced the rolling cost level to between 225 and 250 MSEK. Part of this has gradually been realised, mainly in savings from indirect spend, lower costs of goods for sale and a more efficient organisation. The remaining about 150-160 MSEK will be realised in the 2020/21 financial year. Combined with a continuing focus on online growth and sales per square metre and per customer, this will help us achieve our long-term profitability target of an operating margin of 6-8 per cent. Besides completing the CO100+ programme, we took additional measures during the quarter to tackle the consequences of the corona pandemic. In April, about 300 store employees were temporarily laid off, due to shorter opening hours and fewer visitors.  This currently affects only a small number of city stores and stores that have significant cross-border shopping. Furthermore, about 200 office employees have had their working hours reduced until mid-June. The layoffs for this group will not be extended and the assessment is that they will not be resumed after the holiday period. Negotiations are being held with property owners regarding rent relief. We have also put in place a more cost-efficient and agile organisation by simplifying our management structure and reducing the number of administrative positions. Well-equipped for the journey ahead The macroeconomic climate and the impact on customer behaviour are the greatest uncertainty factors for our business related to coronavirus. We are also affected by fluctuations in the currency market. Furthermore, we must add that the retail sector is already undergoing extensive change. I believe that after the pandemic we will see a new normal and that, coupled with the underlying structural change in the retail sector, this new normal will require a great deal of flexibility, sensitivity and continued upgrading of the business model. I am also convinced that the companies that offer their customers the opportunity to live more sustainably will have a competitive advantage. In addition to the clear results of our change process, we have in recent months also received confirmation that our business model is robust and flexible to meet unforeseen external events. In the spirit of our founder Clas Ohlson, who always placed the customer first and sought simplicity, we are now continuing to develop our operations. We are well equipped for the future on which the road ahead is based on: offering an even more relevant range of products, stores in the right locations, attractive online shopping on our own and other companies’ platforms, flexible delivery options and a strong service offering. On this journey, we bring with us the strength of our extensive, and now accelerated, work on sustainability. This is how Clas Ohlson will continue to generate customer and shareholder value. Finally, I would particularly like to sincerely thank all of my fantastic Clas Ohlson colleagues whose strength of purpose makes a difference every day! Webcasted presentation today at 9:00 a.m CET President and CEO Lotta Lyrå and CFO Pär Christiansen will comment on the report today at 9:00 a.m CET in a webcasted presentation which is reached via this link . The presentation takes place in English and is followed by a Q&A session. To participate in the conference via telephone, and thereby be able to ask questions verbally, please dial in on any number below a couple of minutes before the start of the call: SE: +46856642707, UK: +443333009032, US: +18335268347 For further information, please contact: Niklas Carlsson, Group Head of Communications, +46 247 444 29, niklas.carlsson@clasohlson.se  This is information that Clas Ohlson AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. This information was submitted for publication, through the agency of the contact person set out above, at 7:00 a.m. CEST on 3 June 2020. 

Instalco now established in Sundsvall

Miljöventilation works with both heating and ventilation, offering project planning, installation, service and maintenance. For the 2019 business year, sales were approximately SEK 60 million. “For quite some time, Instalco has been wanting to establish the business in Sundsvall and this section of the eastern coast, where we haven’t been represented before. The acquisition of Miljöventilation gives us a foothold in this exciting market and geographically important area. In the area of ventilation, we are now starting to cover larger portions of the important markets in the north. Getting the business established in Sundsvall is an important first step towards becoming multidisciplinary in the area,” says Johan Larsson, Business Area Manager for Instalco North. Miljöventilation primarily serves Sundsvall, but it also does business in the region around Härnösand, Kramfors and Sollefteå. The company was established in 2008 and it has 23 employees with extensive experience in the electricity, heating and ventilation sector. Its customers are primarily property companies, county councils, municipalities and construction firms.  “We've always pursued a customer-first strategy and being a part of the Instalco Group will benefit both us and our customers. We're looking forward to participating in the Instalco network and helping grow the business along the northernmost coast of Sweden,” says Ulf Hallvede, CEO of Miljöventilation i Mellannorrland AB. Miljöventilation has a wide offering of solutions for air treatment and control & regulation technology at, primarily, healthcare facilities, schools, offices, stores, and other facilities in both the public and private sectors. Instalco will acquire 100 percent of the shares in Miljöventilation i Mellannorrland AB as of 2 June 2020.   For further information Fredrik Trahn, Head of IR and Communications,phone +46 70 913 67 96, e-mail fredrik.trahn@instalco.se   Instalco is one of the leading installation companies in the Nordic region, active in the areas of heating, plumbing, electricity, cooling and industrial solutions. We offer installation, service and maintenance of systems installed at properties and facilities throughout Sweden, Norway and Finland. The operations are conducted through approximately 70 leading and highly specialised local companies, with the support of a small central organisation. Instalco is listed at Nasdaq Stockholm under the ticker INSTAL. For further information, visit www.instalco.se 

IONITY chooses Caverion as a service partner for EV high power charging stations in five countries

IONITY chooses Caverion as a service partner for EV high power charging stations in five countries Caverion and IONITY have established an international service partnership. Caverion will be responsible for the service and maintenance of transformers at the electric vehicle (EV) high power charging stations in Norway, Finland, Lithuania, Latvia and Estonia. IONITY’s high-power 350-kW charging stations are located along major highways and they allow drivers to charge their EV’s with an exceptional speed, in less than 20 minutes (depending on the capacity of their battery). “IONITY’s goal is to build a high power charging network along major highways in Europe. We look for international partners who can offer us reliable, professional and fast service with consistent quality. We have worked with Caverion in Norway and based on our experience, we were ready to take the next step in our partnership,” says Jan Haugen Ihle, IONITY Regional Head of EU North. Maintaining high power charging stations requires extensive technical expertise and certified experience. Operations are centrally managed by Caverion and carried out by local experts in each country. Currently, Caverion is also installing new charging stations for IONITY in Norway and Sweden. “E-mobility provides an exciting growth opportunity for Caverion, well matching with our strong capabilities in the area of smart technologies. We are very proud to expand our partnership with IONITY to support Northern Europe’s move towards a sustainable future,” says Laura Karotie, Vice President, Services Business Development. IONITY is a joint venture of BMW Group, Ford Motor Company, Mercedes Benz AG and Volkswagen Group with Audi and Porsche. With over 400 charging stations along major European highways, IONITY is building Europe’s leading, high power charging network for electric vehicles. Photo: IONITY

Flexion Mobile launches Chapters on Amazon App Store

LONDON, 3rd of June, 2020 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company today announced that it has launched Chapters: Interactive Stories on the Amazon App Store. This marks the 5th Google Play Top 100 US grossing game launched by Flexion on the Amazon App Store since the collaboration with Amazon began in 2017. The company also announced that Amazon App Store is its biggest app store partner in terms of revenue generated to its developers and that monetization per user is generally higher than on Google Play.  "User acquisition has become a critical part of every developer's life and it is very competitive and costly. That's why distribution through stores such as Amazon App Store is becoming increasingly attractive for many developers", says Jens Lauritzson, CEO of Flexion Mobile. Amazon App Store was one of the first to launch on Android in 2011 and is the most known alternative to Google Play. It is available in more than 200 countries. "There is a lot more to it than just launching and technically supporting a game. Each store has its own processes and tools and Amazon App Store in particular offers developers a range of great marketing tools. We invested early into the growing ecosystem outside Google Play and can help developers maximise this opportunity", says Jens Lauritzson. Flexion is the leader in game distribution to new stores and makes it easy for game developers to get their games onto Amazon App Store as well as many other stores. The agreement with Crazy Maple Studios for Chapters: Interactive Stories was announced on the 28th of January 2020.

Isofol’s rights issue oversubscribed

Not for publication, distribution or release, directly or indirectly, in whole or in part, within or into the US, Canada, Japan, Australia, Hong Kong, New Zeeland or any other jurisdiction in which such publication, distribution or release may be contravening to any applicable laws or rules. Additional restrictions are applicable, please see “Important information” in the end of this press release. The result of the Rights Issue of maximum 42,739,736 shares shows that 41,501,048 new shares, corresponding to approximately 97.1 percent of the Rights Issue, have been subscribed for with subscription rights. Additionally, 94,170,568 shares were subscribed for without subscription rights of which 1,238,688 shares, corresponding to 2.9 percent of the Rights Issue, have been allotted to investors that have subscribed for shares without subscription rights. The Rights Issue is thus oversubscribed. Allotment of shares subscribed for without subscription rights has been made in accordance with the resolved allotment principles. Notice of allotment of shares subscribed for without subscription rights will only be sent to those who have been allotted shares. Payment shall be made in accordance with the instructions on the contract note. Nominee-registered shareholders will receive notice of allotment and payment in accordance with the procedures of each nominee. Due to the oversubscription of the Rights Issue, the Board of Directors of Isofol has exercised the Over-Allotment Option to meet additional demand from strategic investors through a directed issue of 8,571,428 new shares. Shares in the Over-Allotment Option were allotted to several investors, among others, The Fourth Swedish National Pension Fund (“AP4”), thereby broadening Isofol’s shareholder base. Isofol’s CEO Ulf Jungnelius comments: “We are very pleased with the strong support from both existing and new shareholders in the Rights Issue which made it possible to exercise the Over-Allotment Option. The Rights Issue in combination with the Over-Allotment Option will give Isofol the financial resources to execute the global Phase III study AGENT and ensure that we continue our successful development of arfolitixorin in accordance with our business plan and strategy.” Following the Rights Issue and Over-Allotment Option, Isofol’s share capital will increase by approximately SEK 1,570,993.9 to approximately SEK 2,552,442.3 and the number of shares in Isofol will increase by 51,311,164 shares to 83,365,966 shares. The shares subscribed for with subscription rights are expected to be registered with the Swedish Companies Registration Office (the “SCRO”) on or about June 5, 2020 and are expected to begin trading on Nasdaq First North Premier Growth Market on June 9, 2020. The shares subscribed for without subscription rights and through exercise of the Over-Allotment Option are expected to be registered with the SCRO on or about June 16, 2020 and are expected to begin trading on Nasdaq First North Premier Growth Market on June 18, 2020. Advisers Carnegie Investment Bank AB (publ) and Pareto Securities AB act as Joint Bookrunners in connection with the Rights Issue and the potential Over-Allotment Option. Vinge law firm acts as legal adviser to Isofol, and Baker McKenzie acts as legal adviser to the Joint Bookrunners. For further information, please contact Isofol Medical AB (publ)Jarl Ulf Jungnelius, M.D., Chief Executive OfficerE-mail: jungnelius@isofolmedical.comMobile: +46 (0) 709 16 89 55 Certified AdviserFNCA Sweden ABE-mail: info@fnca.sePhone: +46 (0)8 528 003 99 This information is such information that Isofol Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU) No 596/2014. The information was submitted for publication through the agency of the Company’s CEO at 08:00 CET on June 3, 2020. About arfolitixorin Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase III study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective. About Isofol Medical AB (publ) Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB is traded on the Nasdaq First North Premier Growth Market. Certified Adviser is FNCA Sweden AB Important information This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in Isofol in any jurisdiction, not from Isofol or from any other person. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zeeland, the United States, or in any other jurisdiction where such announcement, publication or distribution of the information may not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. The securities referred to herein have not and will not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. Forward-looking statements This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release. www.isofolmedical.com

Sectra’s year-end report 2019/2020: Sectra grows with increased profitability—operating profit for the year increased 25.4%

2019/2020 fiscal year · Order bookings amounted to SEK 1,816.0 million (2,132.8). The comparative year included Sectra’s largest order ever—a 13-year agreement with NSW Health in Australia worth SEK 560 million. · Net sales rose 17.5% to SEK 1,661.1 million (1,413.5). Adjusted for currency fluctuations, sales increased 14.7%. · Operating profit rose 25.4% to SEK 295.3 million (235.5), corresponding to an operating margin of 17.8% (16.7). Adjusted for currency fluctuations, operating profit increased 19.2%.  · Profit before tax amounted to SEK 303.0 million (248.8).  · This result includes nonrecurring items (refer to Secure Communications, page 10). These items had a positive net effect of SEK 1.4 million on operating profit. · Cash flow after changes in working capital amounted to SEK 296.3 million (252.5).  · The Board and the President propose that the 2020 Annual General Meeting (AGM) resolve to distribute SEK 4.50 per share to the shareholders through a 2:1 share split in combination with a mandatory redemption process (refer to page 13). No ordinary dividend is proposed. Fourth quarter, February–April 2020 · Order bookings amounted to SEK 716.2 million (1,104.9). The comparative quarter included the major order from NSW Health. Of the order bookings during the quarter, 36% were recognized during the fourth quarter and a further estimated 34% to 44% pertains to revenue within 12 months after the end of the quarter.  · Net sales increased 7.1% to SEK 507.6 million (474.1). Adjusted for currency fluctuations, sales increased 5.0%. · Operating profit rose 18.1% to SEK 123.6 million (104.7), corresponding to an operating margin of 24.3% (22.1). Adjusted for currency fluctuations, operating profit increased 12.5%. · Profit before tax amounted to SEK 126.7 million (110.9).  · Cash flow after changes in working capital amounted to SEK 81.0 million (72.1).  · The outbreak of COVID-19 has not had any significant effect on Sectra’s financial outcome. Torbjörn Kronander, CEO and President Sectra AB, comments"When our customers in the healthcare sector become more efficient in their daily work and can thus provide care for more people, or when society’s vulnerability decreases through the use of our data security solutions, then we have also succeeded. It is deeply satisfying that our long-term efforts in creating real value for customers, patients and society at large have enabled us to report the best earnings year in Sectra’s history."   "Several of our projects are extensive, which leads to broad fluctuations between quarters since a significant portion of earnings is recognized in conjunction with services going online and project deliveries. Accordingly, it is important to look more at trends than at the output for an individual quarter when assessing our development. In the coming fiscal year we expect a weaker first quarter than normal and a sharp focus on deploying our services to customers during the second half of the year, particularly during the spring months. This is due in part to natural seasonal variations, when many customers want to come online before the relatively calm summer period, but also to delays in projects and orders because of COVID-19. Over the long term, our new subscription model for software licenses will enable more balance between quarters, but it is believed this will not have a major effect over the next few years." "Our stable development and positive underlying cash flows and profitability give me every reason to remain optimistic. We have a number of exciting projects in the pipeline as well as completely new geographic markets that could eventually become significant. Our possibilities for growth are strong in all operating areas for the foreseeable future, even if COVID-19 will likely mean temporarily dampened demand in certain markets. With our work and investments in the field, and innovation that has the potential to increase customer value, we are creating value for our customers and are thus helping to make society healthier and safer. This customer value is the foundation of our success, and also determines how we successfully create shareholder value and returns for our owners.See the attached year-end report for further CEO comments and information."Presentation of the interim report with in-depth information on the new subscription model Torbjörn Kronander, President and CEO of Sectra AB, and Mats Franzén, CFO of Sectra AB, will present the financial report and answer questions. Fredrik Gustavsson, CTO and Pre-Sales/Product Marketing Manager at Sectra Imaging IT Solutions AB, will present Sectra’s new subscription model for software licenses. The presentation will be held in English. When: Time: June 3, 2020, at 10:00 amFollow live or listen to the recording afterward: investor.sectra.com/q4report1920 SE: +46850558366UK: +443333009035US: +18335268397  This information constitutes information that Sectra AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and/or the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 8:15 a.m. (CET) on June 3, 2020.

PowerCell receives orders for fuel cell stacks and fuel cell systems from Bumhan worth MSEK 3.5

Bumhan Industries Co., Ltd is PowerCell Sweden’s distributor, partner and service partner in the South Korean market since 2018. Bumhan Industries Co., Ltd was founded in 1990 and is specialized in the manufacturing of air and gas compressors. In order to increase its efforts within fuel cells Bumhan has decided to establish a new subsidiary, Bumhan Fuel Cells Co., Ltd, focusing exclusively on fuel cells and the fuel cell technology. The subsidiary will also take over the distribution contract that the parental company has with PowerCell Sweden.   “South Korea is investing heavily in the fuel cell technology and by increasing our focus on the sector we want to better capitalize on the opportunities presented. Our new subsidiary will put all its efforts into the fuel cell segment something we are convinced will further increase our sales and strengthen the company”, Hyun Khil Shin, vice president at Bumhan Industries said. The MSEK 3,5 order includes fuel cells and fuel cell stacks for stationary applications. The order is estimated to be delivered during the second and third quarter 2020. “South Korea is at the forefront of the development of the fuel cell technology and is a leader within automotive and stationary applications. Bumhans increased efforts within the technology is yet another proof of the development and the importance of the South Korean market”, Yibo Zhao, Manager Sales Area Asia at PowerCell Sweden AB. For further information, please contact: Per WassénCEO, PowerCell Sweden AB (publ)Phone: +46 (0) 31 720 36 20Email: per.wassen@powercell.se About PowerCell Sweden AB (publ)PowerCell Sweden AB (publ) develops and produces fuel cell stacks and systems for stationary and mobile applications with a world class energy density. The fuel cells are powered by hydrogen, pure or reformed, and produce electricity and heat with no emissions other than water. As the stacks and systems are compact, modular and scalable, they are easily adjusted to any customer need. PowerCell  was founded in 2008 as an industrial spinout from the Volvo Group. The share (PCELL) is since 2014 subject to trade at Nasdaq First North Growth Market, Stockholm. G&W Fondkommission is Certified Adviser, e-mail: ca@gwkapital.se, phone: +46 8 503 000 50.

Harding, Mattei, Byström - Don Giovanni live from Swedish Radio Concert Hall

­Peter Mattei, Daniel Harding and Malin Byström in Mozart's Don Giovanni at the Swedish Radio Concert Hall, Berwaldhallen on June 13.Daniel Harding conducts his first concert on Friday June 5 with a programme built around the four movements of Sibelius’ Fourth Symphony and Thomas Tranströmer’s poems of isolation. Ann Hallenberg sings Mahler and Bach, and the Swedish Radio Choir perform Purcell. Harding says of this programme: "The music touches on the contrasting natures of being alone, of isolation and loneliness, the courage required to look life straight in the eyes (as Sibelius himself wrote) and to contemplate reality however unforgiving it may be."    ­ On Saturday June 13, Harding and the Swedish Radio Symphony Orchestra are then joined by an elite cast of Swedish opera stars, including Peter Mattei, Malin Byström and Johanna Wallroth, for a unique, staged performance of Mozart's opera Don Giovanni at Berwaldhallen. It is directed by Andrew Staples, who also sings, with scenography by Bengt Gomér and Helle Carlsson, broadcast live for free on Berwaldhallen Play.    ­ The theme of separation also features at the heart of Andrew Staples’ staging of Don Giovanni: "One of the things this situation has taught me is how much I rely on my electronic devices. In this staging we explore the darker side of a reliance on screens and remote images, allowing us to examine Don Giovanni’s need for intimacy and adapt that idea to our own current situation. We imagine a world similar to ours now, where the characters maintain a physical distance and satisfy their craving for validation through their proximity to screens. In this world Don Giovanni is less concerned with physical contact. Instead, he desires to capture and curate the moment of seduction."    ­ Staffan Becker, Berwaldhallen General Manager, commented: "At a time when we need music more than ever, I am proud of what we have achieved in Berwaldhallen this Spring. The orchestra, choir and whole team adapted quickly to the situation and continued to bring live concerts to our audiences. To close our season with Don Giovanni, at a time when too many concert halls and opera houses remain dark, is a unique and extraordinary moment."  Friday, 5 June 2020 at 19.00 h CET"SOLITUDE"A programme built around the four movements of Sibelius' symphonyand Thomas Tranströmer’s poems SIBELIUS: Symphony No. 4 in A minorMAHLER: "Der Einsame im Herbst" from Das Lied von der ErdePURCELL: Music for the Funeral of Queen MaryJ.S. BACH: "Erbarme dich" from St Matthew Passion Swedish Radio Symphony OrchestraSwedish Radio ChoirDaniel Harding conductorAnn Hallenberg mezzo sopranoPoems read by Krister Henriksson  Available to watch live for free and for a further 90 days on:► https://www.berwaldhallen.se/play/◀︎ Available to listen live for free on:► https://sverigesradio.se/p2 ◀︎ Saturday, 13 June 2020 at 19.00 h CETMOZART: DON GIOVANNI Swedish Radio Symphony OrchestraSwedish Radio ChoirDaniel Harding conductorPeter Mattei Don GiovanniJohan Schinkler Il CommendatoreMari Eriksmoen Donna AnnaAndrew Staples Don OttavioMalin Byström Donna ElviraJohn Lundgen LeporelloHenning von Schulman MasettoJohanna Wallroth Zerlina Bengt Gomér, Helle Carlsson creative teamAndrew Staples director Available to watch live for free and for a further 30 days on:► https://www.berwaldhallen.se/play/ ◀︎ Available to listen live for free on:► https://sverigesradio.se/p2 ◀︎ Berwaldhallen is the Swedish Radio Concert Hall and home to the Swedish Radio Symphony Orchestra and Choir. It is part of the Swedish Public Service company Sveriges Radio. For more information, contact

NENT Group launches Norwegian drama-comedy ‘Suck It Up’ as next original production

· Series created by Henriette Steenstrup (‘Ragnarok’; ‘Lilyhammer’; ‘Beware of Children’) · NENT Group’s most recent Norwegian original, ‘The Machinery’, delivered most successful premiere of any Viaplay production · NENT Group to premiere at least 30 original productions in 2020 Families, frustration and fulfilment are the themes of Norwegian drama-comedy ‘Suck It Up’, which is the next original series from Nordic Entertainment Group (NENT Group), the Nordic region's leading streaming company. Created, written by and starring award-winning Norwegian actress Henriette Steenstrup, the six-part show will premiere exclusively across the Nordic region on NENT Group's Viaplay streaming service in 2021. Three teenagers and an ageing father to look after at home, thirty more children to care for at work and no time for any of them – being a working parent is far from child’s play for Pernille, brought to life by Henriette Steenstrup (‘Ragnarok’; ‘Lilyhammer’; winner of the prestigious Dragon Award for Best Acting at the 2020 Gothenburg Film Festival for ‘Beware of Children’). And will she ever find a moment for her love life? Filming of ‘Suck it Up’ (Norwegian title: ‘Pørni’; Swedish title: ‘Pernille’) is currently underway in Oslo. The series is produced by Bård Fjulsrud (‘Nobel’) and Ida Håndlykken Kvernstrøm (‘Unge lovende’) at Monster, and is directed by Gunnar Vikene (NENT Group’s ‘Occupied’) with Charlotte Blom (‘Neste sommer’). NENT Group’s most recent Norwegian original series, the action thriller ‘The Machinery ’, premiered exclusively on Viaplay on 24 May. The show was streamed more times in its opening 24 hours than any other Viaplay original production so far, supported by Viaplay’s fast-growing addressable customer base and high customer engagement. At the end of March, NENT Group had a total of 2,510k paying Viaplay subscribers. Filippa Wallestam, NENT Group Chief Content Officer: “Our latest original series is at once heartwarming, infuriating and joyful – just like parenting. Henriette Steenstrup’s career continues to hit new heights and ‘Suck It Up’ is her most personal project yet, headlined by a complex character living a quietly heroic life that will resonate with audiences everywhere. With our most recent smash hit ‘The Machinery’ currently breaking Viaplay records across the Nordic region, we are continuing to invest in the broadest and best streaming experiences in the business.” About NENT Group’s original productions NENT Group is set to premiere a minimum of 30 original productions in 2020. In the past six months, ‘The Machinery ’; season two of ‘The Lawyer ’; ‘Cold Courage ’; ‘Big Lars ’; ‘The Last Journey of the Vikings ’; season two of ‘Saga’s Stories ’; ‘Thicker than Water ’; ‘The Children’s Queen’; season two of ‘Rig 45 ’; ‘Mia’s Magic Playground ’; season two of ‘Couple Trouble’; ‘Box 21 ’; ‘The Art of Living ’; and season three of ‘Occupied’ have premiered on Viaplay across the Nordic region. Recently announced originals include ‘Orca ’; ‘The Swarm ’; ‘Delete Me ’; season two of ‘The Truth Will Out ’; ‘Harmonica ’; season two of ‘Pros and Cons ’; ‘Perfect People ’; season two of ‘Face to Face ’; ‘Huss ’; season two of ‘Those Who Kill ’; seasons two and three of ‘Fixi in Playland ’; season two of ‘Honour ’; ‘Hammarvik ’; season two of ‘Love Me ’; ‘First Responders ’; ‘Partisan ’; seasons one and two of ‘American Runestone ’; ‘Home Invasion ’; ‘The Professionals’; ‘Shadowplay ’; ‘The Ambassador ’; ‘Margeaux ’; ‘Cryptid ’; and ‘Commando ’. As well as breaking Nordic viewing records, NENT Group’s originals are also reaching audiences around the world. Amongst others, ‘ALEX’ has been sold in Europe, Asia and the US ; ‘Veni Vidi Vici’ has premiered on Hulu  and is set for a US remake in partnership with Lionsgate ; ‘Pros and Cons’ has been picked up by Canal+ and Topic ; ‘Honour’ has been sold to RTL and VRT ; and ‘Those Who Kill’ is available on the BBC and ARTE . During 2019, NENT Group announced a UK-based joint venture with FilmNation Entertainment  and invested in US studio Picturestart . **** NOTES TO EDITORS Nordic Entertainment Group AB (publ) (NENT Group) is the Nordic region’s leading entertainment provider. We entertain millions of people every day with our streaming services, TV channels and radio stations, and our production companies create content that is experienced around the world. We make life more entertaining by telling stories, touching lives and expanding worlds – from live sports, movies and series to music and original shows. Headquartered in Stockholm, NENT Group is listed on Nasdaq Stockholm (‘NENT A’ and ‘NENT B’). Contact us:press@nentgroup.com (or Nicholas Smith, Acting Head of External Communications; +46 73 699 26 95)investors@nentgroup.com (or Stefan Lycke, Head of Investor Relations; +46 73 699 27 14) Download high-resolution photos: Flickr  Follow us:nentgroup.com  / Facebook  / Twitter  / LinkedIn  / Instagram  Privacy policy:To read NENT Group’s privacy policy, click here 

Bactiguard initiates collaboration with online pharmacy Apotea on sales of Hydrocyn® aqua

“We are pleased that Bactiguard initially has chosen to work exclusively with Apotea for the launch of Hydrocyn to consumers,” says Per Svärdson, Apotea's CEO. “We are seeing a continued high demand for disinfectants. That we can now offer advanced disinfection, which has a proven effect against the coronavirus, is important in the fight against the spread of covid-19. Apotea is Sweden's largest online pharmacy with deliveries all over Sweden, every day of the week,” Per Svärdson continues. “The spread of the covid-19 pandemic has been much greater and more severe than anyone could imagine. The lack of effective remedies and vaccine increases the need for prevention. Hand disinfection is one of the most important measures to prevent being infected or spreading the virus to others. Therefore, we are very pleased that we are now able to offer Hydrocyn, which effectively kills the Corona virus to private individuals in collaboration with Apotea,” says Cecilia Edström, CEO of Bactiguard. Bactiguard launched Hydrocyn in the Swedish market in mid-March and received customer orders, including from the Police Authority, in the first days after the launch, at a total value of just over SEK 20 million. Initially, customers with critical societal functions were given priority. On June 2, the results of tests conducted by the Swedish National Veterinary Institute (SVA) on the new coronavirus (SARS-CoV-2) that causes covid-19 were published. The tests show that 99.9% of the virus particles were killed after exposure to Hydrocyn (link to press release ). From Friday, June 5, private individuals will also be able to order Hydrocyn through the Swedish online pharmacy Apotea. About Hydrocyn® aquaHydrocyn® aqua is an advanced disinfectant that is pH-neutral and water-based and can be used as a disinfectant solution for, for example, skin and surfaces. Unlike alcohol-based disinfectants, Hydrocyn® aqua is not irritating, toxic or harmful to the body. It is also not flammable. The active substance (HOCl) is a natural part of the human immune system. The product is CE marked (approved in the EU), registered by the US FDA and approved by the Swedish Chemicals Agency.Film about Hydrocyn >>>   This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-06-03, at.11.05.       For further information, please contact:Cecilia Edström, CEO, e-mail cecilia.edstrom@bactiguard.se, phone: +46 8 440 58 80 Christian Huber, procurement manager Apotea, e-mail christian.huber@apotea.semobile: +46 701 981 016 

Peptonic has completed the acquisition of a majority of the shares in Lune Group Oy

Acquisition of existing shares in Lune Peptonic has today completed the acquisition of 60 of in total 100 existing shares in Lune from the current shareholders of Lune (the “Sellers”) The fixed purchase price for the existing shares amounts to approx. 1.8 MEUR, corresponding to approx. 19.2 MSEK (based on a SEK/EUR exchange rate of 10.64), and shall be paid in its entirety in the form of new shares in Peptonic (the “Consideration Shares”) through a share issue against payment in kind (see below). Further, Peptonic has a call option which entails a right to acquire the remaining shares in Lune from the Sellers during the period of three years after closing against a consideration based on the same valuation. If Peptonic exercises the call option, the total purchase price for the existing shares in Lune (excluding a potential earn-out) will amount to approx. 3.0 MEUR, corresponding to 32.0 MSEK. The Sellers are also entitled to a variable earn-out based on the net sales and gross profits of Lune in the financial years 2021 and 2022.  See the press release from 14 May, 2020 for more information regarding Lune and the transaction.  Capital contribution and subscription of new shares in Lune As described in the press release from 14 May 2020, Peptonic has undertaken to make a capital injection to Lune of in total 1.5 MEUR, corresponding to approx. 16.0 MSEK, by subscribing for in total 50 new shares in Lune. 25 shares (Tranche 1) have been subscribed for by Peptonic in connection with closing. The subscription price for the newly issued shares in Tranche 1 amounts to 0.75 MEUR, corresponding to approx. 8.0 MSEK. The remaining 25 shares (Tranche 2) shall be subscribed and paid for no later than 28 February 2021.  Share issue to the Sellers against payment in kind The board in Peptonic has today resolved, in accordance with the authorization from the annual general meeting 2019, on an issue of 12,228,133 new shares, the so-called Consideration Shares, to the Sellers against payment in kind, on the terms and conditions described in the press release from 14 May 2020. The reason for the share issue is to fulfill the Company's obligations under the share transfer agreement with the Sellers. Through the share issue, the share capital is increased with 1,222,813.30 SEK. The subscription price in the share issue is 1.567 SEK per share, which is equal to 115 percent of the volume weighted average price of Peptonic's share on Spotlight Stock Market during the period 29 April 2020 to 13 May 2020. Payment for the shares shall be made in kind through contribution of 60 existing shares in Lune. The non-cash consideration is estimated to be taken up in the Company´s balance sheet to a total value of 19,158,175 SEK. 7,336,880 shares have been subscribed for by Heli Kurjanen and 4,891,253 shares have been subscribed for by Mika Kurjanen.  The Sellers have entered into lock up undertakings, which means that the Sellers undertake not to transfer, pledge or otherwise dispose of the Consideration Shares during a certain period of time on the terms and conditions described in the press release from 14 May 2020.  Directed share issue to Vidarstiftelsen and loan from Vidarstiftelsen The board has today resolved, in accordance with the authorization from the annual general meeting 2019, on a directed share issue of 4,787,037 new shares on the terms and conditions described in the press release from 14 May 2020. Through the share issue, the share capital of Peptonic is increased by 478,703.70 SEK and Peptonic receives a cash contribution of 7.5 MSEK. The reason for the deviation from the shareholders' preferential right is to secure time and cost-effective partial financing of the cash consideration to be paid by Peptonic for the newly issued shares in Lune. The subscription price in the directed share issue to Vidarstiftelsen shall be the same as the subscription price in the directed share issue to the Sellers as described above, i.e. 1.567 SEK per share. Payment for the shares has been made through cash payment. All issued shares have been subscribed for by Vidarstiftelsen. Vidarstiftelsen is foundation with a mission to support the general public. The mission is to be fulfilled through grants given for e.g. scientific research, preparation of teaching and education, health care and hospital care, culture and environmental conservation. The income of the capital is to be used for the above mission. As described in the press release from 14 May 2020, Vidarstiftelsen has further undertaken to provide a loan to Peptonic in the amount of 7.5 MSEK. The Company may in its sole discretion determine whether to take up the loan or not. If Peptonic takes up the loan, it may be converted to shares in Peptonic. The further terms and conditions for the potential loan and conversion are set out in the press release from 14 May 2020.  Dilution effects and costs Through the new share issues described above, the share capital increases with in total 1,701,517 SEK through the issue of in total 17,015,170 shares. The total number of shares outstanding in the Company after such share issues will amount to 155,143,476 shares. The share issues will thus result in a total dilution effect for existing shareholders of approx. 11 percent. The costs for the share issue to the Sellers and the directed share issue to Vidarstiftelsen is expected to amount to approx. 50 TSEK. In addition, Peptonic has incurred cost of approx. 3 MSEK in legal, due diligence and analysis costs prior to the signing. These costs will be posted as acquisition costs.

Clarifying queries related to the AGM 2020

First of all, we are very glad to see the high interest in our Annual General Meeting. The fact that the shareholders are dedicated to contribute to Brighter’s long-term vision to this degree is fantastic. Unfortunately the formal requirements of the Notice of Annual General Meeting are considerable and the language may come across as complicated.  We have received a considerable number of questions from shareholders this week – most of which are related to the Annual General Meeting (”AGM”) to be held on June 15. We have also noticed that there are some faulty interpretations and conclusions drawn from the AGM proposals circulating in certain discussions. Therefore, Brighter would like to officially address this and hopefully clarify these issues. Nectarine HealthThere are rumours circulating saying that the item 19 proposal indicates that we are selling 35% of Nectarine Health, and at a below market price. This is not correct – Brighter currently holds 1.4 million preferential shares, 85% of Nectarines tax value and 90% of the votes, and 1.4 million normal shares, 15% of the tax value and 10% of the votes. The proposal suggests that a maximum of 35% of the normal shares may be sold to Nectarines employees and key personnel (which means 3.5% of the votes and thus also only 3.5% of the valuation). In addition, if the participants resign during the vesting period, Brighter has the right to buy back shares.  Long-term Incentive Programs for the employees, management and Board of DirectorsThe main reasons for implementing long-term incentive programs (LTI) are the same for Brighter as any company. The reason is to strengthen a company’s ability to attract and retain sought-after expertise, be an attractive employer, maintain its workforce and to ensure a common focus on long-term growth in shareholder value. Through a performance-based incentive program, the rewards provided to the participants can be linked to Brighter’s future prospects thereby prioritizing long-term growth and ensuring that the shareholders and participants have the same targets. The programs are assessed by the Remuneration Committee as critical to be able to achieve Brighters ambitious goals for the future, and without such risk a loss of key individuals and reduced opportunities for recruiting relevant talents. The LTI programs not stating the specific performance targets is in lime with general market practice since performance targets are commonly confidential information. The performance targets are established before the programs are implemented but will not be disclosed until after vesting.  However, after the program has run its course the performance targets will be publicly available so that there will be full disclosure. This is a practice also used by big companies such Clas Ohlson, Electrolux, Husqvarna, Intrum and Saab. ”Programs of this type are common among companies and are created primarily to attract and retain expertise over time and to create incentives to achieve good results in the business,” says Ola Svanberg, lawyer at Advokatfirman Lindahl and co-author of the book About incentive programs ("Om Incitamentsprogram", Norstedts Juridik). An alternative would be to increase salaries, or implement cash-driven programs, directly affecting the company’s cash flow. For Brighter, being investment driven, this would result in an increased need for additional capital acquisition and could potentially have a negative effect on the recently launched commercial activities. Furthermore, those alternatives would not need to be as transparent to the market. The proposed long-term incentive programs are based on a number of performance targets that have to be achieved, besides that the participants have to stay with Brighter for 3 years.  The cap for the share price factor of SEK 22.5 is so that the programs can not grow to insane levels. The link between share price in 2023 to today’s share price is to ensure that all participants have an incentive that is aligned with the shareholders. It is a future-oriented incentive, not only to reward employees who, if targets are reached, have made the company successful, but also to maintain the motivation to succeed over time. But perhaps the most crucial factor is to attract and retain the sought-after expertise. The reason for having the same targets for all programs is to make sure that everyone is aligned. As both EBITDA and revenue are performance factors besides share price, the programs are designed so that the management cannot skew the results by sacrificing profit for volume or vice versa. It is also important to know that the LTIs are structured so that they are cash neutral and put no strain on Brighters cash flow. The programs under item 15 & 17 are proposed to address the tax expense for Brighter resulting from the LTI programs under item 14 & 16. The LTI programs carry their own costs and do not affect company resources, thus they trigger no cost or cash flow effect on the normal business. The cash remuneration for the board is well below average for a listed company of Brighters size and market cap. Comparable figures from PWC puts Brighters level of cash remuneration below the lowest 10% of comparable companies. The LTI under item 16 for the board is to ensure that Brighter can attract and retain talented individuals willing to take on the risk of being a board member without putting a strain on Brighters cash flow as well as making sure that they have a long term focus that is in line with shareholder value created. For further information, please contact: ir@brighter.se Certified AdviserBrighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se. About Brighter AB (publ)Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.

Shape Robotics publishes prospectus for its initial public offering

Wednesday, June 3, 2020 15:55 CET NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. This announcement does not constitute a prospectus. No one should purchase or subscribe any securities in Shape Robotics A/S (“Shape Robotics” or “the Company”) except on the basis of information in the prospectus published by the Company in connection with the offering and admission of such securities to trading and official listing on Nasdaq First North Growth Market in Denmark. · Shape Robotics offers a minimum of 2 040 817 and a maximum of 2 755 102 new shares at a price of DKK 9.80 per share in connection with a listing on Nasdaq First North Growth Market in Denmark. · The proceeds of a maximum of DKK 27 million (gross) are to accelerate Shape Robotics growth by penetrating new markets and increasing market share in existing markets. · Irrevocable subscription undertakings of DKK 15.9 million has been obtained from cornerstone investors. · The offer corresponds to a pre-money valuation of Shape Robotics before the offer of DKK 40 million. · Offer period from 4 June to 18 June 2020. About Shape Robotics A/SShape Robotics A/S (”Shape Robotics” or ”the Company”) is a Danish robotics company with a strong position in the global educational technology (”EdTech”) market. The Company has developed Fable, a unique modular robot that makes it easy and fun for students to build and program their own robots. The development of Fable began in 2011 where the Company’s founders were working as robotics researchers together with other engineers, designers, and researchers from DTU, MIT Media Lab and LEGO®. The founders observed a need for a radically different educational robotics system where transition from idea to solution had to be smoother for both teacher and students. Since the launch of Fable in 2017 more than 5000 robots have been sold and shipped to schools around the world.Shape Robotics helps educational institutions provide excellent teaching that will prepare students for a fast-changing future where digital technologies, artificial intelligence, and automation are transforming life and work. Fable is a modular robot that students can build in seconds. The robot system is robust, can withstand everyday usage in classrooms and can be used to solve demanding tasks. Students code Fable depending on their experience - from simple block programming to coding in the advanced Python language. Comprehensive teaching materials has been developed in collaboration with professional educators. Therefore, Shape Robotics provides complete teaching solutions for educational institutions from the 3rd grade to high-school and vocational schools. Background for the offeringShape Robotics has built a platform for growth and market penetration on the global market for educational robots. The Company will take advantage of this opportunity to become a leading educational robotics company with strong global growth. By expanding and nurturing its sales network the Company will grow in existing markets and penetrate new high-opportunity markets. The Company also plans to launch new subscription services and will continue to develop new products, platforms and content. The Company’s ambition is to empower all teachers to create profoundly better learning using robotics. The type of learning that have a lasting positive impact and enables the students to get ready for their future education, job and life.Shape robotics has reached a point, where Fable has proven to be a highly attractive and competitive EdTech product. In order to take full advantage of the market traction and monetize on the rapidly growing market for educational robotics, the Company will require additional equity funding. Use of proceedsThrough the Offering, Shape Robotics is expected to raise gross proceeds (including the conversion of debt of 2.1 MDKK) of minimum DKK 20 million and maximum DKK 27 million before deduction of transaction costs, which are estimated to approximately DKK 3.5 million. Below is an estimate of the use of proceeds: · 60 percent will be used for sales and marketing to: · Continue to build a solid market foundation through existing and new distributors and resellers around the world. · Create awareness about Fable in key markets, e.g. by sales effort outreach to untapped market segments, participation in exhibitions and launching of campaigns and Fable robotics competitions. · Build and broaden the launch of subscription services. · 20 percent will be used for business infrastructure to: · Increase gross margin by implementing cost-reductions in the production, make the production scalable by outsourcing and by increasing stock of inventory. · Establish cost-effective global delivery by setting up logistics partnerships around the world. · 15 percent will be used for research and development: · Strengthen the product portfolio by developing new Fable products and improving the existing products, e.g. by developing new features and tools. · 5 percent will be used on educational content: · Adapt educational content for key markets, e.g. translating and mapping it to national curriculums. · Develop new educational content, e.g. content packages to teach artificial intelligence and IoT. Financial objectivesShape Robotics is operating towards the following financial targets: · Average revenue growth rate of more than 80% per annum between 2021 to 2023, with a target revenue of 55 MDKK in 2023; and · Positive cash flow from operating activities for the full year 2023. In 2019, Shape Robotics generated revenues of DKK 8.1 million and a negative EBIT of DKK 9.5 million. Prospectus and offering materialThe prospectus is available on www.shaperobotics.com and on www.vhcorp.se.The prospectus may also be obtained by contacting Shape Robotics or Västra Hamnen Corporate Finance AB. Information about the offeringVästra Hamnen Corporate Finance AB is financial advisor and Certified Adviser, and Moalem Weitemeyer Bendtsen advokatpartnerselskab is legal advisor to the Company. Danske Bank A/S acts as settlement and issuing agent, while Nordnet acts as selling agent in Sweden and Denmark.The offering comprises a minimum of 2 040 817 and a maximum of 2 755 102 new shares. Offer priceThe offer price is DKK 9.80 per share. Brokerage commission will not be charged. Based on the offer price, Shape Robotics market capitalization is expected to amount to a maximum of DKK 67 million after completion of the offering. Subscription period and submission of applications to subscribeApplications to subscribe Offer Shares are to be submitted during the period of 4 June - 18 June 2020. Applications should be made by submitting the application form enclosed in the prospectus, which may also be found on the Company’s website. The application form must be submitted to the investor’s own account holding bank in due time to allow the investor’s own account holding bank to process and forward the application to ensure that it is in the possession of Danske Bank no later than 16.00 (CET) on 18 June 2020. Applications may also be submitted directly to the selling agent Nordnet no later than 23:59. (CET) on 17 June 2020. Applications are binding and cannot be altered or cancelled. Reductions of subscriptionsIn the event that the total number of Offer Shares applied for in the offering exceeds the number of Offer Shares, reductions will be made as follows:  · With respect to applications for amounts of up to and including DKK 299,999, reductions will be made mathema­tically. However, no individual allocations will be made for less than 500 Offer Shares. · With respect to applications for amounts of DKK 300,000 and up, individual allocations will be made. Subscription undertakingsThe Company has obtained binding subscription undertakings for a total of DKK 15.9 million from Cornerstone Investors. In addition, existing shareholders have signed statements of intent for conversion of outstanding debt for a total of DKK 2.1 million. The conversion of debt, which was raised in April 2020, concerns funds already paid to the Company and thus will not form a part of the cash received from the Offering (i.e. cash proceeds). The subscription undertakings and conversion of outstanding debt amounts to a total of DKK 18.05 million, corresponding to approximately 66.8 percent of the maximum Offering and 90.2 percent of the minimum Offering.For a list of the Cornerstone Investors please refer to the table on page 40 in the pdf-version of the Prospectus. Admission to tradingThe result of the offering and the final number of Offer Shares will be published on 19 June 2020. First day of trading on Nasdaq First North Growth Market in Denmark is expected to be 25 June 2020. The Company has applied for admission to trading under the symbol “SHAPE”. Admission to trading is conditional on Nasdaq First North Growth Market in Denmark approving the distribution of shares to investors, among other things.It is expected that delivery against cash payment in DKK for the Offer Shares will take place on 23 June 2020 under the temporary ISIN code DK0061273208 to investors’ accounts with VP Securities A/S. The temporary ISIN code is expected to be merged into the permanent ISIN code DK0061273125 on June 26, 2020. All dealings in the Offer Shares prior to settlement of the offering will be for the account of, and at the sole risk of, the parties involved. Conditions for completionCompletion of the Offering is conditional upon the Offe­ring not being withdrawn. The Offering may be withdrawn by the Company at any time before the announcement of the result of the Offering takes place. The Offering may also be withdrawn if Nasdaq First North Growth Market Denmark is not satisfied that there will be a sufficiently broad distribution of the Shares to investors or if, for other reasons, the Shares cannot be admitted for trading on Nasdaq First North Growth Market Denmark. Any withdrawal of the Offering will be announced immediately through Nasdaq First North Growth Market Denmark. Further informationDavid Johan Christensen, CEO Shape Robotics A/STel. (+45) 26 85 09 03Email: david@shaperobotics.comRugmarken 18, 3520 Farum, Denmark Certified AdviserVästra Hamnen Corporate Finance ABChrister NilssonTel. (+46) 733 968 404Email: ca@vhcorp.seJungmansgatan 12, 211 11 Malmö, SwedenBredgade 30, 1260 Copenhagen, Denmark Important informationThis announcement does not constitute an offering circular. No one should purchase or subscribe for any shares in Shape Robotics A/S (“Shape Robotics” or “the Company”), except on the basis of information in the offering circular published by the Company in connection with the offering and admission of shares to trading on Nasdaq First North Growth Market in Denmark. Copies of the offering circular are available from the Company's registered office and, subject to certain exceptions, on the website of the Company. This announcement is not an offer to sell or a solicitation of any offer to buy any shares issued by Shape Robotics in any jurisdiction where such offer or sale would be unlawful and the announcement and the information contained herein are not for distribution or release, directly or indirectly, in or into such jurisdictions. In any member state of the European Economic Area (“EEA Member State”), other than Denmark, that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any EEA Member State, the “Prospectus Directive”), this announcement is only addressed to and is only directed at investors in that EEA Member State who fulfil the criteria for exemption from the obligation to publish an offering circular, including qualified investors within the meaning of the Prospectus Directive. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. Matters discussed in this release may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as “believe”, “expect”, “anticipate”, “intends”, “estimate”, “will”, “may”, “continue”, “should”, and similar expressions. The forward-looking statements in this announcement are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice.

Immunovia Intends To Carry Out A Directed Share Issue Through An Accelerated Book Building Process

INSIDE INFORMATION: Immunovia AB (publ) ("Immunovia" or the "Company") intends to carry out a directed issue of shares of approximately 15 percent of the issued share capital, with the potential to upsize the transaction, through an accelerated book building procedure (the "Directed Issue"). The proceeds from the Directed Issue will be used for the Company's investments in an accelerated commercialization start for IMMray™ PanCan-d and for general corporate purposes in accordance with the Company's communicated strategy. Immunovia has engaged Kempen & Co, Danske Bank and Vator Securities to explore the possibilities to conduct the Directed Issue. The Directed Issue Immunovia has, based on the authorization given by Immunovia's Annual General Meeting on 7 May 2020, engaged Kempen & Co, Danske Bank and Vator Securities to investigate the possibilities to conduct a directed issue of shares of approximately 15 percent of the issued share capital, with the potential to upsize the transaction, directed to Swedish and international investors of institutional character through an accelerated book building procedure. The book building process will begin immediately after the announcement of this press release. The Directed Issue is contingent on a resolution by the Board of Directors, which, alongside pricing and allocation is expected to occur prior to the beginning of trading on Nasdaq Stockholm at 09.00 CET on 4 June 2020. The Board of Directors may decide to extend or shorten the application period and can at any moment decide to terminate the book building process and thus refrain from conducting the Directed Issue. The proceeds from the Directed Issue are intended to finance the Company's investments in an accelerated commercialization start for IMMray™ PanCan-d and for general corporate purposes in accordance with Immunovia's communicated strategy. Assuming the Directed Issue provides the Company with gross proceeds of approximately MSEK 470, Immunovia's Board of Directors currently sees the Company's cash runway extended to Q3 2022. The reason for the deviation from the shareholders' preferential rights is to perform a capital raise in a time and cost-effective manner and to raise capital at favorable conditions for the Company's continued expansion. In connection with the Directed Issue, the Company has undertaken, with customary exceptions, not to issue additional shares for a period of 180 calendar days after closing of the Directed Issue. Board members and persons of the management holding shares and/or warrants have undertaken not to sell any shares in the Company for a period of 180 calendar days after registration of the shares with the Swedish Companies Registration Office, with customary exceptions. Advisors Kempen & Co and Danske Bank are Joint Global Coordinators and Joint Bookrunners, and Vator Securities is Joint Bookrunner. Baker McKenzie is legal advisor to the Company and White & Case is legal advisor to Kempen & Co, Danske Bank and Vator Securities in connection with the Directed Issue. Responsible person This information is such information as Immunovia AB (publ) is obliged to disclose under the EU Market Abuse Regulation 596/2014. The information was provided by the contact person below for publication at the point in time specified by Immunovia's news distributer Cision at the publication of this press release. For further information, please contact:  Julie Silber, Director of Investor Relations, Immunovia Email: julie.silber@immunovia.com Tel: +46 7 93 486 277   About Immunovia Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature". The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q4 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome. Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories.  Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. IMPORTANT INFORMATION The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions and the recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Immunovia in any jurisdiction, neither from Immunovia nor from someone else. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations. This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Immunovia has not authorized any offer to the public of shares or other securities in any member state of the EEA and no prospectus has been or will be prepared in connection with the Directed Issue. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it. Forward-looking statements This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the Group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the Group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq Stockholm rule book for issuers. Information to distributors Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in Immunovia have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in Immunovia may decline and investors could lose all or part of their investment; the shares in Immunovia offer no guaranteed income and no capital protection; and an investment in the shares in Immunovia is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Directed Issue. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Immunovia. Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Immunovia and determining appropriate distribution channels.

Nel ASA: Receives purchase order from Nikola

(Oslo, 3 June, 2020) Nel Hydrogen Inc., a wholly owned subsidiary of Nel ASA (Nel, OSE:NEL), has received a purchase order from Nikola Corporation (Nikola), a global leader in zero-emissions transportation and infrastructure solutions, for 85 megawatt alkaline electrolysers related to the deployment of the world’s first 8 ton/day hydrogen fueling stations.  “We’re very excited to have reached this landmark milestone with Nikola. Since our partnership began in 2017, we have been working together to develop a massive large-scale hydrogen fueling station. It’s been amazing to see the significant progress made by the Nikola team specific to vehicle development and the station design, and now we are ready to start building,” says Jon André Løkke, chief executive officer of Nel. “We are building the largest hydrogen network in the world and I couldn’t be prouder to have Nel part of it,” said Trevor Milton, Nikola Corporation’s founder and executive chairman. “These electrolysers will support five heavy-duty hydrogen stations which will cover multiple states and trucking routes in the USA. The future of clean transportation is here, and fleets are lining up to be part of the transition with Nikola.” The purchase order has a value in excess of USD $30 million, and the electrolysers will primarily be delivered from the new electrolyser mega-factory currently under development in Norway. This purchase order will support Nikola’s five initial stations with 8 ton per day hydrogen production capacity. The remaining equipment will be covered by a separate purchase order that is expected to be finalized within the coming months. “The framework agreement was one of the key triggers for deciding to develop our alkaline electrolyser mega-factory in Norway, and has enabled Nikola to reserve capacity in the new plant,” Løkke concludes. The purchase order is subject to final approval by Nel. ENDS For further information, please contact: Jon André Løkke, CEO, +47 907 44 949Bjørn Simonsen, VP Investor Relations & Corporate Communication, +47 971 79 821 About Nel ASA | www.nelhydrogen.com Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store, and distribute hydrogen from renewable energy. We serve industries, energy, and gas companies with leading hydrogen technology. Our roots date back to 1927, and since then, we have had a proud history of development and continuous improvement of hydrogen technologies. Today, our solutions cover the entire value chain: from hydrogen production technologies to hydrogen fueling stations, enabling industries to transition to green hydrogen, and providing fuel cell electric vehicles with the same fast fueling and long range as fossil-fueled vehicles - without the emissions. About Nikola CorporationNikola Corporation is globally transforming the transportation industry. As a designer and manufacturer of battery-electric and hydrogen-electric vehicles, electric vehicle drivetrains, vehicle components, energy storage systems, and hydrogen fueling station infrastructure, Nikola is driven to revolutionize the economic and environmental impact of commerce as we know it today. Founded in 2015, Nikola Corporation is headquartered in Phoenix, Arizona and becomes publicly traded on the Nasdaq beginning June 4[th] under the ticker NKLA. For more information, visit nikolamotor.com or Twitter: @nikolamotor .

Nel ASA: Receives purchase order from Nikola

(Oslo, 3 June, 2020) Nel Hydrogen Inc., a wholly owned subsidiary of Nel ASA (Nel, OSE:NEL), has received a purchase order from Nikola Corporation (Nikola), a global leader in zero-emissions transportation and infrastructure solutions, for 85 megawatt alkaline electrolysers related to the deployment of the world’s first 8 ton/day hydrogen fueling stations.  “We’re very excited to have reached this landmark milestone with Nikola. Since our partnership began in 2017, we have been working together to develop a massive large-scale hydrogen fueling station. It’s been amazing to see the significant progress made by the Nikola team specific to vehicle development and the station design, and now we are ready to start building,” says Jon André Løkke, chief executive officer of Nel. “We are building the largest hydrogen network in the world and I couldn’t be prouder to have Nel part of it,” said Trevor Milton, Nikola Corporation’s founder and executive chairman. “These electrolysers will support five heavy-duty hydrogen stations which will cover multiple states and trucking routes in the USA. The future of clean transportation is here, and fleets are lining up to be part of the transition with Nikola.” The purchase order has a value in excess of USD $30 million, and the electrolysers will primarily be delivered from the new electrolyser mega-factory currently under development in Norway. This purchase order will support Nikola’s five initial stations with 8 ton per day hydrogen production capacity. The remaining equipment will be covered by a separate purchase order that is expected to be finalized within the coming months. “The framework agreement was one of the key triggers for deciding to develop our alkaline electrolyser mega-factory in Norway, and has enabled Nikola to reserve capacity in the new plant,” Løkke concludes. The purchase order is subject to final approval by Nel. ENDS For further information, please contact: Jon André Løkke, CEO, +47 907 44 949Bjørn Simonsen, VP Investor Relations & Corporate Communication, +47 971 79 821 About Nel ASA | www.nelhydrogen.com Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store, and distribute hydrogen from renewable energy. We serve industries, energy, and gas companies with leading hydrogen technology. Our roots date back to 1927, and since then, we have had a proud history of development and continuous improvement of hydrogen technologies. Today, our solutions cover the entire value chain: from hydrogen production technologies to hydrogen fueling stations, enabling industries to transition to green hydrogen, and providing fuel cell electric vehicles with the same fast fueling and long range as fossil-fueled vehicles - without the emissions. About Nikola CorporationNikola Corporation is globally transforming the transportation industry. As a designer and manufacturer of battery-electric and hydrogen-electric vehicles, electric vehicle drivetrains, vehicle components, energy storage systems, and hydrogen fueling station infrastructure, Nikola is driven to revolutionize the economic and environmental impact of commerce as we know it today. Founded in 2015, Nikola Corporation is headquartered in Phoenix, Arizona and becomes publicly traded on the Nasdaq beginning June 4[th] under the ticker NKLA. For more information, visit nikolamotor.com or Twitter: @nikolamotor .

Evolution adds Power Blackjack to its growing ‘Infinite’ range of games

As in all of Evolution’s Infinite games, Power Blackjack offers an unlimited number of seats for players at a single table. What’s unique with Power Blackjack is the added opportunity for players to multiply their winnings by choosing to double, triple or quadruple down their bet on the two initial dealt cards, even after a split. Evolution strives to continuously improve its offering while, at the same time, developing the entire Live Casino market by means of cutting-edge product innovation. As we introduce games for new audiences in the form of our Game Shows category, we continue to develop our offering for traditional live players. During the year, we have released several new innovations of classic table games of which Power Blackjack is the latest. The release of this new version of Blackjack is in line with us constantly striving to further strengthen Evolution’s leading position as a developer in these traditional gaming categories. Todd Haushalter, Chief Product Officer at Evolution Gaming, said: “With this game the mission was to give players more of what they love about Blackjack without changing the underlying gameplay. We know that players love classic Blackjack, but we are always looking for new ways to keep it fresh. Creating a version where players can triple and quadruple down, instead of just double down, felt like a great way to do this.” He added: “A few years ago we created Infinite Blackjack, which is simply a Blackjack platform that allows an unlimited number of players at just one table, instead of the standard seven seats. Building on the success of our proven Infinite format, we have created further new Blackjack game types such as Free Bet Blackjack and now Power Blackjack, with more to come in the future.”

Bublar to develop interactive e-commerce tool in 3D/AR for Aritco

Bublar Group receives an order to develop an advanced and tailored interactive e-commerce tool based on a 3D configurator to the lift manufacturer Aritco Lift. The project is a collaboration between the subsidiaries Vobling and Sayduck, based on Sayduck's 3D/AR platform and Vobling's expertise to adapt the solution for Aritco. The order value is estimated to approximately SEK 2 million over 24 months and is based on a combination of license revenue and a fixed fee. The e-commerce tool will be available on Aritco's website in the second half of 2020 and will be aimed primarily at Aritco's private and corporate customers. The advanced and dynamic configurator will initially visualize four of Aritco's lifts. “We look forward to develop this 3D and AR solution in collaboration with Bublar. It gives our customers and partners around the world the opportunity to tailor and visualize the lifts in their intended environment. By broadening our range of digital services, we continue to be one of the leading players in our industry,” says Klas Dybeck, CIO/ CDO at Aritco Lift AB. Aritco's customers should be able to choose type of lift, number of floors, height, location of doors/windows, choice of material, lighting and more, according to their wishes. The lifts can be turned and seen from different angles and could also be presented via AR in a mobile device. “I'm glad for the trust from Aritco. Aritco stands for engineering, quality and design excellence. Aritco's customers expect premium products and will have the opportunity to have the products presented in a professional manner, says Magnus Rudling,” Sales Director at Vobling & Bublar Enterprise. Sayduck's 3D/AR platform will be expanded using Vobling's know-how and adapted to handle dynamic 3D models as well as other customized solutions.“The collaboration is fully in line with our strategy to create value by combining 3D and AR on the web. Utilizing the Sayduck platform, we take visualization and personalization to the next level for both consumers and professional buyers. We see an increasing demand for these solutions,”  says Anders Ribbing CEO at Vobling & Head of Bublar Enterprise.Vobling represents Bublar's Work business area and develops AR/VR applications, platforms and products in areas such as education, transport and industrial applications for companies such as Kalmar (Cargotec Sweden), Saab, Electrolux, SJ, Norwegian Vy. Read more at https://www.vobling.com/  About AritcoAritco is an award-winning manufacturer of platform lifts and home lifts. The company supplies lifts to public and private market all over the world. Today, almost 4,000 lifts are produced per year sold in 40 different countries through more than 170 distributors.  For more information please contact: Magnus Rudling, Sales Director at Vobling & Bublar Enterprise  magnus.rudling@vobling.com Phone: +46 73 544 38 41 Anders Ribbing, CEO at Vobling & Head of Bublar Enterpriseanders.ribbing@vobling.com. Phone: +46 70 936 88 68  Bublar GroupBublar Group AB (publ) is the Nordic region's leading listed XR technology company specializing in Augmented Reality (AR) and Virtual Reality (VR). The company offers XR solutions in E-commerce, Entertainment, Training and Manufacturing. The company includes the subsidiaries Vobling, Sayduck and Virtual Brains. Bublar is headquartered in Stockholm and is listed on Nasdaq First North Growth Market. In essence, Bublar Group will change the game. We change how we Work, Shop and Play.  The company has G & W fondkommission as Certified Adviser, Kungsgatan 3, Stockholm,email: ca@gwkapital.se, phone +46 8 503 000 50   Bublar Group AB (publ)   Kungstensgatan 18, SE 113 57 Stockholm, Sweden  Phone:  +46 8 559 251 20 www.bublar.com 

Cline’s Share Issue Oversubscribed by 142.4 percent

The issue was carried out with the purpose of obtaining resources to take the next step in the company's strategy. This means that a great focus will be placed on the company's two development projects; 1. A new cell-based diagnostic application for metastatic breast cancer, 2. A new stem cell therapy to replace damaged cartilage in joints that can be used to treat osteoarthritis and other health conditions.  “The issue proceeds give Cline the opportunity to continue expanding its business and start working towards clinical studies in the breast cancer project - CellRACE,” says Patrik Sundh, CEO of Cline Scientific AB. “We are now in an exciting phase where we will take our two projects far along in the process towards clinical studies. With the capital raised, we aim to be prepared for the studies in fall 2020 and then begin the studies in 2021.” The share issue increases the number of Class A shares by 159,333 to 659,333 Class A shares and the number of Class B shares by 3,847,037 to 11,788,149 Class B shares. Following registration with the Swedish Companies Registration Office, which is expected to take place at the end of June 2020, the share capital has increased by SEK 400,637 to SEK 1,244,748.20. This information constitutes such information that Cline Scientific AB is obligated to disclose in accordance with the EU Market Abuse Regulation. The information was submitted by the above-mentioned contact persons for publication on June 4, 2020. Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation. For more information, please contact: Patrik Sundh, CEOEmail: patrik.sundh@clinescientific.comPhone: 0703-585 088About Cline Scientific Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase.   Cline Scientific AB (publ)                      Phone: 031-387 55 55 Argongatan 2C                Email: info@clinescientific.com 431 53 MÖLNDAL          Website: www.clinescientific.com

Videns IT Services and Enea partner to deliver second-generation SD-WAN solutions and services

STOCKHOLM, Sweden, and AMSTERDAM, The Netherlands 4 June 2020. Enea, a global supplier of innovative software components for telecommunications and cybersecurity, and Videns IT Services, a network independent service provider delivering fully managed SD-WAN and Secure Access Service Edge (SASE) services, today announced that they have entered into a partnership enabling Videns to deliver second-generation SD-WAN solutions and services to customers worldwide. The services will be based on Enea NFV Access, a virtualization platform for universal Customer Premise Equipment (uCPE). Ferran van den Berg, Director Sales and Business Development at Videns: “We see our partnership with Enea as strategically important. With Enea NFV Access we are able to deliver our services and solutions on a standardized platform called Videns Intelligent Edge. This approach offers significant benefits to Videns and our enterprise customers.” Benefits include a more efficient service delivery process since the hardware is fully separated and uniform across all network services. Furthermore, Enea NFV Access is open and supports virtually any network environment and SD-WAN or SASE workload. This means that vendor lock-in situations will be avoided, and that customized solutions can always be offered. The new partnership strengthens Videns IT Services’ value proposition to its customers by using a single appliance to run multiple services such as SD-WAN, Firewall, Application Monitoring, and even services such as local Active Directory controller, file or print servers or VoIP gateways. This allows international organizations to extend corporate IT to their branch offices in the most efficient and flexible way. Before entering into the agreement with Enea, Videns tested several uCPE virtualization solutions. Ferran van den Berg: “We choose Enea’s virtualization platform because it provides the best fit with our needs. Enea NFV Access is tailor-made for uCPE environments and user friendly, which is an important factor for us as network specialists. And last but not least, we were very impressed with the proactive support we received from Enea during the evaluation process.” Adrian Leufvén, Senior Vice President the OS Business Unit at Enea: “Videns IT Service is a great example of a new kind of innovative service provider with focus on flexible and agile networking services, exactly in line with enterprise needs for digital transformation. By working with Enea, Videns IT Services can provide a second-generation SD-WAN platform with unrivaled flexibility to match the high pace of innovation and change in enterprise networking.”   More info: Enea NFV Access: https://www.enea.com/products/nfv-virtualization-platforms/enea-nfv-access/ Videns IT Services: https://www.videns-it.com/solutions/

IRLAB’s Phase IIb/III study in Parkinson’s disease to target Good ON

"When mesdopetam was given in addition to standard Parkinson medication, patients experienced considerably longer periods of good daily motor function without aggravated involuntary movements. This is highly relevant since involuntary, levodopa-induced dyskinesia is a major problem in the treatment of Parkinson's disease preventing optimal treatment.", says Joakim Tedroff, CMO at IRLAB. "Mesdopetam represents a new approach that, by inhibiting the mechanisms in the brain that has the most impact on levodopa dependent development of troublesome dyskinesias, and thus, can prevent these, improving the daily function in these severely affected patients." "The treatment effects seen in our Phase IIa study exceeds the results published for other treatment strategies in troublesome dyskinesias. We believe that mesdopetam has a very good chance to offer a completely new and better treatment strategy for the large group of Parkinson’s patients with levodopa induced dyskinesia”, said Nicholas Waters, CEO at IRLAB. The strategy for the Phase IIb/III study has been developed in collaboration with international regulatory and clinical experts. The strategy is based on the results from IRLAB’s Phase I, Phase Ib and Phase II studies with mesdopetam as well as the common use of patient diaries in previous marketing authorizations granted by regulatory authorities for pharmaceutical drugs in the treatment of Parkinson’s disease. “The strategy planning for the Phase IIb/III-study with mesdopetam in Parkinson’s disease is now completed. We have recently also secured financing for the study and initiated a collaboration with a highly reputable CRO", said Nicholas Waters. The study preparations are progressing according to plan.  As a part of the work with the Phase IIb/III study with mesdopetam, preparations are now underway for the applications to regulatory agencies and ethics committees in selected countries for permission to start the study in the second half of 2020.

AlzeCure announces positive data from clinical study with ACD856

The results demonstrate that ACD856, the lead drug candidate within the company's NeuroRestore platform, has a good pharmacokinetic profile with a significantly shorter human half-life than its predecessor ACD855, as well as a suitability for further clinical development, e.g. in oral treatment of Alzheimer's disease. “We are very pleased that ACD856 has a suitable profile for further clinical development”, said Johan Sandin, CSO at AlzeCure Pharma. “The compound has previously shown potent cognitive and memory enhancing properties in our preclinical studies, such as the results  we presented in April together with researchers from Karolinska Institutet. With its potential to improve memory functions in a variety of disorders, ACD856 can play a significant role in treating indications where these key functions are impaired, such as Alzheimer’s disease, sleep apnea, traumatic brain injury and Parkinson’s disease.” AlzeCure Pharma initiated the study in December 2019 and now presents the results of this first clinical study with ACD856 according to plan. Preparations are ongoing to initiate further clinical trials, with a planned start by the end of 2020. These upcoming Phase I studies are aimed to evaluate tolerability in humans, as well as early efficacy signals. “The results of the NeuroRestore candidate ACD856 are demonstrating the great value of AlzeCure's broad portfolio of candidates, which together with the company's strong financial position, enables a strategy where we can develop several candidates in parallel. Due to the fact that AlzeCure is not centered around one single drug candidate, a quick follow-up strategy is possible while opening up opportunities for multiple indications,” said Martin Jönsson, CEO of AlzeCure. "We are now looking forward to taking ACD856 further into the planned clinical studies. This will also stimulate potential partnership and out-licensing discussions as well as increase interest in the NeuroRestore platform." For more information, please contact Martin Jönsson, CEO Tel: +46 707 86 94 43 martin.jonsson@alzecurepharma.com This is information that AlzeCure Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 10.30 am CET on June 4, 2020. About AlzeCure[®] Pharma AlzeCure Pharma AB is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe disorders that affect the central nervous system, such as Alzheimer’s disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallell drug candidates based on the three research platforms, NeuroRestore[®], Alzstatin[®] and Painless. NeuroRestore comprises three symptom-relieving drug candidates where the unique target mechanism opens up for multiple indications – Alzheimer’s disease, but also cognitive dysfunction in traumatic brain injury, sleep apnea and Parkinson’s disease. Alzstatin is comprised of two disease modifying and preventive drug candidates for treatment of early Alzheimer’s disease. Painless, which is the company’s research platform in the field of pain, contains two projects: VR1/ACD440 which is a clinical candidate for the treatment of neuropathic pain, and TrkA-NAM that is targeting pain disorders such as osteoarthritis. AlzeCure[ ]aims to pursue its own projects through preclinical research and development to an early clinical phase. FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company’s certified adviser. For further information, please visit our website at www.alzecurepharma.se. About NeuroRestore NeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive ability is impaired, e.g. Alzheimer’s Disease, sleep apnea, traumatic brain injury and Parkinson’s disease. NeuroRestore stimulates several important signaling pathways in the brain, which among other things leads to improved cognition. In preclinical studies with NeuroRestore we have been able to show that our drug candidates enhance communication between the nerve cells and improve cognitive ability. NeuroRestore stimulates specific signaling pathways in the central nervous system known as neurotrophins, the most well-known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). The levels of NGF and BDNF are disturbed in several disease states and the signaling is reduced. The impaired function impairs communication betweenthe synapses, i.e. the contact surfaces of the nerve endings, as well as reducing the possibility of survival for the nerve cells, which gives rise to the cognitive impairments. Neurotrophins play a crucial role for the function of nerve cells, and a disturbed function of BDNF has a strong genetic link to impaired cognitive ability in several different diseases, such as Alzheimer’s, Parkinson’s disease, traumatic brain injury and sleep apnea. About Alzheimer’s diseaseAlzheimer’s disease is the most common form of dementia, affecting approximately 45 million people worldwide. Alzheimer’s disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer’s are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases is estimated to about 1,000 billion USD globally in 2018. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute.The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer’s disease is estimated to reach more than 10 billion USD in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer’s disease with a healthcare cost of about 63 billion SEK yearly, which is more than for cancer and cardiovascular diseases combined.

Proposed targeted new share issues in myFC expected to generate about SEK 32 million

The Board of Directors of myFC is continuously working toward long-term financing of the company, and now proposes a targeted new issue to a group of current and new European investors. Further to this, a major shareholder proposes an additional directed new share issue to executive management and the Board of Directors. The directed new issues of in total 16,201,900 shares at a price of SEK 2 per share are subject to the approval of an Extraordinary General Meeting on June 24, 2020. The price implies a premium compared to the closing price on June 3 of about 25 %. Notice of the Extraordinary General Meeting will be given in a separate press release. ”I’m very pleased to announce that we are on track with our rigorous strategic growth plan as we reach another important milestone today. We have successfully secured substantial funding for myFC, which will further enable myFC to capitalize on the commercialization of its unique fuel cell technology with a highly motivated and ambitious leadership team under CEO Michael Glantz,” says Markus Hermanek, Chairman of the Board at myFC. “The funds we have secured will be used to further enable zero emission carbon footprint and e-mobility, in line with legislations being implemented by governments and leading companies across Europe and around the world. With this, we clearly and further capitalize on myFC’s unrivalled position as global leader within the micro fuel cell industry which makes me very proud,” adds Markus Hermanek. Following the new share issues, the total number of shares in myFC will increase from 156,683,087 to 172,884,987 and the share capital will increase by approximately SEK 947,479.62, from SEK 9,162,754.46 to SEK 10,110,234.07, corresponding to a dilution of the votes and the capital of approximately 9,4 %, after registration at the Swedish Companies Registration Office. The following have been invited to subscribe to the targeted new share issues:  Investment (SEK) No of sharesEuropean Investors 29,824,000 14,912,000 Board and Executive ManagementAlex Guy 2,230,000 1,165,000Markus Hermanek 139,800 69,900Johnny Bräster 50,000 25,000Ulf Henning 20,000 10,000Sebastian Weber 20,000 10,000Michael Glantz 20,000 10,000 Total 32,403,800 16, 201,900 Current major owner H119 AG will together with Markus Hermanek and Alex Guy hold approximately 27% of the shares in myFC once the proposed rights issues are completed. This information is information that myFC is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 13:00 CEST on 4 June 2020.

Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology

Lund, Sweden, June 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), today announced signing of a collaboration agreement. The two companies have agreed to explore the anti-tumor efficacy of the CD40 antibody mitazalimab (Alligator Bioscience) in combination with SCO-101 (Scandion Oncology) as an addition to chemotherapy in resistant preclinical tumor models. The expectation is that SCO-101 will revert chemotherapy resistance and thereby further strengthening the anti-tumor effects of mitazalimab.  Immuno-oncology (IO) drugs have proven very effective in subsets of cancer patients. Recently, data from large clinical trials have shown that the combination of IO drugs and standard chemotherapy results in additive anti-tumor effects and more durable remissions in cancer patients. However, many cancers develop resistance to chemotherapy and consequently, no additive effects will be expected in these patients.   The Alligator Bioscience drug candidate mitazalimab enhances presentation of antigens released by cancer cells and is thought to be beneficial in combination with chemotherapy, where large amounts of antigens are being released by dying tumor cells. Scandion Oncology’s drug candidate SCO-101 acts by blocking resistance mechanisms in cancer cells, allowing chemotherapy to kill previously resistant cancer cells. Thereby, SCO-101 would restore the release of antigens and re-activate the anti-cancer effects of the IO drugs.    “This collaboration will further validate mitazalimab’s potential in combination therapy with diverse chemotherapeutic agents, as well as the power of SCO-101 as a solution to the widespread issue of chemoresistance," said Per Norlén, CEO of Alligator Bioscience. “This is a dream scenario for Scandion Oncology. Combinations between SCO-101, chemotherapy and an IO drug like mitazalimab could easily become the future of anti-cancer therapy” says Nils Brünner, CEO of Scandion Oncology.    Results from the studies in this collaboration are expected during first half of 2021.  For further information, please contact:Cecilia Hofvander, Director Investor Relations & CommunicationsPhone +46 46 540 82 06E-mail: cecilia.hofvander@alligatorbioscience.com This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 2:00 p.m. CEST on June 4, 2020. About Alligator BioscienceAlligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes six lead clinical and preclinical drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com. About Scandion OncologyScandion Oncology A/S is a clinical-stage biotechnology company that addresses one of the greatest challenges in modern oncology - the effective treatment of cancer which contains chemotherapy-resistant cells, or which has developed resistance to a previously prescribed cancer drug. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For more information, please visit www.scandiononcology.com.

Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology

Immuno-oncology (IO) drugs have proven very effective in subsets of cancer patients. Recently, data from large clinical trials have shown that the combination of IO drugs and standard chemotherapy results in additive anti-tumor effects and more durable remissions in cancer patients. However, many cancers develop resistance to chemotherapy and consequently, no additive effects will be expected in these patients.   The Alligator Bioscience drug candidate mitazalimab enhances presentation of antigens released by cancer cells and is thought to be beneficial in combination with chemotherapy, where large amounts of antigens are being released by dying tumor cells. Scandion Oncology’s drug candidate SCO-101 acts by blocking resistance mechanisms in cancer cells, allowing chemotherapy to kill previously resistant cancer cells. Thereby, SCO-101 would restore the release of antigens and re-activate the anti-cancer effects of the IO drugs.    “This collaboration will further validate mitazalimab’s potential in combination therapy with diverse chemotherapeutic agents, as well as the power of SCO-101 as a solution to the widespread issue of chemoresistance," said Per Norlén, CEO of Alligator Bioscience. “This is a dream scenario for Scandion Oncology. Combinations between SCO-101, chemotherapy and an IO drug like mitazalimab could easily become the future of anti-cancer therapy” says Nils Brünner, CEO of Scandion Oncology.    Results from the studies in this collaboration are expected during first half of 2021.    For further information, please contact:Nils Brünner, CEO Phone: +45 26 14 47 08 E-mail: nb@scandiononcology.com This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2:00 p.m. CEST on June 4, 2020. About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes six lead clinical and preclinical drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com. About Scandion Oncology Scandion Oncology A/S is a clinical-stage biotechnology company that addresses one of the greatest challenges in modern oncology - the effective treatment of cancer which contains chemotherapy-resistant cells, or which has developed resistance to a previously prescribed cancer drug. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For more information, please visit www.scandiononcology.com.

Stora Enso’s Annual General Meeting and decisions by the Board of Directors

Stora Enso’s Annual General Meeting (AGM) was held on 4 June 2020 at the Company's Head Office in Helsinki, Finland. In order to prevent the spread of the Covid-19 pandemic, a shareholder or his/her proxy representative could not be present at the venue of the meeting. A total of 2,488 shareholders representing approximately 468 million shares and 192 million votes were represented at the meeting. The AGM supported all the proposals by the Shareholders’ Nomination Board and the Board of Directors by at least 91 percent of the votes cast. The AGM adopted the accounts for 2019 and granted the Company’s Board of Directors and Chief Executive Officer discharge from liability for the period. Resolution on the use of the profit shown on the balance sheet and the payment of dividendThe AGM approved the proposal by the Board of Directors that the Company distributes a dividend of EUR 0.15 per share for the year 2019. The dividend shall be paid to shareholders who on the record date of the dividend payment, Monday 8 June 2020, are recorded in the shareholders’ register maintained by Euroclear Finland Oy or in the separate register of shareholders maintained by Euroclear Sweden AB for Euroclear Sweden registered shares. Dividends payable for Euroclear Sweden registered shares will be forwarded by Euroclear Sweden AB and paid in Swedish crown. Dividends payable to ADR holders will be forwarded by Citibank N.A. and paid in US dollars. The AGM approved the proposal by the Board of Directors that the dividend be paid on or about Monday 15 June 2020. In addition, the AGM approved the proposal that the Board of Directors to decide at its discretion on the payment of dividend up to a maximum of EUR 0.35 per share. A resolution on the distribution of a dividend will be made at a later stage when it is possible to make a more reliable estimate on the impacts of the Covid-19 pandemic on Stora Enso’s business and liquidity.  Members of the Board of DirectorsThe AGM approved the proposal that of the current members of the Board of Directors – Jorma Eloranta, Elisabeth Fleuriot, Hock Goh, Mikko Helander, Christiane Kuehne, Antti Mäkinen, Richard Nilsson and Hans Stråberg – be re-elected members of the Board of Directors until the end of the following AGM and that Håkan Buskhe be elected new member of the Board of Directors for the same term of office. The AGM elected Jorma Eloranta as Chair of the Board of Directors and Hans Stråberg as Vice Chair. Remuneration The AGM approved the proposed annual remuneration for the Board of Directors as follows: Chair                                   EUR 197 000 (2019: EUR 192 000) Vice Chair                           EUR 112 000 (2019: EUR 109 000) Members                             EUR 76 000 (2019: EUR 74 000) The AGM also approved the proposal that the annual remuneration for the members of the Board of Directors, be paid in Company shares and cash so that 40% will be paid in Stora Enso R shares to be purchased on the Board members’ behalf from the market at a price determined in public trading, and the rest in cash. The shares will be purchased within two weeks from the AGM or as soon as possible in accordance with applicable legislation. The Company will pay any costs and transfer tax related to the purchase of Company shares. The AGM approved the proposed annual remuneration for the Board committees as follows: Financial and Audit Committee Chair                                   EUR 21 200 (2019: EUR 20 600) Members                             EUR 14 800 (2019: EUR 14 400)                                                                 Remuneration Committee Chair                                   EUR 10 600 (2019: EUR 10 300) Members                             EUR 6 400 (2019: EUR 6 200) Sustainability and Ethics Committee Chair                                   EUR 10 600 (2019: EUR 10 300) Members                             EUR 6 400 (2019: EUR 6 200) AuditorThe AGM approved the proposal that PricewaterhouseCoopers Oy be elected as auditor until the end of the following AGM. PricewaterhouseCoopers Oy has notified the company that Samuli Perälä, APA, will act as the responsible auditor. It was resolved that the remuneration for the auditor shall be paid according to invoice approved by the Financial and Audit Committee.  Board authorisation to decide on repurchase and issuance of sharesThe AGM approved the proposal that the Board of Directors be authorised to decide on the repurchase of Stora Enso R shares as follows: The amount of R shares to be repurchased shall not exceed 2 000 000 shares, which corresponds to approximately 0.25% of all shares and 0.33% of all R shares in the Company. Own shares can be repurchased otherwise than in proportion to the shareholdings of the shareholders (directed repurchase). Own shares can be repurchased using the unrestricted equity of the Company at a price formed in public trading on the date of the repurchase or otherwise at a price determined by the markets. Own shares may be repurchased primarily in order to use the shares as part of the Company's incentive and remuneration scheme. The repurchased shares may be held for reissue, canceled or transferred further. The AGM also approved the proposal that the board of Directors be authorised to decide on the issuance of Stora Enso R shares on the following terms: The amount of shares to be issued based on this authorisation shall not exceed a total of 2 000 000 R shares, corresponding to approximately 0.25% of all shares and 0.33% of all R shares. The authorisation covers both the issuance of new shares as well as the transfer of own shares held by the Company.  The issuance of shares may be carried out in deviation from the shareholders’ pre-emptive rights for the purpose of using the shares as part of the Company's incentive and remuneration scheme. Decisions by the Board of DirectorsRichard Nilsson (chair), Jorma Eloranta, Elisabeth Fleuriot and Hock Goh were elected members of the Financial and Audit Committee. Jorma Eloranta (chair), Antti Mäkinen, and Hans Stråberg were elected members of the Remuneration Committee. Christiane Kuehne (chair), Håkan Buskhe and Mikko Helander were elected members of the Sustainability and Ethics Committee. Speeches and minutes of the AGMThe recorded speeches by Chair of the Board Jorma Eloranta and President and CEO Annica Bresky are available on the Company's website at storaenso.com/agm . The minutes of the AGM will be available on the website later today. Investor enquiries:Ulla PaajanenSVP, Investor Relationstel. +358 40 763 8767 Part of the bioeconomy, Stora Enso is a leading global provider of renewable solutions in packaging, biomaterials, wooden constructions and paper. We believe that everything that is made from fossil-based materials today can be made from a tree tomorrow. Stora Enso has some 25 000 employees in over 30 countries. Our sales in 2019 were EUR 10.1 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com  STORA ENSO OYJ

Lotta Lyrå appointed new President and CEO of Södra

“I am very proud to present Lotta Lyrå as our new President and CEO. She has the right competency profile to develop Södra within the context of the new Group strategy that has been developed. With a background in Södra and experience in both forestry and industry, she has an understanding of the development potential of family forestry and the innovation-driven culture that exists within the Group,” said Lena Ek, Chair of Södra.Lotta Lyrå has served as CEO of Clas Ohlsson since 2017 and also held various senior positions in the IKEA Group. At Södra, she was previously employed as Head of Productivity for the Group and Sawmill Manager at Mönsterås.“I am delighted and honoured to be entrusted with this opportunity – together with Södra’s members, employees, customers and contractors – to nurture and further develop Södra for the future. Södra has a unique platform, in terms of both raw material and mills, for future profitability, growth and innovation. Especially in light of the climate benefits that forests and forest products can provide through both forest growth and the replacement of fossil-based products. I am really looking forward to returning Södra, with its strong set of values, optimism and competence, and reconnecting with colleagues, members and customers,” said Lotta Lyrå. For more information, please contact:Södra’s Pressroom,Tel: +46 470-890 90E-mail: press@sodra.com

Calliditas Therapeutics prices its initial public offering on The Nasdaq Global Select Market in the United States

The Global Offering · The Global Offering price has been set to USD 19.50 per ADS in the U.S. Offering, and SEK 89.70 per share in the concurrent Private Placement. · The U.S. Offering comprises 4,153,385 ADSs, each representing two (2) underlying new common shares of Calliditas. The Private Placement comprises 924,000 common shares. To cover any over-allotment in the Global Offering, Calliditas has granted the Book Running Managers (as defined below) an option to acquire and sell up to 692,307 additional ADSs, corresponding to 15 percent of the Global Offering (the “Over-Allotment Option”), exercisable in whole or in part through July 4, 2020. If the Over-Allotment Option is exercised in full, the Global Offering will consist of 4,845,692 ADSs and 924,000 common shares. · The Global Offering will provide Calliditas with gross proceeds of USD 90 million (equivalent to SEK 828.0 million based on the June 4, 2020 exchange ratio of USD 1 = SEK 9.20) assuming no exercise of the Over-Allotment Option by the Book Running Managers. Calliditas estimates that the net proceeds of the Global Offering will be approximately USD 79.9 million (SEK 735.2), after deducting approximately USD 10.1 million (SEK 92.8 million) in underwriting commissions and offering expenses. Assuming the Over-Allotment Option is exercised in full, the Global Offering will provide Calliditas with gross proceeds of USD 103.5 million (equivalent to SEK 952.2 million) and net proceeds of approximately USD 92.5 million (equivalent to SEK 850.7 million), after deducting approximate underwriting commissions and offering expenses. · The Global Offering was upsized from the USD 75 million indicated in Calliditas’ press release on June 1, 2020. · Calliditas’ Board of Directors has resolved to issue the common shares in order to deliver ADSs and common shares to investors in the Global Offering, by virtue of the share issue authorization granted at the Extraordinary General Meeting held on March 3, 2020. · The offered ADSs are in their entirety expected to be subscribed for by Citigroup Global Markets Inc., Jefferies LLC and Stifel, Nicolaus & Company, Inc. as the global coordinators and joint book-running managers of the Global Offering (the “Book Running Managers”), with an instruction to deliver the securities to investors in the U.S. Offering. · Trading of the ADSs on The Nasdaq Global Select Market commences on June 5, 2020, under the symbol “CALT”. · The Global Offering is expected to be completed, and settlement is expected to occur, on June 9, 2020 (subject to the satisfaction of customary closing conditions). Use of Proceeds Calliditas intends to use the net proceeds from the Global Offering, together with its existing cash resources, for the purposes of funding of its ongoing Phase 3 clinical trial and related trials of Nefecon, pre-commercialization and, if approved, commercialization activities for Nefecon and development of additional product candidates. Prospectuses and Preliminary Timetable The Form F-1 registration statement, including the preliminary prospectus, related to the Global Offering has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”). The U.S. Offering of the ADSs is being made only by means of such U.S. prospectus. A copy of the final U.S. prospectus related to the Global Offering may be obtained at no cost, when available, by visiting EDGAR on the U.S. Securities and Exchange Commission website (www.sec.gov). Copies of the final prospectus relating to the U.S. Offering may be obtained from Citigroup Global Markets Inc., Attention: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at +1 (800) 831-9146; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, via telephone: +1 877-821-7388 or via email: Prospectus_Department@Jefferies.com or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at +1 (415) 364-2720 or by email at syndprospectus@stifel.com. A Swedish prospectus, prepared solely for the purpose of admitting underlying newly issued common shares, as well as common shares for the Private Placement, on Nasdaq Stockholm, is expected to be registered with the Swedish Financial Supervisory Authority on June 5, 2020, pursuant to Regulation (EU) 2017/1129, and will be available at www.calliditas.com. A timetable of expected future principal events can be seen below: Event Expected dateThe ADSs start trading on The Nasdaq June 5, 2020Global Select Market:Publication in the United States of the June 5, 2020final U.S. prospectus:Publication of the Swedish prospectus for June 5, 2020the listing of shares on Nasdaq Stockholm:Completion of the Global Offering and June 9, 2020settlement: Other Information In connection with the Global Offering, Calliditas has, with customary exceptions, agreed to a lock-up undertaking on future share issuances for a period of 90 days after the pricing of the Global Offering. In addition, Calliditas’ executive management and members of the Board of Directors, together with certain major shareholders (including Stiftelsen Industrifonden, Investinor AS and Linc AB), have undertaken not to sell any shares in Calliditas during the same period, subject to customary exceptions. Calliditas’ common shares are currently listed on Nasdaq Stockholm under the symbol “CALTX” and Calliditas intends to maintain the listing on Nasdaq Stockholm. The filing of the prospectus in the United States with the SEC has no direct implications for Calliditas’ listing on Nasdaq Stockholm in Sweden. In connection with the offer or sale of securities referred to herein, the Book Running Managers may over-allot securities/conduct stabilization or effect transactions on The Nasdaq Global Select Market with a view to support the market price of the securities at a level higher than that which might otherwise prevail. Any stabilization action or over-allotment will be conducted by the Book Running Managers in accordance with all applicable laws and rules. Advisors Citigroup Global Markets Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated are acting as the global coordinators and joint book-running managers of the Global Offering. Carnegie Investment Bank AB is acting as co-manager of the Global Offering. Citigroup Global Markets Inc. and Jefferies LLC are acting as representatives of the underwriters in the U.S. Offering. Citigroup Global Markets Limited and Jefferies International Limited are acting as representatives of the underwriters in the Private Placement. Goodwin Procter LLP and Advokatfirman Vinge are acting as legal advisors in the Global Offering. Cooley LLP and Baker McKenzie are acting as legal advisors to the underwriters. For further information, please contact: Renée Aguiar-Lucander, CEO at Calliditas Tel.: +46 722 52 10 06, email: renee.lucander@calliditas.com Mikael Widell, Head of Communications and IR Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com The information in the press release is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person above, on June 5, 2020 at 8.40 am (CEST). About Calliditas Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and The Nasdaq Global Select Market (ticker: CALT). Important information This announcement does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No announcements or information regarding the initial public offering may be disseminated to the public in jurisdictions where a prior registration or approval is required for such purpose. No steps have been taken, or will be taken, for the offering of Shares or ADSs in any jurisdiction where such steps would be required. The issue or sale of shares or ADSs, and the subscription for or purchase of shares or ADSs are subject to special legal or statutory restrictions in certain jurisdictions. Calliditas is not liable if these restrictions are not complied with by any other person. This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. Calliditas has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection therewith. In any EEA member state, this communication is only addressed to and is only directed at qualified investors in that member state within the meaning of the Prospectus Regulation. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it. Safe Harbor/Forward-Looking Statements This announcement contains forward-looking statements, including as to the intended use of net proceeds from the Global Offering described herein and the timing of the closing of the Global Offering. These statements are based on expectations in light of the information that is currently available, as well as assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from such statements. These risks and uncertainties include, but are not limited to, domestic and international economic conditions, industry and market conditions, and changes of interest rate and currency exchange rate, in general, and completion and discontinuation of clinical trials, obtaining regulatory approvals, claims and concerns about product safety and efficacy, technological advances, domestic and foreign healthcare reforms, and changes of laws and regulations, in particular, with respect to Nefecon. Calliditas disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. This announcement contains information on pharmaceuticals (including pharmaceuticals under development) but is not intended to, and does not, make any representations, warranties or claims regarding the efficacy or effectiveness of these pharmaceuticals or provide medical advice of any kind.

New version of PONSSE Manager improves reporting of machine chain productivity

Printable load certificate The PONSSE Manager load certificate displays work area identification data and local transportation per storage location, both as sum totals and operator-specific values. The printable load certificate also includes the volume of each load, the assortments delivered, and the distance travelled. “Forwarder production volumes will be updated in PONSSE Manager reports if the forwarder is equipped with a compatible PONSSE Load Optimizer loader scale or the Opti 4G operator load details feature, which allows operators to enter their roadside deliveries in the Opti 4G system. These features raise machine chain reporting to a whole new level and offer a better overview of total harvesting production”, says Juho Leskinen, Product Group Manager, information systems and digitalisation. PONSSE Parts Online, a system for ordering spare parts, can be accessed from the PONSSE Manager main menu in countries where Parts Online service is available. PONSSE Manager is a continuously developed data management system To support their operations, forest machine entrepreneurs need a reliable partner to develop services that truly improve customers’ business. PONSSE Manager is a modern forest machine monitoring and data transfer system that forest machine entrepreneurs can use to see their machines’ location, productivity figures and fuel consumption, among others. With PONSSE Manager, entrepreneurs can improve the efficiency of their business and enhance productivity, thanks to real-time field operations monitoring. With Manager, entrepreneurs can monitor the progress of stands, plan and manage machine transportation, keep track of machine outputs according to assortment and print out measuring certificates. In addition, Manager informs entrepreneurs of machine maintenance needs and displays any maintenance-related notes made by the operator. Read more: www.ponsse.com/en/web/guest/services/online-services#/  Further information

Bambuser enters a pilot agreement for Live Video Shopping with one of the world's largest retailers

Bambuser AB has signed a pilot agreement for Live Video Shopping with one of the world's largest and most established retail chains. The customer in question is a global fashion group with a portfolio of several brands established in over 50 online markets with approximately 179,000 employees and a total net sales of SEK 233 billion for the 2019 financial year. The agreement gives the customer the right to use Live Video Shopping at a fixed cost of SEK 350,000 for one of the Group's brands in one market during the pilot phase, which lasts for a total of three months. - Great to see Live Video Shopping being used by yet another world-leading group. We see the pilot agreement as a natural first step in what will hopefully be a very strategic and long-term partnership, something that would take Bambuser to new heights, says Maryam Ghahremani, CEO of Bambuser. This is information that Bambuser AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out below, on 5 June 2020. Contact informationMaryam Ghahremani, CEO | +46 8 400 160 02 | maryam@bambuser.com or visit bambuser.com/ir Certified AdviserErik Penser Bank AB | +46 8 463 83 00 | certifiedadviser@penser.seBambuser was founded in 2007 as the world's first company with a platform for interactive mobile live video broadcasting and is a leading supplier in the live video segment. In 2019, Bambuser introduced Live Video Shopping, which enables live shopping directly on the brand's website. Bambuser is listed on the Nasdaq First North Growth Market and is headquartered in Stockholm.